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YLL Years of Life Lost due to premature mortality 
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EXECUTIVE SUMMARY 
Allergies are chronic immunological disorders that occur when a person's immune system 
mounts an abnormal response to substances in the environment (allergens) that do not 
normally bother other people.  In this report, to accord with data sources, allergies are 
grouped as: 
 allergic rhinitis (hay fever) and conjunctivitis; 
 allergic asthma; 
 allergic chronic sinusitis; and 
 other allergies, which include food, drug, latex, sting and bite allergies, urticaria (hives, 
nettle rash), contact dermatitis and anaphylaxis, among other disorders. 
Allergy testing for diagnosis involves the detection of Immunoglobulin E (IgE) antibodies 
directed against environmental allergens, either by skin prick testing (SPT) or blood allergy 
testing.  Patch testing can also be used to detect non-IgE mediated disorders such as 
contact allergic dermatitis.  Allergies can cause significant discomfort, affect sleep, and 
impair learning, memory and behaviour in children.  In children with severe food allergy, 
management in the community is complex and has the potential to cause anxiety within 
affected families regarding care in schools, risk of death and the need or otherwise for 
injectable adrenaline.  For affected adults, allergic disorders can lead to impaired quality of 
life, absenteeism from work, other reduced productivity, aids (especially self-care aids such 
as dressings for atopic eczema) and home modifications (eg, to prevent or reduce allergen 
levels in the home).  Most patients with allergic disorders have associated comorbidities. The 
relative risk of death in people with allergic disorders is slightly elevated, estimated in this 
report as 1.02 across all Australians with allergies. 
Prevalence of allergies in Australia 
Allergies have emerged as a major public health problem in developed countries during the 
twentieth century; Australia and New Zealand have among the highest prevalence of allergic 
disorders in the developed world.  This report estimates that in 2007: 
 4.1 million Australians (19.6% of the population) have at least one allergy, of which 
2.2 million (55%) are female and 1.9 million (45%) are male; 
 the highest prevalence of allergies is in the working age population, with 78% of people 
with allergies aged 15 to 64 years (see chart below), and  
 there are 7.2 million cases of allergy (ie, an average of 1.74 comorbid allergies per 
person). 
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Literature evidence indicates increases in the prevalence of many types of allergies in recent 
decades.  For example, hospital admissions for food anaphylaxis in Australia have doubled 
over the last decade, and increased five-fold in children aged 0-4 years.  Peanut allergy has 
doubled in prevalence in young children over a five year period. 
Linear estimation from historical data from the Australian Bureau of Statistics National Health 
Survey suggests that the age-gender prevalence of allergies has changed in Australia over 
the period 1995-2005, for males and females together, by: 
 -0.08% per annum for allergic asthma; 
 0.22% per annum for allergic rhinitis; 
 -0.04% per annum for allergic sinusitis; 
 -0.06% per annum for other allergies; and 
 0.09% per annum for all allergies – this means that while prevalence is 19.6% this 
year, if current trends continue, it would be 19.7% next year and so on. 
There is stronger overall growth in the number of older Australians (particularly males).  If 
current trends continue, there would be a 70% increase in the number of Australians 
with allergy, from 4.1 million currently to 7.7 million by 2050 (26.1% of the population 
or more than one in four Australians compared to one in five Australians today).  If the 
rise in age-gender prevalence rates could be immediately arrested, there would be 
5.62 million Australians with allergies by 2050 (with growth in numbers due solely to 
population growth and ageing) and in fact a decline relative to population from 19.6% now to 
19.1% by mid-century. 
Costs 
In 2007, the financial cost of allergies was $7.8 billion.  Of this: 
 $5.6 billion (72%) was productivity lost due to:  
 lower productivity while at work – ‘presenteeism’ ($4.2 billion) 
 lower employment rates ($1.1 billion);  
 absenteeism and lost household productivity ($196 million); and 
 premature death, including employers’ search and hiring costs ($84 million). 
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 $1.2 billion (15%) was the direct health system expenditure of which: 
 allergic asthma was an estimated $808 million; and 
 non-asthma allergy (NAA) was an estimated $349 million; and 
 $262 million (3%) was other indirect costs such as aids and home modifications and 
the bring-forward of funeral costs; and 
 $783 million (10%) was the deadweight loss from transfers including welfare payments 
(mainly Disability Support Pension and Carer Payment) and taxation forgone. 
To put this financial cost in perspective, it is more than twice as large as schizophrenia 
($1.8 billion) and bipolar affective disorder ($1.6 billion) combined.  Additionally, the net 
value of the lost wellbeing (disability and premature death) was a further $21.6 billion. 
For 156,144 Disability Adjusted Life Years (DALYs).  This represents almost double the 
same figures for either arthritis or hearing loss (both $11.7 billion). 
In per capita terms, this amounts to a financial cost of around $1,912 per person with 
allergies per annum.  Including the value of lost wellbeing, the cost is $7,200 per person per 
annum. 
Individuals with allergies bear 48% of the financial costs, and their families and friends bear a 
further 1%.  Federal government bears 32% of the financial costs, mainly through taxation 
revenues forgone ($1.9 billion), funded health expenditures ($497 million) and welfare 
payments ($78 million), as well as other expenditures ($65 million).  State and Territory 
governments bear around 5% of the costs, with the remaining 13% borne by others in society 
(including employers).   
If the burden of disease (the economic cost of disability and premature death) is included, 
individuals bear 86% of the costs.  Total cost shares are depicted in the following charts. 
TOTAL COSTS OF ALLERGIES, BY TYPE OF COST AND BY BEARER (% TOTAL) 
BoD
73%
Health System Costs
4%
Other financial Costs 
1%
Productivity Costs
19%
DWLs 3%
Society
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Workforce considerations 
Australia would need 178 allergy/immunology specialists by 2017 to correct the current 
maldistribution and achieve the benchmark of NSW/ACT specialist to population ratios 
(SPRs) over the ten-year period till then.  This contrasts with the likely 115 specialists who 
would be available if training places are kept at the six per year currently projected.  The 
additional 63 specialists could be achieved by training 127 over the period rather than 64, 
given the simple assumptions of the basic modelling in this report.  There would be little 
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impact by 2012, with the SPR only 0.52 compared to 0.51 in the likely case; however, the 
benefits would start to emerge from 2013 onwards. 
Future directions 
In Australia there is a lack of public and professional appreciation of the impact of allergic 
and immune disorders on quality of life, and even less of the economic impact to society and 
individuals who suffer allergic disease.  Raising awareness of the economic and health 
impacts is an important factor in facilitating the early recognition and control of allergic 
disease. 
Development of a framework of best practice for management of allergic disease in Australia 
will be enhanced by: 
 timely access to specialist allergy/immunology services; 
 access to early and accurate diagnosis; 
 access to affordable and cost-effective therapy and novel therapies; 
 support for community and medical education outside the current paradigm; 
 support for local research to develop interventional strategies to reduce the burden of 
disease in the community; and 
 development of a model of allergy as a chronic disease. 
Access Economics 
November 2007 
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1. INTRODUCTION 
Access Economics was commissioned by the Australasian Society for Clinical Immunology 
and Allergy (ASCIA) to estimate the demographic prevalence, financial cost and disease 
burden of allergic disorders in Australia.  Allergic disorders are chronic immunological 
disorders that can impact negatively on quality of life and productivity. 
ASCIA is the peak professional body of Australian and New Zealand Allergy and Immunology 
specialists. The aims of ASCIA are to improve the care of patients by providing evidence-
based information on allergic and immune disorders within the medical and lay community. 
Its aims are supported by the provision of educational material for health professionals and 
patients, support for research, and collaboration with other professional and government 
organisations such as the National Asthma Campaign and Commonwealth Department of 
Health and Ageing (DoHA). 
This report is structured as follows. 
 The rest of this chapter provides background information on the immune system, 
specific allergic diseases and their symptoms and treatment, as well as methods of 
diagnosis. 
 Chapter 2 presents current and projected future prevalence of allergy in Australia.  
 Chapters 3 and 4 discuss the health system costs and other financial costs associated 
with allergic disease. Other financial costs include productivity losses (due to lower 
employment rates, worker absenteeism and premature death), carer and other costs, 
as well as deadweight (efficiency) losses (DWLs) from transfer payments, such as 
government welfare and income support payments1.  
 Chapter 5 presents burden of disease (BoD) estimates, which refers to the years of 
healthy life lost due to disability and premature mortality caused by allergic disease, 
and is measured by Disability Adjusted Life Years (DALYs). 
 Chapter 6 summarises the economic impacts of allergies. 
 Chapter 7 reviews the adequacy of the allergy and immunology workforce in Australia, 
based on simple projections of demand and supply. 
 Chapter 8 presents strategic, forward-looking conclusions from the analysis. 
1.1 THE IMMUNE SYSTEM 
The immune system is a complex network of cells and proteins that defends the body against 
infection and protects against the development of malignancy. In the simplest terms, 
diseases of the immune system result from either a deficiency of normal immune responses, 
or overactive or inappropriate immune responses (Shearer et al, 2006; Verbsky and 
Grossman, 2006).  Inappropriate immune responses include allergies (where the immune 
system responds to innocuous environmental substances) and autoimmune diseases (where 
the immune system responds to components of the body as if they were foreign and 
harmful).  
                                               
1
 A cost analysis of the economic impact of immune diseases (other than allergy) is beyond the scope of the 
current report. 
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Disorders managed by allergy and immunology specialists include the following conditions, 
some of which may also be occupational. 
 Classical Allergic Disorders 
 Allergic rhinitis (hay fever) 
 Asthma 
 Food Allergy   
 Drug Reactions (eg, antibiotics, pain killers or anaesthetics) 
 Latex allergy 
 Stinging insect allergy   
 Urticaria/angioedema (hives, swellings) 
 Atopic eczema 
 Anaphylaxis (serious allergic reactions) 
 Disorders usually managed by allergy specialists 
 Non-allergic (vasomotor) rhinitis 
 Non-allergic adverse food reactions (food intolerance)  
 Overlapping disorders sometimes co-managed with other specialties 
 Chronic sinusitis 
 Nasal polyps 
 Aspirin triad (nasal polyps, late onset asthma, aspirin allergy) 
 Eosinophilic oesophagitis and gastroenteritis  
 Coeliac disease 
 Contact allergic dermatitis  
 Extrinsic allergic alveolitis (Farmer’s lung) 
 Sarcoid 
 Other immune disorders 
 Hypereosinophilia syndromes 
 Non-allergic disorders often erroneously attributed to allergy  
 Migraines 
 Irritable bowel syndrome 
 Chronic fatigue syndrome 
 Some psychological disorders (attributed to environmental factors such as food 
or inhaled substances) 
 Immune deficiency 
 Primary Immune Deficiency 
 Acquired Immune Deficiency (eg, HIV infection, cancer chemotherapy) 
 Autoimmune disorders 
 Vasculitis 
 SLE/Systemic Lupus Erythematosus 
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1.2 WHAT IS ALLERGY? 
Allergy occurs when a person's immune system mounts an abnormal response to 
substances in the environment that do not normally bother other people. These substances 
are known as allergens. They are usually small proteins and include house dust mites, 
animal skin and saliva, pollen, moulds and foods. When allergic people are exposed to 
allergens, they can form Immunoglobulin E (IgE) antibodies against that allergen.2 A person 
allergic to pollen protein, for example, will have IgE antibodies capable of recognising the 
shape of pollen protein (the allergen), in much the same way that a lock ‘recognises’ the 
shape of a key. 
IgE antibodies stick to the surface of mast cells within tissues and act as remote sensors 
within the environment. Mast cells are like ‘land-mines’, and contain ‘bean bags’ filled with 
irritant chemicals including histamine. When IgE antibodies attach, mast cells are triggered to 
dump their contents into the tissues. When these are released in small amounts, they cause 
local itch and irritation. In much larger amounts, the result can be much more serious.  
Symptoms may include the sneeze and itch of hay fever, the cough and wheeze of asthma, 
or the devastating top to toe rash, severe difficulty breathing and vascular collapse of 
anaphylaxis.  
FIGURE 1-1:  IGE PRIMED MAST CELL, ANTIGEN, DEGRANULATION 
 
Source: Dr P Smith. 
A delayed inflammatory response may often follow over the next several hours, resulting in 
the attraction of white cells into the tissues, and the ongoing inflammation characteristic of 
asthma, atopic eczema and allergic rhinitis. 
                                               
2
 While the word ‘allergy’ is often used by the lay community to represent any perceived adverse reaction to an 
environmental insult, it is important to bear in mind that the diagnosis of allergy is critically dependent on 
identifying the immune process involved in the allergic response. 
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FIGURE 1-2:  INFLAMMATION OF ECZEMA 
 
Source: Dr R Mullins. 
There are numerous forms of allergic disorders and comorbidity makes classification difficult.  
To accord with the estimates of prevalence in later sections, this section is structured to 
describe the symptoms and treatment of: 
 allergic rhinitis (hay fever) and conjunctivitis; 
 asthma; 
 chronic sinusitis; and 
 other allergies (including food, drug, sting allergies and anaphylaxis, among other 
things). 
1.2.1 ALLERGIC RHINITIS (HAY FEVER) AND CONJUNCTIVITIS 
Various sources from around the world (Wilson et al, 2006, Asher et al, 2006; Wist et al, 
2005; Hopper et al, 1995) suggest that allergic rhinitis3 and conjunctivitis are rare in infants 
but estimated to affect around one in six children aged 6-7 years, one in ten children aged 
13-14 years, 18% of those aged 15-34 years and 10% of older adults aged 35-54 years.4  
Symptoms generally persist for at least ten years, often longer (Greisner et al, 1998).  Typical 
complaints are those of a blocked and runny nose with clear mucus, itchy nose, sneezing 
                                               
3
 Non-allergic rhinitis is a term used to describe symptoms triggered by changes in temperature or humidity, or 
exposure to irritants such as cigarette smoke or perfume and occasionally dietary factors.  Pregnancy and some 
medications (particularly antihypertensive agents) can also cause nasal congestion.  There are various theories 
describing how this condition may arise, including an imbalance in the function of nerves that make mucous 
glands secrete fluid and which cause blood vessels to swell or contract and ‘subclinical allergy’ (Kaliner, 2007; 
Ciprandi, 2004; Garay, 2004). In some, non-allergic rhinitis is an inflammatory condition associated with 
eosinophilic inflammation of the nasal mucosa, and is associated with the development over time of chronic 
sinusitis, nasal polyps and the ‘aspirin triad’ (see Section 1.2.3). 
4
 Note these prevalence rates are somewhat different from the findings for Australia presented in Chapter 2. 
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and cough from post nasal drip, a symptom that can be mistaken for asthma cough.  Allergic 
rhinitis may masquerade as continuous or recurrent respiratory infection, frequent sore 
throats and may be complicated by sinusitis or otitis media.  Those with allergic rhinitis suffer 
more frequent and prolonged sinus infection, and treatment of the allergic component may 
reduce the risk (Cirillo et al, 2007).  Allergic conjunctivitis is usually accompanied by rhinitis, 
with red and itchy eyes, sometimes complicated by infective conjunctivitis due to frequent 
rubbing.  Seasonal symptoms are most commonly triggered by pollen exposure, with 
perennial rhinitis aggravated by exposure to house dust mite, mould spores or indoor pets 
(Plaut and Valentine, 2005; Van Hoecke and Van Cauwenberge, 2007). 
Lethargy, poor concentration and behavioural changes may arise as a result of persistent 
symptoms and poor quality sleep, and impact on learning in young children (Simons, 1996; 
Marshall and Colon, 1993: Gauci et al, 1993).  These factors may be aggravated by use of 
sedating (as opposed to the more expensive non-sedating) antihistamines as a cost saving 
measure (Nolen, 1997; Storms, 1997; Vuurman et al, 1993).  Since avoidance of exposure to 
the allergen is often not possible, the cornerstones of management revolve around the use of 
medication (one or more of topical nasal corticosteroids, oral or topical antihistamine nasal 
sprays or eyedrops) or immunotherapy, a specialist supervised procedure also known as 
‘desensitisation’ (Plaut and Valentine, 2005; Van Hoecke and Van Cauwenberge, 2007). 
Allergic rhinitis may predispose people to obstructive sleep apnoea, which results from 
collapse of the upper airways during sleep.  This results in reduced airflow, a drop in oxygen 
levels and disturbed sleep.  Factors predisposing to this condition include being overweight 
and having a blocked nose.  Nasal blockage is associated with more severe obstructive 
sleep apnoea, arousals during sleep and daytime sleepiness even when sleep apnoea is 
absent.  These abnormalities had been found to be reversible with surgical correction of 
anatomical abnormalities, topical nasal steroid sprays in patients with allergic rhinitis and 
reduced allergen exposure in patients with seasonal allergic rhinitis (Craig et al, 1998; 
University of Wisconsin Sleep and Respiratory Research Group, 1997; McNicholas et al, 
1982; Santos et al, 2006). 
Observational studies have linked chronic mouth breathing to structural changes of the face. 
Nasal obstruction due to allergic rhinitis or adenoid hypertrophy (the so-called ‘adenoid 
facies’) have been associated with a long and narrow face, a long narrow tongue, high 
arched palate, small lower jaw, over bite and cross bite and dental crowding and 
malocclusion.  Animal studies have demonstrated the development of similar abnormalities in 
experimental models.  Furthermore, some have been shown to be reversible when the 
obstruction has been relieved.  These observations have cosmetic and functional 
implications for patients with severe dental abnormalities (Spector, 1997; Settipane, 1999; 
Slavin, 1998).  Patients with allergic rhinitis also suffer from more frequent and prolonged 
respiratory infections, and asthma has been shown to be more difficult to control unless 
allergic rhinitis is also managed (Gaugris et al, 2006; Cirillo et al, 2007). 
Allergen immunotherapy is the only treatment that addresses the immune problem that 
causes allergies and can alter the natural history of disease.  This treatment involves 
administration of increasingly larger amounts of commercial allergen extracts with the aim of 
inducing tolerance to allergen with natural exposure.  This form of treatment has been found 
to be very effective at reducing the severity of allergic rhinitis and conjunctivitis and to have a 
beneficial impact in some patients with asthma.  There is also preliminary evidence that early 
use may also reduce disease progression from allergic rhinitis to asthma and reduce the 
development of new sensitisation.  Injection of allergen has been the traditional method of 
choice for several decades, but recent research has demonstrated the efficacy of high dose 
sublingual/oral immunotherapy, opening up this form of treatment to young children who 
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might otherwise not have been able to tolerate treatment by traditional methods (Pajno, 
2007; Canonica and Passalacqua, 2006; Saltoun, 2002).  This form of therapy has been 
shown to be cost effective compared to medication alone (Keiding and Jorgensen, 
2007; Petersen et al, 2005; Ariano et al, 2006). 
FIGURE 1-3:  ALLERGIC RHINITIS 
 
Source: Dr P Smith. 
 
FIGURE 1-4:  ALLERGIC CONJUNCTIVITIS 
 
Source: Dr R Mullins. 
1.2.2 ASTHMA 
Asthma is an inflammatory condition affecting the largest to the smallest airways.  The result 
is ‘irritable’ bronchial tubes that contract in response to many irritants.  In some cases, 
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scarring of the airways with loss of lung capacity may result (Olaguibel Rivera et al, 2007).  
Most patients will have allergic rhinitis or eczema as well and there is also a strong genetic 
component.  The major causes of airway inflammation are exposure to allergen (eg, dust 
mite, animals, cold air, mould spores or pollens), cigarette smoke and infections (the major 
trigger in infants).  This provides a rationale for recommending avoidance of such factors, 
and using medications that reduce airway inflammation when symptoms are regular or 
severe (Rimmer and Ruhno, 2006).  
Recurrent wheezing is common, affecting around one in three infants aged 3 years or 
younger, and one in ten children aged 6-7 years5 (Asher et al, 2006).  Allergy becomes a 
more important contributor as children age.  Children with other evidence of allergy 
(eg, eczema, allergic rhinitis or food allergy), those sensitised to inhalant allergen and those 
with more regular symptoms (between respiratory infections), are more likely to have 
persistent symptoms into adult life.  By contrast, those without evidence of allergy or frequent 
symptoms between respiratory infections, have a better prognosis, with around three 
quarters growing out of their symptoms by their adult years (Sears et al, 2003).  
United Airways disease is a concept linking the inflammation that occurs in the upper and 
lower airways in patients with allergic disease.  Around 80% of people with asthma suffer 
from rhinitis, and around one in four with rhinitis have asthma.  In some, asthma may be the 
dominant presenting complaint, whereas in others, asthma may be silent or subclinical, 
sometimes manifesting as complaints of lack of fitness or exercise-related complaints.  There 
is accumulating evidence that treatment of rhinitis may improve asthma control and reduce 
exacerbations (Rimmer and Ruhno, 2006; Foresi et al, 1996; Wade et al, 1993; Yawn et al, 
1999; Taramarcaz and Gibson, 2003; Passalacqua et al, 2000).  The principles of 
management are similar to those used in allergic rhinitis; allergen minimisation, use of 
medication and specific allergen immunotherapy.  Use of a written management plan and 
regular review have been shown to reduce disease exacerbation and hospital attendance 
(Bhogel et al, 2006). 
1.2.3 CHRONIC SINUSITIS, NASAL POLYPS AND THE ASPIRIN TRIAD 
Chronic sinusitis is an inflammatory condition of the soft tissue lining of the sinuses. 
Symptoms include nasal congestion, loss of sense of smell and taste, bad taste and bad 
breath, facial pain, sore teeth and purulent nasal discharge.  Sinus drainage pathways are 
often blocked, leading to secondary infection and many of the symptoms experienced.  Not 
all patients with chronic sinusitis are allergic, and the degree to which allergic mechanisms 
(as opposed to other factors) contribute to this condition is uncertain, as opposed to acute 
sinusitis, where infections are much more common in those with allergic rhinitis (Cirillo et al, 
2007).  Theories as to its cause include chronic bacterial or fungal infection.  There is no 
evidence that treatment specifically directed at allergies (allergen avoidance, 
immunotherapy) can alleviate the symptoms of sinusitis but it may relieve superimposed 
allergic symptoms (Dolor et al, 2001; Borish, 2002; Vining, 2006).  Approximately 30% of 
people are aspirin sensitive.  Most patients are co-managed by allergy/immunology 
specialists and ear nose and throat (ENT) surgeons. 
Nasal polyps are soft, jelly-like overgrowths of the lining of the sinuses that occur in around 
1 in 200 people.  They look like grapes on the end of a stalk.  Most develop by the age of 
40 years.  Polyps do not always cause symptoms.  As they often grow through the tunnel 
that connects the sinuses to the nose, the result is often a blocked nose.  More importantly, 
                                               
5
 Note these prevalence rates are somewhat different from the findings for Australia presented in Chapter 2. 
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they can block the tunnels connecting the nose to the sinus cavities.  Like water in a stagnant 
pond, this often leads to frequent sinus infections.  The cause is unknown, but chronic 
inflammation (from allergy or infection) may trigger polyps and make them grow faster, and 
come back faster after sinus operations.  Sometimes other conditions may occur with greater 
frequency in people with nasal polyps.  These include sinus infections, asthma and allergy to 
aspirin.  Options for management include sinus surgery to remove them (but 50% eventually 
recur), cortisone tablets to shrink their size (but this only offers temporary relief, and 
treatment is limited by side-effects) and topical steroid sprays to slow their growth (Blaiss, 
2005; Hissaria et al, 2006).  
The aspirin ‘triad’ (also known as Samter’s triad), is characterised by the development of 
adult onset asthma (not always allergic), nasal polyps and aspirin allergy.  People with this 
condition over-produce inflammatory chemicals known as leukotrienes.  These chemicals are 
made by white cells in the tissues, which then attract more white cells, which then produce 
more leukotrienes and so on.  Leukotrienes also cause mucus production in the lungs and 
make wheezing worse by triggering contraction of the muscle around the airways in the lung.  
They also promote inflammation in the sinuses and cause nasal polyps to grow faster, 
leading to blocked sinuses, the development of frequent sinus infections and the need for 
antibiotics and sinus surgery.  Even though these patients are allergic to aspirin, most can be 
made to tolerate high doses by starting off at a very low dose of aspirin initially and 
increasing it day by day.  Once a higher dose is reached (generally one to two tablets per 
day), there is reduced production of leukotrienes.  Studies following patients over ten years 
have shown the benefit of aspirin desensitisation to reduce asthma severity, the need for 
asthma medication, the rate of polyp regrowth, and the severity of sinusitis (Pfaar and 
Klimek, 2006). 
FIGURE 1-5:  CT SINUSES WITH POLYPS 
 
Source: Dr R Mullins. 
1.2.4 OTHER ALLERGIES 
1.2.4.1 ATOPIC ECZEMA AND CONTACT DERMATITIS 
One of the earliest signs of allergies is atopic eczema, affecting around one in five infants, 
reducing to around one in six children aged 6-7 years, one in ten children aged 13-14 years 
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and one in 14 adults (Asher et al, 2006)6.  Dry scaly skin, scratch marks, weeping vesicles 
and sores can not only disturb sleep, but may also result in long term changes in skin 
pigmentation and thickening, and is sometimes complicated by bacterial infection of the skin 
(Gold and Kemp, 2005; Katelaris and Peake, 2006).  A number of factors can make the 
symptoms of eczema worse – the warmth of bed clothes at night, winter heating, the use of 
soaps, swimming in chlorinated water, wearing wool or synthetics next to the skin, playing in 
sandpits, infection, allergen (such as dust mite or pet dander) and sometimes diet (Werfel et 
al, 2007).  While atopic eczema may appear in isolation, more commonly it is accompanied 
by allergic rhinitis and asthma, and in young infants with severe eczema, food allergy may 
occur in up to 30% of cases.  Severe eczema has a substantial effect on quality of life in the 
sufferer and their family, impacts on social functioning, influences career choices and may 
result in substantial out of pocket costs for families of young children.  Beattie and Lewis-
Jones (2006), studying a spectrum of chronic childhood diseases found that impact of 
allergic dermatitis on the health-related quality of life of children was greater than that from 
renal disease or cystic fibrosis. Measurements of the impact on mothers of having a child 
with eczema is greater than for that experienced with a child with deafness or insulin 
dependent diabetes (Kadyk et al, 2003; Jowett and Ryan, 1985; Housman et al, 2002; 
Faught et al, 2007; Kemp, 1999, Beattie and Lewis-Jones, 2006).  In children with moderate 
to severe atopic eczema, around 50% will have persistent symptoms into adult life (Williams 
and Strachan, 1998). 
FIGURE 1-6:  ATOPIC ECZEMA 
 
Source: Dr P Smith. 
Contact allergic dermatitis (contact dermatitis) develops after skin contact with external 
allergens.  A red, itchy and often blistering weeping rash develops, typically within a few days 
of contact with external allergens (Militello et al, 2006).  Over 2,000 contact allergens have 
been identified, of which nickel, plants, perfumes, glues, dyes and cosmetic preservatives 
are the most common.  Management involves identification and avoidance of the cause, and 
use of medication such as topical or oral corticosteroids if accidental exposure occurs. 
Contact allergic dermatitis is a major occupational problem in some industries, such as those 
involved in the food industry, health professions and hairdressing (eg, latex allergy) (Amado 
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 Note these prevalence rates are somewhat different from the findings for Australia presented in Chapter 2. 
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and Taylor, 2006; Biebl and Warshaw, 2006; Dhir, 2006; Khumalo et al, 2006; Noonan and 
Moyle, 2005; Doutre, 2005; Belsito, 2005).  Contact with airborne plant-derived allergens can 
also cause dermatitis.  This is commonly known as ‘Australian bush dermatitis’, ‘ragweed 
dermatitis’ or ‘weed dermatitis’.  Dermatitis often occurs after being outside on windy days in 
the warmer months of the year, when wind-blown allergens come into contact with exposed 
areas of skin over the face, eyelids, sides of neck and ‘V’ area of the neck and upper chest.  
There is usually a sharp line between affected areas and normal skin protected by clothing. 
FIGURE 1-7:  CONTACT ALLERGIC DERMATITIS 
 
Left:  Contact dermatitis due to eye drops.              Right: Shoe dermatitis due to colophony allergy. 
Source: Dr R Mullins. 
1.2.4.2 URTICARIA /ANGIOEDEMA 
Urticaria (hives, nettle rash) is a common condition characterised by itchy swelling of the 
skin.  The lifetime incidence is estimated to be approximately one in six, with current 
prevalence estimated at one in one thousand.  Infection is one of the most common triggers 
for symptoms, particularly in young children.  Allergic reactions to food, medication or insect 
stings may also trigger short-lived episodes of hives, but in most cases, no cause is 
identified.  Occasionally, urticaria is a recurrent problem that reappears throughout life, or a 
chronic condition that persists for many years (Greaves, 2000).  In recent years, evidence 
has arisen suggesting that chronic urticaria may be an autoimmune disease (Gratten, 2004).  
The mainstay of treatment is use of non-sedating antihistamines, with the addition of 
corticosteroids or immunosuppressive medication in refractory cases (Powell et al, 2007; 
Zuberbier et al, 2006).  Chronic disease is associated with sleep disturbance, reduced 
productivity, psychological morbidity and changes in quality of life comparable to that 
experienced in ischaemic heart disease (Poon et al, 1999; Beattie and Lewis-Jones, 2006).  
Severe symptoms frequently trigger attendance at hospital accident and emergency facilities, 
and resulted in 1,977 admissions to Australian hospitals in the 2004-05 financial year.  Use 
of cheaper sedating antihistamines (as a cost-saving measure) is associated with sedation, 
impaired motor skills and increased risk of work-related and motor vehicle accidents (Nolen, 
1997; Storms, 1997). 
Angioedema is a related condition of the deeper parts of the skin, where swellings can also 
be painful, and sometimes involve the tongue or throat, causing difficulty breathing.  Causes 
include infection, medications (specifically angiotensin converting enzyme inhibitors and non 
steroidal antiinflammatory drugs) and less commonly, hereditary angioedema due to deficient 
C1 inhibitor enzyme deficiency or dysfunction (Frigas and Park, 2006).  Upper airway 
swelling (with or without difficulty breathing) may also prompt attendance at emergency 
facilities, is a source of anxiety and may sometimes be mistaken as anaphylaxis. 
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FIGURE 1-8:  URTICARIA 
 
Source: Dr R Mullins. 
FIGURE 1-9:  ANGIOEDEMA 
 
Source: Dr P Smith. 
1.2.4.3 STINGING INSECT ALLERGY AND BITES 
Local itch and swelling are very common from insect stings, such as those inflicted by honey 
bees, wasps and ‘Jack Jumper’ ants (JJAs).  They usually settle within a few days.  Swelling 
can sometimes be severe, and can last up to a week.  Fortunately, only a small proportion go 
on to develop generalised allergic reactions (such as hives all over) or more serious allergic 
reactions (anaphylaxis) with dangerous features, such as difficulty breathing or light 
headedness or loss of consciousness due to low blood pressure (vascular collapse) (Golden, 
2007).  
Population surveys estimate that approximately 1% of the population in endemic areas have 
experienced a potentially dangerous allergic reaction to JJA stings and that between 1% and 
2.7% have experienced allergic reactions to honey bees (Brown et al, 2003, Douglas et al, 
1998; Roberts-Thomson et al, 1985; Stuckey et al, 1982).  JJA anaphylaxis is a uniquely 
Australian problem.   
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Allergic reactions to wasps are considered to be less common.  Deaths from sting-related 
anaphylaxis in Australia are estimated at approximately 3.25 per year (bees 2; wasps 1; JJA 
0.25 – Brown et al, 2001,2003a; McGain and Winkel, 2002).  Management of these patients 
involves strategies to reduce the risk of accidental exposure, provision of emergency 
medication (injectable adrenaline, EpiPen) and the commencement of specific 
immunotherapy to ‘switch off’ the allergy and reduce the risk of further reactions (Golden, 
2007; Brown et al, 2003b), shown to improve quality of life in those with this condition (Oude 
Elberink and Dubois, 2003).  Commercial extracts of honey bee and wasp venom are 
available as registered products for treatment of affected patients.  While level 1 evidence of 
effectiveness of JJA venom immunotherapy has been demonstrated in Australian studies 
(Brown et al, 2003c), availability of treatment has been hampered by the lack of funding to 
make such treatment more widely available, and for research studies to examine simplified 
treatment regimens. 
FIGURE 1-10:   JACK JUMPER ANT 
 
FIGURE 1-11:  PAPER WASP 
 
 
Source: Dr R Mullins. 
Mosquitoes and ‘March flies’ can cause nasty bites, but allergic reactions are exceedingly 
rare.  One of the most common causes of severe irritating reactions follow contact with 
caterpillars.  The spines projecting from caterpillars (or their dormant pupae on trees or in 
letter-boxes) can cause severe local irritation and pain from released toxins.  Local pain and 
sores may develop from spider bites as well.  Allergic reactions to tick bites also occur 
usually with local swelling and itching only, but occasional life-threatening reactions to ticks 
have been reported, typically soon after the tick is removed (Brown and Hamilton, 1998).  
Most bites result in minor local swelling that settles within a few days.  Occasionally, large 
hot local swellings that last several days to a week may occur, and can sometimes be 
mistaken for secondary infection.  Rarely, local weeping blisters may occur at and around the 
bite site, which can be difficult to control and be distressing, particularly in young children. 
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FIGURE 1-12:  BLISTERING REACTION TO INSECT BITES 
 
Source: Dr R Mullins. 
1.2.4.4 FOOD ALLERGY AND ASSOCIATED SYNDROMES 
Food allergy is estimated to affect 6% of young children and 3-4% of adults7 (Milss et al, 
2007; Venter et al, 2006a,b; Osterballe et al, 2005; Sicherer and Sampson 2006).8  Recent 
studies from the UK and USA suggest that peanut allergy has doubled in the last five years 
(Grundy et al, 2002; Sicherer et al, 2003).  Admissions to hospital with anaphylaxis (which 
have been mainly attributed to food allergy) have also doubled in the last decade in both 
Australia and the UK, particularly in young children (Gupta et al, 2007; Mullins, 2007).  The 
most common causes of food allergy in children are cow’s milk, hen’s egg, peanut/tree nuts 
and sesame seeds in young children.  While the majority of those allergic to milk, egg, wheat 
or soy outgrow their allergies by school age, those allergic to nuts/peanuts, seeds or seafood 
usually have persistent allergy.  
The most common symptoms in infants are urticaria and/or vomiting within two hours of 
ingestion.  In adults, a more diverse range of foods can trigger symptoms, but the majority 
are triggered by peanut, tree nuts, sesame seed or seafood (Allen et al, 2006; Sicherer and 
Sampson, 2006; Nowak-Wegrzyn and Sampson, 2006).  A diagnosis of food allergy has a 
significant effect on quality of life in children and their parents, comparable on formal 
measurement with having a child with insulin dependent diabetes.  The source of stress is 
related more to perceptions of risk than actual episodes of allergic reactions, and the need 
for planning for outings, school camps, preparation of special meals and the need to liaise 
with other caregivers such as school and preschool staff (Marklund et al, 2004,2006,2007; 
Bollinger et al, 2006; Cohen et al, 2004; Avery et al, 2003; Sicherer et al, 2001; Hu et al, 
2005).  In adults with food allergy and anaphylaxis, psychological morbidity (including anxiety 
disorder and panic attacks) has been associated with episodes of anaphylaxis, which are 
frequently recurrent despite precautions to avoid the trigger (Sampson et al, 2006; Mullins, 
2003). 
                                               
7
. In a survey of 232 childcare centres and preschools in the ACT and central Sydney in 2006 (13,573 children 
enrolled), 6.6% were reported to have food allergy (2.1% allergic to peanut), see Loblay R et al (2006). 
8
 In Australia, a questionnaire-based study of 4,173 South Australian school children aged 3-18 years (published 
in 2000) estimated an incidence of food allergy and food-induced anaphylaxis of 1.3% and 0.4% respectively 
(Boros et al, 2000). 
 The economic impact of allergic disease 
 
 
 
14 
Oral allergy syndrome (pollen-food syndrome): Around  one if ten people with seasonal 
allergic rhinitis or conjunctivitis will develop itch and irritation of the tongue, mouth and throat 
after ingestion of some fresh fruits and vegetables, known as Oral Allergy Syndrome 
(Mullins, in press). The majority of patients are allergic to cross-reactive proteins common to 
some pollens and foods.  Cooking normally destroys these protein allergens, so that the 
same food when cooked is often tolerated.  While it is generally a benign disorder, 
angioedema or even anaphylaxis may occasionally occur, particularly if ingestion of a large 
amount of food allergen is followed by vigorous exercise.  The mainstay of therapy is 
avoiding the food or cooking it well.  Patients who are unable to tolerate fruit or vegetables in 
an uncooked form are forced to rely on well-cooked food in conjunction with vitamin 
supplements.  Such people usually require advice from a specialist dietitian.  There is 
preliminary evidence that this condition is becoming increasingly common in adults, a not 
unexpected finding when one considers the recent rise in allergic rhinitis (Egger et al, 2006; 
Mari et al, 2005; Yagami, 2002; Sloane and Sheffer, 2001; Bohle, 2007; Caballero and 
Martin-Esteban, 1998). 
Eosinophilic oesophagitis is an inflammatory condition of the oesophagus, where food 
allergy may play a causative role in the majority of patients.  In children, this condition tends 
to present as severe oesophageal reflux unresponsive to conventional medications, and 
adults can have a similar presentation, often accompanied by choking episodes and 
dysphagia of solid foods or even food impaction.  In recent reported studies, some groups 
claimed that a combination of skin prick testing and food patch testing with staple foods, will 
identify potential food allergens which, if avoided, will result in a clinical improvement.  This 
condition appears to not resolve.  This is a complex medical condition requiring the advice of 
gastroenterologist, allergy specialists and dieticians. If suspected, referral to a 
gastroenterologist is recommended in the first instance to confirm the diagnosis, then an 
allergy specialist if confirmed.  Therapy involves the use of diet manipulation, anti-reflux 
medication, the use of ‘swallowed’ asthma corticosteroids eg, Singulair (montelukast) and 
sometimes dilatation (stretching) of the constricted oesophagus (Noel et al, 2004; Markowitz 
et al, 2003; Lucendo et al, 2004). 
Delayed immune-mediated reactions to food:  The majority of allergic food reactions in 
infants result in immediate symptoms (eg, acute urticaria, vomiting or asthma).  Occasional 
children, however, do not have reactions that occur quickly.  Instead, delayed immune 
reactions start after several hours or days, most commonly in response to dairy products, soy 
or wheat (Allen et al, 2006; Sicherer and Sampson, 2006; Nowak-Wegrzyn and Sampson, 
2006).  Patients generally present with one or more of severe atopic dermatitis/eczema, 
chronic diarrhoea (sometimes accompanied by blood), failure to thrive, or severe reflux of 
food or formula.  Symptoms occur due to inflammation of the skin or gut, and result from 
attraction of white cells from the blood into the tissues.  Routine allergy testing is often 
negative, making diagnosis more difficult.  Diagnosis usually rests on the history of possible 
reactions to food, and responses to food withdrawal and re-challenge.  Most of these delayed 
reactions resolve by the age of 3 years.  At times, even small amounts of food allergen 
passing through breast milk can aggravate atopic eczema or gut symptoms.  Allergy testing 
of the infant may or may not be positive, depending on the mechanism of the sensitivity 
(immediate versus delayed).  If one of these conditions is suspected, specialist advice is 
indicated. 
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FIGURE 1-13:  CHILD WITH FOOD ALLERGY 
 
Source: Dr P Smith. 
Celiac disease is considered to be an autoimmune disorder resulting from exposure to 
dietary gluten within cereals, such as wheat, rye and barley.  Previously considered to be a 
rare disease, population studies suggest a prevalence of approximately 1% of the population.  
Symptoms result from inflammation of the upper bowel, resulting in malabsorption of 
nutrients and presentation with fatigue, anaemia, iron deficiency and osteoporosis as well as 
the more classical symptoms of diarrhoea and weight loss.  Management involves 
confirmation of the diagnosis by specific serological testing confirmed by biopsy of the 
duodenum and lifelong avoidance of dietary gluten (Monsuur and Wijmenga, 2006; NIH 
Consensus Development Conference on Celiac Disease, 2004; Craig et al, 2007; Kwon and 
Farrell, 2006). 
1.2.4.5 ADVERSE REACTIONS TO MEDICATION 
Allergic reactions to a large number of medicines can occur.  Reactions to pain killers or 
arthritis tablets (such as aspirin, ibuprofen, naproxen) and antibiotics are the most common, 
but reactions have been described to many other medicines, including some herbal remedies 
such as echinacea, Royal Jelly and chamomile (Mullins RJ and Heddle R, 2004).  Severity 
may range from mild rashes through to asthma and potentially life-threatening anaphylaxis.  
While most adverse reactions to medication are due to side effects or dose-dependent 
toxicity, rather than immune-mediated reactions, accurate diagnosis of drug-related allergy 
(where the immune system is involved) is essential (Romano and Demoly, 2007; Thien, 
2006).  Unnecessary avoidance of some medications (such as penicillin) may impede 
necessary treatment, may result in selection of more expensive medication instead or, in 
some cases (such as patients wishing to enter the Defence Forces), influence their career 
options.  Conversely, lack of appreciation of the concept of cross-reactivity may expose the 
patient to the unnecessary risk of re-exposure.  
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Adverse reactions to drugs are common in hospitals and are a very significant and increasing 
cause of morbidity and mortality responsible for one-fifth of in-hospital adverse events 
(Leape et al, 1991). Many of these reactions are due to allergic drug reactions. In a recent 
large epidemiological survey from the UK, drug sensitivity accounts for 47% of all mortality 
due to generalised allergic shock (anaphylaxis)  and anaesthetic allergy accounts for 19% of 
total anaphylaxis deaths, nearly half of all drug-related deaths (Pumphrey et al, 2004). 
Allergic reactions to antibiotics and anaesthetics are one of the most common causes of drug 
reactions occurring in hospitals with very significant adverse consequences with respect to 
length of stay and patient outcomes (Classen et al, 1997). 
Aspirin allergies are estimated to occur in 1% of people overall, but in up to 10% of those 
with asthma (Vally et al, 2002).  Allergic reactions to medicines are no more likely to occur in 
people with other allergies (such as hay fever or eczema) than anyone else in the general 
population.  While there are reports of some families who have many people with allergic 
reactions to medicine, most drug allergies are not inherited.  
In general practice surveys, allergic reactions to medication are estimated to have occurred 
in up to 1% of patients in the preceding six months.  By contrast, allergic reactions to X-ray 
contrast agents and general anaesthetics (approximately one in 10,000 exposures) and 
vaccinations (approximately one in a million exposures) are relatively rare (Cashman et al, 
1991; Fisher and Baldo, 1993; D’Souza et al, 2000).   
When evaluating patients with possible drug allergy, the circumstances surrounding the 
episode are analysed to help determine the likelihood of allergy being responsible. 
Unfortunately, the circumstances of such reactions are not always clear from the history, 
making evaluation of possible ‘drug allergy’ a complex process.  Assessment is complicated 
by the fact that allergy testing is of predictive value for only a limited number of IgE-mediated 
reactions to some medications such as penicillin, some other antibiotics and anaesthetic 
agents.  Testing for some drug allergies can be expensive (eg, penicillin minor determinants), 
and often requires hospital-based allergy services for their performance.  For other 
medicines, such as painkillers (eg, aspirin) or tablet-only antibiotics, there is no accurate test 
to confirm the presence of allergy, and there is no validated test to help prove or exclude 
delayed hypersensitivity reactions.  
When it is important to prove or disprove sensitivity, deliberate challenge is sometimes 
required to determine the presence or absence of drug allergy.  This is normally performed 
under medical supervision, using small doses first.  Since some adverse reactions may be 
serious, the availability of specialised hospital-based allergy units is essential, even if initial 
evaluation is performed in community-based allergy/immunology practices. 
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FIGURE 1-14:  ADVERSE DRUG REACTION 
 
Source: Dr R Mullins. 
 
1.2.4.6 LATEX ALLERGY 
Natural latex or rubber is a natural product obtained from the sap of the Havea tree.  
Preservatives, stabilisers and antioxidants may be added during manufacture to assist its 
stability.  It may be dipped into a mould, then heated and dried.  A dry powder lubricant 
(usually cornstarch) is often added to prevent the rubber surfaces from sticking together.  
Allergic reactions can occur to latex protein as well as the chemical preservatives added to it, 
but not to cornstarch.  Allergic reactions to latex may be divided into two groups; immediate 
hypersensitivity (mediated by IgE) and contact allergic dermatitis (Katelaris, 2006).  Around 
1% of the general population is latex allergic, whereas up to 7% of health care personnel 
have evidence of sensitisation to latex, with a lower proportion being clinically sensitive. 
 With immediate hypersensitivity, reactions can occur within minutes and include 
hives or swollen lips or face at the site of contact.  Others will develop irritation after 
wearing a condom, having a Pap smear taken or after dental treatment.  Allergic rhinitis 
and asthma may occur, typically in an occupational (usually hospital) setting where 
frequent changing of gloves can result in suspension of fine latex particles in the air.  
More serious reactions can occur.  In very sensitive people, rapid absorption of latex 
through moist surfaces such as the mouth, nose, throat, vagina or rectum can result in 
difficulty breathing, a drop in blood pressure or even shock and anaphylaxis.  Those at 
greatest risk are health care workers, and those with a history of frequent latex 
exposure, such as patients with frequent surgery, particularly in childhood (Bousquet et 
al, 2006). 
 Contact allergic dermatitis is a reaction to the chemicals added to rubber during 
manufacture, but only occasionally to latex proteins.  Rough, scaly and sometimes 
weeping rashes can develop within hours or days of contact.  As with irritant dermatitis, 
absorption of latex through damaged skin increases the risk of later developing 
immediate and delayed contact allergy with continued exposure.  
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Proteins in latex are present in some foods as well.  Latex-allergic people sometimes find 
that some foods cause an itchy mouth or throat swelling.  The most common foods described 
are banana and avocado and sometimes kiwi fruit, passionfruit, plums, strawberry, tomato or 
other fruits.  Symptoms arise from cross-reactive allergic responses to protein allergens of 
similar structure present in latex, as well as other plants such as the fruit and vegetables 
mentioned above. These foods do not have to be avoided routinely – just if they cause 
problems. 
Management of established disease involves avoidance and substitution of non-latex 
containing gloves in those with occupational exposures or in those undergoing medical 
procedures.  Use of non-latex containing barrier contraceptives is also necessary.  The 
provision of a MedicAlert bracelet is essential, in case a patient requires urgent medical care 
and is unable to warn health care workers of their sensitivity.  There have been studies of 
immunotherapy to latex, but this is not established routine practice in this condition.  
Universal adoption in the workplace of low-protein, powder-free gloves and avoidance of 
latex in non-clinical areas (eg, cleaning, food preparation) has been shown to dramatically 
reduce exposure and the risk of developing sensitisation LaMontagne et al, 2006).  
1.2.4.7 OCCUPATIONAL ALLERGY 
Occupational allergy is defined as the presence of allergy-related symptoms caused or 
aggravated by occupational exposure.  Given the frequency of allergic disorders and their 
increasing prevalence in Australia, identification of avoidable environmental triggers is an 
important part of management (Pedan and Bush, 2007; James and Crespo, 2007; Pacheco, 
2007; Brant, 2007; Henneberger, 2007; Thyssen et al, 2007; Beach et al, 2007; Dhir, 2006).  
Examples of occupational allergy include: 
 contact dermatitis to preservatives in latex gloves – most commonly in health care 
workers; 
 occupational asthma and contact allergic dermatitis from hairdressing chemicals in 
hairdressers, and from flours and enzymes in bread-derived products; 
 occupational asthma and rhinitis from animal laboratory workers (and sometimes 
anaphylaxis); 
 contact allergic reactions to food in chefs and food handlers, sometimes leading to 
secondary food allergy and anaphylaxis; 
 contact allergic dermatitis to glues, perfumes, metals, garden plants, dyes and other 
chemicals – conditions affecting multiple industries; and 
 other occupational asthma from multiple triggers including food proteins in processing 
plants, detergent enzymes, aluminium salts, paint products (such as isocyanates), 
plastics industries, wood dust, insects (such as storage mites, worms and flies), 
printing inks and soldering fumes. 
An accurate identification of occupational triggers forms not only the basis of sound clinical 
management, but also forms the basis of occupational health and safety practices, and has 
economic, social and legal consequences.  Furthermore, early identification of an 
occupational trigger may allow changes in work practice or occupation that may present as 
work-related problems from becoming (in some instances) a permanent disability that 
persists even after the triggering agent is removed.  
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1.2.4.8 ANAPHYLAXIS 
Anaphylaxis is a serious allergic reaction, resulting from massive release of inflammatory 
mediators, resulting in one or more of difficulty breathing or vascular collapse.  The most 
common triggers in infants and young children are foods, with drug, latex and stinging insect 
allergy being relatively uncommon.  Poorly controlled asthma is the main risk factor for fatal 
anaphylaxis.  The major triggers for anaphylaxis in adults are peanut, tree nuts, seafood and 
allergic reactions to medication and stinging insects.  Death may occur from low oxygen 
levels due to upper airway swelling, constriction of airways in the lung (bronchospasm) and 
mucus plugging, and/or shock due to massive dilation of blood vessels, leakage of fluid from 
the bloodstream into the tissues and reduced cardiac function.  The cornerstones of initial 
management are placing the patient in the supine position, intramuscular adrenaline into the 
lateral thigh, intravenous fluids, support of the airway and ventilation, and supplementary 
oxygen (Sicherer and Leung, 2006; Brown, 2005,2006; Simons, 2006; Sicherer and Simons, 
2007; Pongracic and Kim, 2007; Brown et al, 2006). 
FIGURE 1-15:  SEVERE UPPER AIRWAY SWELLING IN CASE OF FATAL ANAPHYLAXIS 
 
 
Source: Dr S Brown. 
Estimates as to the incidence of new cases of anaphylaxis are approximately one new case 
per 5,000 people per year, although even this may be an underestimate (Lieberman et al, 
2006)9.  Evidence from the UK and Australia has shown evidence of an increased incidence 
of anaphylaxis, with a doubling in admissions to Australian hospitals with this diagnosis over 
the last 12 years, with a disproportionate five-fold increase in young infants less than 5 years 
of age (Gupta et al, 2007; Mullins, 2007).  Specialist evaluation is recommended after a 
diagnosis of possible anaphylaxis, to identify or confirm the cause, to provide education on 
appropriate avoidance strategies, to assist drafting an emergency action plan and to advise 
whether immunotherapy (eg, for venom allergy) is appropriate.  Such strategies have been 
                                               
9
 A recent study of children treated in a Brisbane accident and emergency department estimated a much higher 
prevalence of 8 cases per 10,000 children aged less than 16 years (Braganza et al, 2005). Many of those who 
have experienced anaphylaxis will have further episodes; an average of once every two years overall, with 
potentially dangerous allergic reactions once every ten years (Mullins, 2003).  The relatively low admission rate to 
Australian public hospitals with anaphylaxis (80.3 per million people per year) is the tip of the iceberg in terms of 
incidence as the majority of cases are treated in accident and emergency departments and discharged. 
Furthermore, Australian studies have also shown that up to 40% patients do not seek medical assistance during 
an episode (Mullins, 2003). 
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shown to reduce the rate of relapse and hospital admission (Kim et al, 2005; Choo and 
Sheikh, 2007; Kapoor et al, 2004). 
Psychological morbidity and negative impact on quality of life is common in patients and their 
caregivers, and some require emotional support and counselling as well as medical advice 
(Mullins, 2003; Elberink, 2006).  Deaths from anaphylaxis are relatively rare and, while 
attempts have been made to predict those at greatest risk, many of those described as 
having had fatal anaphylaxis have never had a serious allergic reaction in the past.  
Provision of a written management plan and patient education in use of EpiPen has been 
shown to reduce anxiety and the rate of hospital presentation (Greenberger et al, 2007; 
Pumphrey and Gowland, 2007).  
FIGURE 1-16:  EPIPEN USE  
 
Source: Dr P Smith. 
1.2.4.9 HYPEREOSINOPHILIA SYNDROMES 
Hypereosinophilia is defined at the presence of sustained high blood levels of white cells 
known as eosinophils.  Minor elevations are common in various allergic disorders such as 
asthma allergic rhinitis and atopic eczema.  Sustained high levels, however, pose the risk of 
damage to the lining of the heart and nerve endings, regardless of the cause of the elevation, 
because of the presence of toxic granules within the eosinophil, which may release their 
contents into the tissues (Fletcher and Bain, 2007; Antoniu, 2006; Roufosse et al, 2006; 
Bain, 2004).   
Causes of hypereosinophilia include drug allergy, parasitic disease (rare in Australia), 
malignancy (lymphoma), vasculitis, some autoimmune disorders, eosinophilic leukaemia and 
the idiopathic hypereosinophilia syndromes.  Clinical manifestations may present as 
recurrent urticaria/angioedema, through to sinus disease with nasal polyps, asthma-like 
symptoms, lung infiltrates presenting with pneumonia-like symptoms (but unresponsive to 
antibiotics), recurrent abdominal pain, neuropathies (nerve damage) and cardiomyopathy 
resulting from damage to the heart.  More serious cases may behave like a leukaemia even 
in the absence of malignancy. Treatment centres around immunosuppressive medication 
such as corticosteroids, cytotoxic and cancer chemotherapy agents, and interferon, as well 
as novel agents such as imatinib (Antoniu, 2006). 
1.3 DIAGNOSIS OF ALLERGIC TRIGGERS – ALLERGY 
TESTING 
Allergy testing involves the detection of IgE antibodies directed against environmental 
allergens, either by skin prick testing (SPT) or blood allergy testing.  This helps prove or 
 The economic impact of allergic disease 
 
 
 
21 
disprove the presence of allergy as a contributor to symptoms and facilitates the identification 
of avoidable triggers.  
Skin prick testing:  SPT is most commonly performed on the forearm, although the back is 
sometimes used.  After first cleaning with alcohol, a drop of commercially-produced allergen 
extract is placed onto a marked area of skin.  Using a sterile lancet, a small prick through the 
drop is made.  This allows a small amount of allergen to enter the skin, where it comes into 
direct contact with tissue mast cells. If a person is sensitised, release of mast cell mediators 
results in the appearance of a small mosquito-like lump.  Results are recorded 15-20 minutes 
after application and are best expressed in terms of the absolute wheal and flare size in 
millimetres.  Testing is slightly uncomfortable, but usually well tolerated, even by small 
children. 
Intradermal testing: Intradermal skin testing (IDT) is also used under some specific 
circumstances to detect allergen specific IgE. A small amount of very dilute allergen is 
injected into the upper layers of the skin, normally using a diabetic insulin syringe. It is a 
more uncomfortable test than SPT and so very rarely used in children. While it is more 
sensitive, is more likely to lead to false positive and clinically irrelevant results. For this 
reason, it is mainly used for evaluation of patients with sensitivity to antibiotics or insect 
venom. 
FIGURE 1-17:  SKIN PRICK TESTING SHOWING THE DEVELOPMENT OF WHEALS AFTER 15 MINUTES 
 
Source: Dr R Mullins. 
Blood allergy testing (ImmunoCap, Immulite, RAST):  Blood allergy testing is also 
available for a selected range of allergens, and is most commonly used when SPT is not 
possible (eg, a patient taking antihistamines, or someone with severe atopic eczema) or 
inadvisable (eg, pregnancy). The usefulness of testing is limited by: 
 the limited number of food allergen tests that have been validated for clinical relevance; 
 the limited number of allergens currently available; and 
 the complexities of current Medicare funding arrangements for the number of tests that 
are subsidised for any one blood collection. 
Patch testing is frequently used in the evaluation of patients with non-IgE mediated allergic 
reactions, most commonly contact allergic dermatitis.  Commercial extracts of allergen are 
applied under occlusion to the skin for a few days.  The presence of a patch of dermatitis 
under the allergen extract indicates sensitivity.  This testing is sometimes used for the 
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evaluation of selected patients with suspected delayed immune reactions to food or 
medications. 
FIGURE 1-18:  PATCH TESTING 
 
Source: Dr R Mullins. 
Alternative testing:  A number of unproven tests have been proposed for evaluating allergic 
patients including cytotoxic food testing, kinesiology, Vega testing, pulse testing, reflexology 
and hair analysis. There is no scientific rationale for these methods. Results have not been 
reproducible when subject to rigorous testing and do not correlate with clinical evidence of 
allergy.  No Medicare rebate is available and their use is not advised.  Issues surrounding the 
use of such tests and lack of evidence of benefit has been examined in an ASCIA Position 
Statement: http://www.allergy.org.au/pospapers/unorthodox.htm (Beyer and Teuber, 2005). 
Allergic disorders are chronic conditions that can impact negatively on quality of 
life, cause significant discomfort, affect sleep, and impair learning, memory and 
behaviour in children (Santos et al, 2006; Baiardini et al, 2006a,b; Chamlin, 
2006).  In children with severe food allergy, management in the community is 
complex and has the potential to cause significant anxiety within affected families 
regarding care in schools, risk of death and the need or otherwise for injectable 
adrenaline (Hu et al, 2005).  For affected adults, allergic disorders lead to 
impaired quality of life, absenteeism from work, reduced productivity and can be 
a substantial financial burden.  Most patients with allergic disorders have 
associated comorbidities, resulting in the need for multiple medical interventions.  
The strong genetic component in allergic disorders often results in several family 
members consuming multiple medications simultaneously for several years 
(Blaiss, 2000). 
1.4 MORTALITY 
Allergies represent a group of chronic disorders in which morbidity rather than mortality is 
predominant.  The major sources of mortality are asthma, and less commonly anaphylaxis, 
drug allergy and complications arising from surgical care of sinusitis. Some deaths from 
anaphylaxis may also be erroneously classified as being due to asthma fatalities (Gupta et 
al, 2007) and even anaphylactic deaths may not be recognised (and thus be underreported) 
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given the lack of any specific features (Schwartz et al 1988, 1995; Low and Stables, 2006; 
Pumphrey and Roberts, 2000).  Australian Institute of Health and Welfare (AIHW)10 mortality 
data indicate 68 anaphylactic deaths over the period 1997 to 2004.  A further 18 deaths over 
the same period have been attributed to adverse drug reactions, of which an uncertain 
proportion may have had an allergic origin, and so may or may not have been counted in the 
anaphylactic deaths described above.  In 2004, 318 people died from asthma (ABS 2006d). 
Available data on the relative risk of mortality for allergy-related conditions have been 
collected and combined according to their contribution to the overall prevalence of allergy.  
This makes it possible to estimate a combined relative risk of mortality due to allergy. 
 A relative risk (RR) of mortality due to asthma of 1.03 was calculated by comparing the 
proportion of deaths in the asthma population, sourced from the AIHW publication 
Asthma in Australia 2005, with the deaths in the general population (sourced from the 
ABS).  This RR of 1.03 was then applied to asthma and allergic rhinitis. 
 A RR of 1.0 for sinusitis was sourced from the AIHW burden of disease publication 
(Mathers et al, 1999)11.  
 Combining these two data with their contribution to the overall prevalence of allergy 
(Section 2.1) provides an estimated RR of 1.02 for other allergies. These estimates 
were triangulated against other available data, including the AIHW anaphylaxis data 
above. 
Overall, this amounted to a RR of 1.02 for all allergy.  This RR was then applied to 
prevalence of allergy in 2007 to estimate that there are around 586 deaths due to allergy in 
2007.  
 
                                               
10
 AIHW special data request. 
11
 That is, the relative risk of death for someone with chronic sinusitis is modeled as being the same as for the 
general population at large. 
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2. PREVALENCE 
Prevalence refers to the number of people with allergic disease in a population at 
a given point or over a certain period of time (one year prevalence is estimated in 
this study). 
Allergies have emerged as a major public health problem in developed countries during the 
twentieth century, with particular impacts on children and young adults (Kemp et al, 2006; 
Linneberg, 2005; Isolauri et al, 2004).  Allergies – especially the ‘big three’ of allergic rhinitis, 
asthma and sinusitis - affect millions of Australians.  Australia and New Zealand have among 
the highest prevalence of allergic disorders in the developed world, with over 20% of 13-14 
year olds having asthma-like symptoms, compared to less than 5% of children in Eastern 
Europe, some Asian and African countries (Asher et al, 2001,2006; Robertson et al, 2004).  
According to public sector sources, four of the top ten most common long term self-reported 
illnesses in youth aged 12-24 years in Australia are allergic rhinitis (‘hay fever’ – 14%), 
asthma (9%), chronic sinusitis (5%) and undefined allergy (3.5%) (NSW Health, 1997; AIHW, 
2007). 
In addition to the prevalence reported for specific allergic conditions from the international 
literature (eg, Robertson et al, 1998; ISAAC Steering Committee, 1998) and Australian 
studies (eg, Wilson et al, 2006; Robertson et al, 2004; Downs et al, 2001) as presented in 
Chapter 1, Access Economics has investigated overall prevalence of allergies, by age and 
gender, using data from the Australian Bureau of Statistics (ABS).  Current prevalence is 
presented in Section 2.1 while Section 2.2 looks at trends in the changing prevalence of 
allergies and Section 2.3 makes projections of prevalence to 2050. 
2.1 CURRENT PREVALENCE OF ALLERGIC DISORDERS 
The National Health Survey (NHS) (ABS, 2005) reports that in 2005 there were over three 
million cases of allergic rhinitis, over two million cases of asthma and over one million cases 
of chronic sinusitis.  Additionally, there are a host of minor allergies that collectively 
accounted for another million cases (Table 2-1). 
TABLE 2-1:  PREVALENCE OF ALLERGY-RELATED CONDITIONS BY TYPE (CASES), AUSTRALIA, 
2005 
Condition Cases (millions) 
Allergic rhinitis 3.17 
Asthma 2.01 
Chronic sinusitis 1.82 
Other allergies 1.04 
Total cases 8.04 
Source:  ABS (2005). 
 The NHS sought self-diagnosis from respondents for each of the four categories in 
Table 2-1 above (see Appendix B for relevant details from the survey questionnaire).  
The categories “asthma” and “chronic sinusitis” over-estimate allergies, as these 
include non-allergic asthma and non-allergic sinusitis.  This report estimates the 
proportions of such conditions attributable to asthma from attributable fractions 
provided by ASCIA (see below).   
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 Where respondents gave further details on “other allergies”, if the allergic conditions 
were organ-specific, the NHS includes them under “other diseases” for those organs.  
For example, “other eye diseases” contains both allergic and non-allergic conjunctivitis, 
and “other skin diseases” contains both allergic and non-allergic dermatitis/eczema12.   
 The Users Guide for the NHS (ABS, 2006c) states that the NHS category “other 
allergies” approximately matches the International Classification of Primary Care 
(ICPC-2) rubric A92 “Allergy/Allergic Reaction NOS” – see Table 2-2 below for details.13   
Where NHS respondents indicated non organ specific allergies, the NHS appears to 
have included these in its “Other Allergies” category.  This would include conditions 
such as angioneurotic oedema, which are not always caused by allergies.  On balance 
however, by excluding organ-specific allergies, the “other allergies” category is likely to 
under-estimate the prevalence of non-respiratory allergies14. 
TABLE 2-2:  ICPC-2 RUBRIC “ALLERGY/ALLERGIC REACTION NOS” 
Category ICPC-2 Rubric 
Allergic reaction A92007 
Allergic reaction; bee sting A92011 
Allergy A92008 
Allergy, food A92004 
Anaphylaxis; non-medication A92012 
Atopy A92009 
Oedema; allergic A92006 
Oedema; angioneurotic A92010 
Shock; anaphylactic A92005 
Source: Family Medicine Research Centre 
According to the NHS data, asthma is the predominant allergy of young people, with almost 
half a million cases occurring in children under the age of 15 during 2005.  However, the 
number of asthma cases steadily falls thereafter, with allergic rhinitis becoming the most 
prevalent condition in the mid-teenage years.  Allergic rhinitis peaks for people in their late 
twenties to early thirties.  The same age group also sees chronic sinusitis rise to overtake 
asthma.  Chronic sinusitis continues to increase in prevalence up until age 35-44, but allergic 
rhinitis still predominates to the oldest age groups (Figure 2-1). 
                                               
12
 Asher et al (2006) surveyed 2,968 Australian children between the ages of six and seven years, and found that 
17% had symptoms of eczema (the majority of which would probably be due to allergies).  If prevalence rates in 
Australia were the same as in the US (Greaves, 2006) some 20,000 Australians would have urticaria. 
13
 The Users’ Guide also states that “Other Allergy” matches the ICD-10 category “Symptoms, signs & conditions 
nec: Allergy (undefined).  However, there is no closely matching ICD-10 category.  “Symptoms, signs & 
conditions” is ICD-10 chapter R, which contains no allergic conditions.  ICD-10 Chapter T “Injury, poisoning and 
certain other consequences of external causes” has a category (T78) that is a reasonably close match to ICPC 
Rubric A92.  While both matchings are approximate, given the ABS has given a numerical rubric for ICPC, this is 
probably a more reliable indication of “Other Allergy” than the ICD-10 matching, which is only a vague textual 
description. 
14
 Using estimates derived from Australian and foreign studies, there could be up to 400,000 cases of food allergy 
(Sicherer and Sampson, 2006); 200,000 persons at risk of sting-related anaphylaxis (Douglas et al, 1998; 
Roberts-Thomson et al, 1985; Stuckey et al, 1982); and around 4,000 new cases of anaphylaxis per year 
(Lieberman et al, 2006). 
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FIGURE 2-1:  PREVALENCE OF ALLEGIES BY AGE (CASES), AUSTRALIA, 2005 
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Source:  ABS (2005). 
To determine age and gender specific incidence rates, 2001 NHS data were used, because 
the 2005 NHS data did not cross-tabulate age and gender (Figure 2-2). Prevalence was 
greater among females between the ages of 15 and 75 years, consistent with published data 
(Osman et al, 2007). Asthma was the dominant allergy for those aged less than 15 years. 
The highest prevalence was found in young adults aged 25-34 years, when allergic rhinitis 
predominates. 
FIGURE 2-2:  ALLERGIES, PREVALENCE RATES BY AGE AND GENDER, AUSTRALIA, 2005 
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People may present with similar symptoms, yet not all have an allergic origin.  As described 
in Section 1.2.1, patients with chronic rhinitis may have allergic rhinitis, or so-called non-
allergic rhinitis, where only the former has a well-defined allergic mechanism.  Similarly, a 
substantial proportion of people with asthma have no evidence of allergic sensitisation, a 
condition described as ‘intrinsic asthma’.   Published literature (Rimmer and Ruhno, 2006) 
and data supplied by Dr Mullins15 suggest that the fraction of asthma that can be attributed to 
allergy (AF) is 85%, the figure used in this analysis. 
While acute sinusitis is more common in patients with allergic rhinitis (Cirillo et al, 2007), it is 
more difficult to determine the contribution of allergic disease to chronic sinusitis.  The 
estimate of  Steinke and Borish (2004) that approximately half of chronic sinusitis could be 
attributable to allergy is consistent with Australian data indicating co-morbid allergic rhinitis in 
49.5% of patients with chronic sinusitis (Mullins data).  Gaby (2005), while agreeing that 
much of chronic sinusitis is allergic, considers that this is most likely to be allergic fungal 
sinusitis 16. 
However, even after removing non-allergic asthma and non-allergic sinusitis, the sum of 
diagnosed allergy cases on the Mullins database is still 24% greater than the number of 
patients with allergic disease, consistent with the concept of comorbidity described 
elsewhere in this report17.  Accordingly, in order to estimate the total number of people who 
suffer from allergies, we have scaled the NHS case totals down by 24% to estimate the 
number of people (as opposed to cases) of allergy in Australia.  This yields a total prevalence 
of 4.08 million people who suffered from allergies in 2007 (Table 2-4), which is significantly 
smaller than the total number of cases of various allergic diseases, at 7.20 million, indicating 
the significant degree of comorbidity.  Also, as shown in Table 2-3, a greater proportion of 
women (21.3%) suffer from allergies than do men (17.9%) 
 A similar outcome was derived using BEACH (Bettering the Evaluation and Care of 
Health) data from the report Allergies in General Practice, April 2000 – March 2006 
published by the Australian General Practice Statistics and Classification Centre 
(AGPSCC, 2007).  The sum of allergy cases in this case was 17% greater than the 
number of allergy patients.  (The Mullins data are used in preference to the BEACH 
data, as the former can identify specific patient comorbidities whereas the later cannot). 
                                               
15
 Data supplied by Dr Mullins from de-identified records, covering over 17,500 allergy patients seen in the ACT 
since 1995, from which diagnostic comorbidity can be estimated.  (By way of comparison, the NHS surveys 
25,000 households.) The possibility of referral bias in the data is acknowledged 
16
 The evidence linking allergic sinusitis with comorbid allergic rhinitis is not as clear cut as it is for allergic asthma 
and allergic rhinitis.  Accordingly, cases of allergic rhinitis are not automatically assumed to be double-counted 
when calculating the total number of people with (one or more) allergies.  Moreover, acute sinusitis is much more 
common in people with allergic rhinitis. 
17
 In fact for person prevalence, asthma can be ignored entirely.  If a case of asthma is allergic, the person has 
already been accounted for under allergic rhinitis.  And if the case of asthma is non-allergic, it is not counted. 
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TABLE 2-3:  ALLERGY PREVALENCE RATES, 2007 
Males 0–14 15–24 25–34 35–44 45–54 55–64 65–74 75+ Total 
Allergic asthma 11.1% 10.1% 7.2% 6.3% 5.7% 5.4% 8.0% 5.2% 7.8% 
Allergic rhinitis 8.8% 17.3% 21.6% 19.7% 16.9% 15.3% 11.4% 11.4% 15.6% 
Allergic chronic 
sinusitis 
1.7% 2.7% 4.5% 4.8% 4.8% 4.8% 4.0% 4.5% 3.8% 
Other allergy 6.4% 3.6% 4.8% 3.6% 3.9% 2.9% 3.1% 4.8% 4.3% 
Total 12.8% 17.9% 23.4% 21.3% 19.3% 17.4% 14.0% 15.7% 17.9% 
 
         
Females 0–14 15–24 25–34 35–44 45–54 55–64 65–74 75+ Total 
Allergic asthma 8.4% 11.0% 11.0% 8.7% 9.9% 9.6% 10.0% 7.8% 9.6% 
Allergic rhinitis 6.6% 21.6% 22.3% 20.9% 21.7% 14.5% 11.9% 10.5% 16.6% 
Allergic chronic 
sinusitis 
1.4% 4.0% 6.7% 6.6% 7.4% 7.4% 6.9% 5.0% 5.4% 
Other allergy 5.9% 5.7% 6.8% 6.6% 6.5% 6.7% 7.8% 3.7% 6.3% 
Total 10.5% 23.6% 27.1% 25.9% 26.9% 21.6% 20.1% 14.5% 21.3% 
 
In summary, in 2007 it is estimated that: 
- 4.08 million Australians (19.6% of the population) have at least one allergy, of 
which 2.23 million (55%) are female and 1.85 million (45%) are male; 
- the highest prevalence of allergies is in the working age population, with 78% of 
people with allergies aged 15 to 64 years (see chart below), and  
- there are 7.20 million cases of allergy (ie, an average of 1.74 comorbid allergies 
per person). 
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TABLE 2-4:  PREVALENCE OF ALLERGIES BY TYPE AUSTRALIA, 2007 
Males
Age
Allergic 
Asthma
Allergic 
Rhinitis
Allergic 
Sinusitis Other Allergy Total Cases Total Persons
0-4 71,726 56,978 11,224 41,447 181,376 82,929
5-9 74,164 58,915 11,606 42,856 187,541 85,748
10-14 78,603 62,440 12,301 45,421 198,765 90,879
15-19 74,307 127,671 20,230 26,722 248,929 132,068
20-24 76,047 130,659 20,703 27,347 254,757 135,159
25-29 51,675 155,766 32,216 34,548 274,205 168,301
30-34 51,564 155,431 32,147 34,474 273,615 167,939
35-39 47,952 151,235 36,602 27,691 263,480 163,005
40-44 46,713 147,328 35,656 26,976 256,673 158,794
45-49 43,458 127,860 35,911 29,148 236,376 145,905
50-54 39,143 115,165 32,346 26,254 212,907 131,419
55-59 34,365 97,707 30,881 18,693 181,646 111,390
60-64 28,715 81,643 25,804 15,620 151,781 93,076
65-69 32,472 46,357 16,052 12,430 107,311 56,601
70-74 25,011 35,706 12,364 9,575 82,656 43,597
75-79 13,237 29,193 11,431 12,210 66,070 39,958
80-84 9,022 19,898 7,792 8,323 45,035 27,236
85-89 4,323 9,534 3,733 3,988 21,577 13,050
90+ 1,789 3,946 1,545 1,651 8,931 5,401
Total 804,286     1,613,432         390,543            445,372            3,253,632         1,852,455         
Females
Age
Allergic 
Asthma
Allergic 
Rhinitis
Allergic 
Sinusitis Other Allergy Total Cases Total Persons
0-4 51737 40,628 8,318 36,141 136,824 64,352
5-9 53599 42,090 8,618 37,442 141,748 66,668
10-14 56671 44,503 9,112 39,588 149,874 70,490
15-19 77679 152,366 28,064 40,015 298,124 166,724
20-24 80010 156,939 28,906 41,216 307,072 171,728
25-29 77192 156,421 46,719 47,873 328,205 189,843
30-34 79379 160,853 48,043 49,230 337,505 195,222
35-39 67386 162,441 51,461 51,585 332,874 200,790
40-44 65400 157,654 49,944 50,065 323,063 194,872
45-49 75254 165,531 56,118 49,560 346,463 205,117
50-54 68021 149,622 50,724 44,797 313,165 185,403
55-59 61570 93,279 47,415 43,012 245,276 138,938
60-64 50481 76,479 38,875 35,265 201,100 113,914
65-69 40819 48,630 28,125 31,823 149,398 82,119
70-74 33578 40,004 23,136 26,178 122,897 67,553
75-79 23450 31,512 15,000 11,024 80,987 43,515
80-84 19078 25,637 12,203 8,969 65,886 35,402
85-89 11632 15,631 7,440 5,468 40,172 21,585
90+ 6858 9,216 4,387 3,224 23,685 12,726
Total 999,793 1,729,438 562,610 652,477 3,944,317 2,226,961
Persons
Age
Allergic 
Asthma
Allergic 
Rhinitis
Allergic 
Sinusitis Other Allergy Total Cases Total Persons
0-4 123,463 97,606 19,543 77,588 318,200 147,281
5-9 127,763 101,005 20,224 80,298 329,289 152,416
10-14 135,274 106,944 21,412 85,009 348,639 161,369
15-19 151,986 280,037 48,294 66,737 547,054 298,792
20-24 156,057 287,598 49,610 68,563 561,828 306,887
25-29 128,866 312,187 78,935 82,421 602,410 358,144
30-34 130,942 316,284 80,190 83,703 611,120 363,161
35-39 115,339 313,676 88,063 79,276 596,354 363,795
40-44 112,114 304,982 85,601 77,040 579,737 353,666
45-49 118,712 293,391 92,029 78,708 582,840 351,023
50-54 107,164 264,787 83,070 71,051 526,072 316,822
55-59 95,935 190,986 78,296 61,705 426,922 250,328
60-64 79,195 158,122 64,679 50,885 352,881 206,990
65-69 73,291 94,987 44,177 44,254 256,709 138,720
70-74 58,590 75,710 35,500 35,753 205,553 111,149
75-79 36,687 60,705 26,431 23,234 147,057 83,473
80-84 28,100 45,535 19,995 17,291 110,921 62,638
85-89 15,955 25,165 11,174 9,456 61,749 34,634
90+ 8,647 13,162 5,932 4,875 32,616 18,128
Total 1,804,078 3,342,870 953,153 1,097,849 7,197,950 4,079,416
 
Sources:  ABS (2005) and the Mullins database. 
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2.2 CHANGING PREVALENCE OF ALLERGIC DISEASES 
National and international studies have shown that allergies have become more common in 
recent times.  The prevalence of allergic rhinitis and eczema has almost doubled over the 
last 10-15 years in Australia and New Zealand.  Similar to observations in the UK and USA, 
there is preliminary evidence that food allergy and potentially fatal allergic reactions 
(anaphylaxis) have increased as well, predominantly in young children (Grundy et al, 2002; 
Sicherer et al, 2003).  The emergence of new allergy-related disorders such as eosinophilic 
oesophagitis in adults and children (Cherian et al, 2006), and the unabated increase in 
demand for hypoallergenic infant formulae are additional evidence that this growth in allergic 
disorders is yet to plateau.  
2.2.1 ASTHMA, ALLERGIC RHINITIS AND ATOPIC ECZEMA 
The prevalence of asthma has increased substantially in Australia and New Zealand (and in 
other developed countries) for much of the last 20 years (Asher et al, 2006, Robertson et al, 
1998; ISAAC, 1998), and has recently plateaued (Robertson et al, 2004) (Figure 2-3, Figure 
2-4 and Figure 2-5).  This has been achieved through the development of management plans 
in partnership between patient and medical professionals, community education, and 
understanding of the role of allergy and development of more effective medication.  
It is less well appreciated that other allergic disorders have also become more common over 
this time in Australia and New Zealand, as they have abroad. Using standardised 
questionnaires, studies of Australian and New Zealand children and adults have shown an 
approximate doubling in the prevalence of allergic rhinitis and eczema over the last 10-15 
years (Robertson et al, 2004; Downs et al, 2001). 
FIGURE 2-3:  PREVALENCE OF RHINITIS, ECZEMA AND ASTHMA IN AUSTRALIANS AGED 6-7 YEARS,  
1993 AND 2002 
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Source: Robertson et al (2004). 
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FIGURE 2-4:  PREVALENCE OF WHEEZE AND RHINITIS IN AUSTRALIANS AGED 8-11 YEARS,  
1982, 1992 AND 1997 
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Source: Downs et al (2001). 
FIGURE 2-5:  PREVALENCE OF ASTHMA IN AUSTRALIANS AGED 15-34 YEARS AND 35-54 YEARS, 
1990-2002 
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Source: Wilson et al (2006). 
2.2.2 FOOD ALLERGY AND ANAPHYLAXIS 
Recent studies from Australia and abroad suggest that food allergy and anaphylaxis are 
increasing as well.  In a study of children aged 3-4 years old on the Isle of Wight (UK) using a 
combination of population surveys, SPT and challenge, sensitisation to peanut trebled from 
1.1% to 3.3% between 1989 and 1994-6, with clinical reactivity increasing from 0.5% to an 
estimated 1.5% (Grundy et al, 2002).  Similar changes in peanut allergy prevalence from 
0.6% to 1.2% between 1997 and 2002 were derived from a random digit telephone survey of 
American children, although without confirmatory SPT or challenge (Sicherer et al, 2003). 
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While there have been no comparable epidemiological studies on food allergy in Australia, it 
is clear that hospital admissions for anaphylaxis have approximately doubled in Australia 
over the last 12 years, similar to findings in the UK (Mullins, 2007; Gupta et al, 2003).  The 
changes in Australian age-adjusted admission rates for food induced anaphylaxis and total 
anaphylaxis over time were even more pronounced in young children aged 0-4 years, where 
admission rates increased five-fold over a 12 year period, and four-fold in older children aged 
5-14 years, compared to an overall doubling in the population taken as a whole (Mullins, 
2007).  
FIGURE 2-6:  AUSTRALIAN AGE-ADJUSTED HOSPITAL ADMISSION RATES FOR ANAPHYLAXIS 
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Source: Mullins (2007). 
2.2.3 INDIRECT MEASURES OF CHANGING DISEASE PREVALENCE 
Measuring demand for allergy-related medication is a less direct and therefore less accurate 
measure of changing prevalence of allergic disease.  Hypoallergenic infant formula 
prescriptions have increased four-fold in the five years ending 2004 (Figure 2-7) but, with 
significant regional variation in prescribing rates, this may reflect increased awareness, 
access to specialist services or inappropriate prescribing as well as an increased incidence 
of food allergy in infants (Kemp, 2006).  The last decade has also seen food allergy related 
disorders such as eosinophilic oesophagitis increasing from 0.05 to 0.89 cases per 100,000 
Western Australian children between 1995 and 2004 (Cherian et al, 2006). 
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FIGURE 2-7:  ELEMENTAL (HYPOALLERGENIC) INFANT FORMULA USE IN AUSTRALIA, 1994-2004 
 
Source: Kemp (2006). 
A second indirect measurement of demand for allergy assessment can be gleaned by 
examination of Australian data for allergy testing in infants aged 0-4 years, which has 
increased three-fold over the last 12 years (Figure 2-8). While there are many ways to 
interpret more frequent testing (increased community awareness of allergy, more frequent 
allergy testing of infants with atopic eczema), inhalant allergy is relatively infrequent in young 
infants, and the data are consistent with increased rates of atopy in children noted in 
published studies. 
FIGURE 2-8:  SPT IN AUSTRALIAN INFANTS 0-4 YEARS (ITEM 12000; LESS THAN 20 TESTS) 
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Source: Medicare Australia data: Item 12000 in children 0-4 yrs. 
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2.3 PREVALENCE PROJECTIONS 
The literature and data from the previous section suggested that, although the prevalence of 
symptomatic asthma has plateaued, (Robertson et al, 2004) there is reliable evidence of a 
recent significant rise in the prevalence of allergic rhinitis, eczema, food allergy and 
anaphylaxis in Australia.  These trends have important implications for public health, medical 
workforce planning, costs of care and the availability of public allergy/immunology services in 
Australia, that are currently lacking in some states of Australia (eg, Tasmania and the 
Northern Territory). 
Data from the ABS National Health Surveys (1995, 2001 and 2004-05) was used to estimate 
trends in prevalence rates for the various allergic conditions modelled (Table 2-5).  Some 
caution should be applied when using these figures, however. 
 Only three points are available (ie, one from each survey) to estimate trends for each 
age-gender / disease combination.  (Data are also available from the 1989 NHS, but 
only for short-term conditions, without any age or gender splits.  The broad totals do, 
however, support the trends observed in later years.) 
 The 1995 NHS, unlike later years, does not provide age or gender splits for long-term 
conditions.  It does, however, provide age splits for the same conditions where they 
have only been experienced over a short term.  The short-term age splits have been 
applied to the long term totals.  Within these age splits, the gender ratios from 2001 
have been applied. 
Trends projected from ABS data support other available evidence that prevalence rates for 
total allergies are increasing.  However, this appears to be mostly driven by strong growth in 
allergic rhinitis prevalence rates, as rates for allergic asthma, allergic chronic sinusitis and 
“other allergies” appear to be slowly decreasing.  Linear estimation from the historical data 
suggests that the age-gender prevalence of allergies has changed in Australia over the 
period 1995-2005, for males and females together, by: 
 -0.08% per annum for allergic asthma; 
 0.22% per annum for allergic rhinitis; 
 -0.04% per annum for allergic sinusitis; 
 -0.06% per annum for other allergies; and 
 0.09% per annum for all allergies. 
These overall trends, however, mask important age, gender and disease specific time trends. 
For example, some allergies (such as allergic rhinitis) are increasing in all age groups. 
Others (such as asthma) appear to be in decline. While “other allergies” appears to be in 
decline (more so in females), the end result may differ according to the respective 
contributions to this group of food allergy and anaphylaxis, which have rapidly increased in 
recent years. A major contribution to the prevalence of allergic disease will of course be 
related to our aging population. 
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TABLE 2-5:  PREVALENCE TRENDS BY AGE, GENDER AND ALLERGIC DISEASE, 1995-2005 
Males Females
Asthma Asthma
0–14 15–24 25–34 35–44 45–54 55–64 65–74 over 75 0–14 15–24 25–34 35–44 45–54 55–64 65–74
1995 14.3% 11.4% 6.1% 6.7% 5.5% 5.8% 8.6% 6.3% 1995 10.9% 12.6% 9.5% 9.5% 9.9% 10.4% 9.6%
2001 12.9% 13.3% 8.6% 6.6% 6.2% 5.8% 7.5% 5.0% 2001 9.8% 14.4% 12.9% 9.0% 10.6% 10.4% 9.2%
2005 11.1% 10.1% 7.2% 6.3% 5.7% 5.4% 8.0% 5.2% 2005 8.4% 11.0% 11.0% 8.7% 9.9% 9.6% 10.0%
Trend -0.32% -0.10% 0.13% -0.05% 0.04% -0.04% -0.07% -0.12% Trend -0.24% -0.12% 0.19% -0.08% 0.01% -0.07% 0.03%
Allergic Rhinitis Allergic Rhinitis
0–14 15–24 25–34 35–44 45–54 55–64 65–74 over 75 0–14 15–24 25–34 35–44 45–54 55–64 65–74
1995 7.6% 16.7% 17.0% 18.6% 12.8% 13.9% 10.7% 6.1% 1995 5.7% 21.1% 17.7% 20.1% 17.3% 13.2% 10.1%
2001 8.1% 16.7% 22.5% 18.5% 15.6% 12.8% 13.7% 12.9% 2001 6.1% 20.7% 22.8% 19.4% 20.1% 12.1% 14.0%
2005 8.8% 17.3% 21.6% 19.7% 16.9% 15.3% 11.4% 11.4% 2005 6.6% 21.6% 22.3% 20.9% 21.7% 14.5% 11.9%
Trend 0.12% 0.05% 0.50% 0.10% 0.42% 0.11% 0.10% 0.58% Trend 0.09% 0.04% 0.49% 0.07% 0.44% 0.10% 0.22%
Allergic Sinitus Allergic Sinitus
0–14 15–24 25–34 35–44 45–54 55–64 65–74 over 75 0–14 15–24 25–34 35–44 45–54 55–64 65–74
1995 2.0% 3.6% 5.1% 5.6% 5.7% 5.0% 3.9% 2.9% 1995 1.6% 5.3% 7.6% 7.9% 9.4% 7.7% 6.1%
2001 2.3% 3.8% 4.7% 5.6% 5.7% 5.0% 4.7% 4.6% 2001 1.8% 5.5% 6.9% 7.7% 8.8% 7.6% 8.1%
2005 1.7% 2.7% 4.5% 4.8% 4.8% 4.8% 4.0% 4.5% 2005 1.4% 4.0% 6.7% 6.6% 7.4% 7.4% 6.9%
Trend -0.02% -0.08% -0.06% -0.08% -0.09% -0.02% 0.02% 0.17% Trend -0.02% -0.12% -0.10% -0.12% -0.19% -0.03% 0.10%
Allergy, other Allergy, other
0–14 15–24 25–34 35–44 45–54 55–64 65–74 over 75 0–14 15–24 25–34 35–44 45–54 55–64 65–74
1995 5.9% 4.5% 4.7% 5.3% 5.0% 3.4% 3.0% 2.6% 1995 5.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
2001 5.7% 4.9% 4.8% 3.9% 4.1% 2.9% 2.9% 4.8% 2001 5.2% 5.9% 4.5% 4.7% 5.3% 5.0% 3.4%
2005 6.4% 3.6% 4.8% 3.6% 3.9% 2.9% 3.1% 4.8% 2005 5.9% 5.7% 6.8% 6.6% 6.5% 6.7% 7.8%
Trend 0.05% -0.08% 0.01% -0.18% -0.11% -0.05% 0.01% 0.23% Trend 0.04% 0.60% 0.69% 0.67% 0.67% 0.68% 0.76%
 
Source: ABS (various years) National Health Surveys. 
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The solid lines in Figure 2-9 indicate the extent to which allergies may increase in the future 
simply due to a growing, ageing population (ie, assuming the same age-gender prevalence 
rates as used to estimate 2007 prevalence).  The broken lines indicate the extent to which 
allergies can be expected to rise - beyond simple demographic effects – if rising prevalence 
rates were to continue at their historical pace.  (The figures following are ‘kinked’ in 2010, 
because the distance between observations thereafter is ten years, while before 2010 it is 
only three years (2007-2010) so it appears flatter over the same length of x axis.  ‘Std’ in the 
figures denotes using one standard prevalence rate (2005), rather than a different rate every 
year - ‘trend’.) 
FIGURE 2-9:  PREVALENCE TRENDS FOR TOTAL ALLERGIES 
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While demographic trends alone would cause the numbers of asthmatics to continue to 
increase, if historical prevalence trends hold, the total number of females with allergic asthma 
will stay roughly constant, and for males could actually fall (Figure 2-10). 
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FIGURE 2-10:  PREVALENCE TRENDS FOR ALLERGIC ASTHMA 
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Allergic rhinitis is projected to grow at broadly similar rates for each gender from both 
demographic and trend effects (albeit slightly greater in both cases for females). 
FIGURE 2-11:  PREVALENCE TRENDS FOR ALLERGIC RHINITIS 
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Allergic chronic sinusitis is also projected to have slower growth from trend rates than from 
demographic impacts alone.  However, unlike asthma, total numbers for both genders are 
still projected to rise (Figure 2-12). 
FIGURE 2-12:  PREVALENCE TRENDS FOR ALLERGIC CHRONIC SINUSITIS 
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Prevalence rates for ‘other allergies’ among males are forecast to fall slightly in future years, 
also below population growth.  However, prevalence rates for females are forecast to fall 
rapidly.  Indeed, numbers of females are projected not only to fall below current numbers, but 
also below the number of males. 
 The economic impact of allergic disease 
 
 
 
39 
FIGURE 2-13:  PREVALENCE TRENDS FOR OTHER ALLERGIES 
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Even if the frequency of allergic disorders remained static, the actual number of patients with 
allergic disorders will increase by 2050, simply based on demographic projections of the age 
and size of Australia’s population. Frequency will, however, be influenced by time trends 
whereby some allergic disorders may become more common (such as allergic rhinitis and 
food allergy) and others less so (eg. “other allergy”). 
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FIGURE 2-14:  INCREASING AVERAGE AGE OF ALLERGY SUFFERERS 
35
40
45
50
55
20
07
20
10
20
20
20
30
20
40
20
50
Year
A
v
er
ag
e 
ag
e 
o
f p
er
so
n
 
w
ith
 
al
le
rg
ie
s 
(ye
ar
s)
Males-Std
Males-Trend
Females -Std
Females-Trend
 
On simple population demographic projections, the numbers of all categories of allergy will 
increase in absolute terms by 2050.  However, if current prevalence trends are to continue, 
the number of ‘other allergies’ would actually fall below current levels.  Conversely, the 
number of people with allergic rhinitis would be over 70% higher than population growth and 
ageing alone would cause. 
TABLE 2-6:  PROJECTED ALLERGY PREVALENCE, 2007 TO 2050 (MILLION PERSONS) 
Disease 2007 2050 no trend 2050 trend 
Allergic asthma 1.80 2.47 1.79 
Allergic rhinitis 3.34 4.54 7.86 
Allergic sinusitis 0.95 1.39 1.14 
Other allergies 1.10 1.51 1.01 
Total 4.08 5.62 7.68 
By 2050, if left solely to population movements, the prevalence rates of the total and most 
individual allergic diseases would actually fall slightly (to 19.1% of the population).  However, 
again allowing for current trends to continue, a significant increase in allergic rhinitis 
prevalence, as well as some other allergies such as food allergy, will cause total allergy 
prevalence rates to be a third higher than they are today.  
 The economic impact of allergic disease 
 
 
 
41 
TABLE 2-7:  PROJECTED ALLERGY PREVALANCE RATES, 2007 TO 2050 (% POPULATION) 
Disease 2007 2050 no trend 2050 trend 
Allergic Asthma 8.7% 8.4% 6.1% 
Allergic Rhinitis 16.1% 15.4% 26.7% 
Allergic Sinusitis 4.6% 4.7% 3.9% 
Other Allergies 5.3% 5.1% 3.4% 
Total 19.6% 19.1% 26.1% 
 
 The economic impact of allergic disease 
 
 
 
42 
3. HEALTH SYSTEM EXPENDITURE 
Direct financial costs to the Australian health system comprise the costs of running hospitals 
and nursing homes (buildings, care, consumables), GP and specialist services reimbursed 
through Medicare and private funds, the cost of prescribed and over-the-counter 
pharmaceuticals (Pharmaceutical Benefits Scheme and private), allied health services, 
research and ‘other’ direct costs (such as health administration).   
There are essentially two ways of estimating each element of cost for each group: 
1 top-down: data may be able to provide the total costs of a program element and then 
allocate those costs by disease eg, health system expenditure by disease as estimated 
by the AIHW, for which asthma (but not non-asthma allergies) is a component; or 
2 bottom-up: data may be available for the number of people with a disease who 
experience a cost impact from the disease (‘n’) and the average cost impact.  The 
product is the total cost eg, the number of emergency department visits to treat food 
allergy in a year multiplied by the average cost of an ED visit.18 
It is generally more desirable to use top-down national datasets in order to derive national 
cost estimates for large and well-studied diseases such as asthma, rather than extrapolate 
bottom-up data from smaller partial datasets.  However, using top-down estimates can be 
problematic in some areas where data are limited (eg, health costs for non-asthma allergies).  
In these cases, to obtain parameters for implementing the bottom-up approach, statistical 
analysis of datasets and a literature review (focussing on Australian literature but sometimes 
supplemented by international material) has been used.   
Available Australian data on diseases and injuries and their associated costs are subject to 
considerable uncertainties, with a number of these detailed below. 
 Surveys: 
 lack of consensus about definitions; 
 variations in survey methodology eg, clinic or population focused; 
 gaps and consistency in data collections eg, different timeframes; 
 reluctance to report disease; 
 limited population size and representativeness of the sample; and 
 survey limitations eg, the wording of questions may affect the answers given. 
 Costs: 
 patchy administrative information on what proportion of costs are attributable to 
different types of diseases; 
 focus on other aspects of diseases (such as treatment outcomes), rather than on 
costs; 
                                               
18
 The bottom-up approach is also used to estimate some indirect cost items such as productivity losses from 
absenteeism, where the average wage rate is multiplied by the average number of days off due to allergies for the 
number of people to whom this applies.  The top-down approach can often be used for program payments such 
as Centrelink payments or community programs such as palliative care, which are allocable by disease (although 
in the case of allergies palliative care expenditure is not required). 
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 comorbidities: there may be another disease that is responsible for part (or all) of 
the costs (such as the presence of another chronic disease having a large impact 
on costs); 
 two-way correlation or causation between variables eg, low socioeconomic status 
(SES) predisposing to illness and illness in turn also reducing income/SES; 
 factor X: there may be another underlying cause of both a disease and the 
resulting cost, which makes them look like one is caused by the other (for 
example, cigarette smoking resulting in both asthma and greater medical visits). 
These issues are addressed by controlling for other factors where possible, and conducting 
sensitivity analysis. 
Section 2.1 developed a total prevalence all allergic conditions by taking account of 
attributable fractions and netting out comorbidities.  This in turn was used to derive a single 
combined prevalence rate for all allergic conditions, which was then applied to changing 
demographic cohorts to project prevalence in future years.  A similar approach is adopted in 
this chapter for health costs.  Total health costs for both asthma and all other allergies are 
developed for 2005 (the last year for which both NHS epidemiological and hospital casemix 
data are available).  This total is then divided by the combined all-allergies prevalence rate to 
find the average health expenditure per person with allergies.  Demographic changes are 
then applied to this per capita rate to find total expenditure in 2007. 
3.1 ASTHMA 
Estimates for the direct health system costs of asthma were drawn from statistics collected 
by the AIHW for all allergy-related disorders, based on an extensive process developed in 
collaboration with the National Centre for Health Program Evaluation for the Disease Costs 
and Impact Study (DCIS). The approach measures health services utilisation and 
expenditure (private and public) for specific diseases and disease groups in Australia (based 
on ICD-10 categorisation2).  The DCIS methodology has been gradually refined over the 
past decade to now estimate a range of direct health costs from hospital morbidity data, case 
mix data, BEACH data, the NHS and other sources.  Health system costs were estimated by 
age, gender and type of cost (hospital inpatient, hospital outpatient, out-of-hospital medical 
services, other professional services, pharmaceuticals, and research).   
However, the AIHW include only 87.5% of total recurrent health expenditure in their 
estimates of expenditure by disease and injury, referred to as ‘allocated’ health expenditure.  
The ‘unallocated’ remainder includes capital expenditures, expenditure on community health 
(excluding mental health), public health programs (except cancer screening), health 
administration and health aids and appliances.  Allowance has been made for the 
unallocated components of health system expenditure in the AIHW estimates.  Top 
down expenditure on asthma of $803 million from the AIHW is presented in Table 3-1 for the 
year 2000-01. 
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TABLE 3-1:  HEALTH SYSTEM EXPENDITURE FOR ASTHMA, 2000-01 
Category $m % 
Admitted patients 97.58  
Non-admitted services 72.21  
Total Hospital 169.79 21.1% 
Aged care homes 16.50 2.1% 
Out-of-hospital medical services 109.74 13.7% 
Other professional services 20.56 2.6% 
Prescription pharmaceuticals  296.04  
Over-the-counter pharmaceuticals 73.83  
Total pharmaceuticals 369.87 46.0% 
Research 6.05 0.8% 
Non-allocated expenditure 98.9 12.5% 
Total expenditure 791.42 100% 
Source:  AIHW (2005). 
Assuming that both allergic and intrinsic asthma generate roughly the same health system 
costs, then for each of the 2.20 million asthmatics reported in the 2001 NHS, average health 
expenditure would have been $360 (2001 dollars).  This cost is updated to current (2007) 
dollars by using an average annual health expenditure inflation rate of 3.7%, to $448.   
Multiplying this by the estimated number of allergic asthmatics in 2007 (1.80 million) yields a 
total health system expenditure for allergic asthma of $808.0 million in 2007  This total 
is then added to the total health system expenditure for other allergies (Section 3.2) to obtain 
a total expenditure for 2007.   
3.2 NON-ASTHMA ALLERGIES (NAA) 
For non-asthma allergies (NAA), health expenditure estimates had to be derived bottom up 
from BEACH data (AGPSCC, 2007) – Allergies in General Practice: April 2000 to March 
2006 – which surveyed 27,916 people who visited their GP with at least one allergy (not 
including asthma).  A total of 27,916 surveyed visits with allergy over six years translates to 
an average of 4,653 GP visits for allergy per year in the survey.  Given the total BEACH 
sample size was 101,993 visits in 2006 (for all conditions) and Australians made 95 million 
visits to their GP that year, applying the population to sample size relativity to surveyed NAA 
visits results in a total of 4.33 million NAA encounters per year.  This means that each of the 
5.39 million cases of NAA in 2007 would have resulted in 0.8 GP encounters per person per 
year.  However, allergy sufferers seem to have more than their fair share of comorbidities, as 
the BEACH data indicates that for each allergy visit they also needed 0.75 other (non-allergy) 
problems dealt with (the average is around 0.3 other problems).  Not surprisingly, two of the 
top three other complaints were asthma and upper respiratory problems.  This means that 
effectively only 57% of the cost of each encounter can be booked against NAA. 
All Medicare fees and AMA fees in the estimates below are current at time of drafting 
(October 2007). 
3.2.1 GP COSTS 
Standard GP consultation costs 
While people with allergy often had non-allergy issues that they wanted treated at the same 
visit, almost none wanted treatment for more than one allergy in the same visit.  Although the 
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same person may have two NAA conditions, to treat these conditions would usually require 
two visits by this person (reactions may occur at different times, for example – an insect sting 
and a sinusitis attack – so visits appear to only rarely be able to be combined).  As the 
number of NAA problems treated was only 1.01 per encounter, costs per visit are treated as 
synonymous with costs per (allergy) case.  Average costs per case are then multiplied by 
total cases in 2007 to derive total medical and pharmaceutical expenditure. 
The BEACH report does not provide data on the length of consultations, but as the 
overwhelming majority of total Medicare claims are for Level B consultations (less than 
20 minutes), this is assumed to be the case for allergies too.  Taking into account bulk-billing 
rates and AMA recommended fees19, the average cost per encounter is $38.06 (Table 3-2).   
TABLE 3-2:  NAA GP COSTS 
GP Costs Cost per 
encounter 
Bulk billing  
rate (%) 
Standard Consultation of 20 minutes (MBS item 23) $32.10 77 
Private fee $58.00 23 
Average cost $38.06  
Source: Medical Benefits Schedule Online  
http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1 
The estimated 4.33 million GP encounters for NAA in 2007 cost 
$94.4 million (after allocating GP fees between NAA and other problems dealt 
with at the same encounter). 
Longer consultation costs 
The most common therapy category, after pharmaceuticals (next Section), reported by 
BEACH for GPs consulting people with NAA, was ‘at least one other treatment’, which refers 
to clinical and procedural treatments provided by the GP.  In total there were 6,100 of these 
treatments (representing 22% of encounters).  Four times out of five (81%), where the GP 
provided further treatment, this was clinical in the form of advice, education and counselling 
on matters such as the nature of the allergy, and the treatments and medications necessary 
to ameliorate it.  Where GPs specify that they have provided ‘at least one other (clinical) 
treatment’, these are modelled as MBS Level C consultations, for which the recommended 
public and AMA fees are $60.95 and $106.00 respectively.  Using the same bulk-billing rates 
as for general consultations, this yields an average fee of $71.31.  However, as BEACH only 
provides point-in-time snapshots rather than patient histories, these encounters are modelled 
as being the same ones already costed in Table 3-2 above, so only the difference between a 
Level B and Level C consultation ($33.25) is used in these cases. 
It is estimated that, of the 4.33 million GP encounters, 768,746 were longer 
(Level C) consultations to deal with more complicated NAA cases.  To account 
for other conditions managed at the same encounter, as with short consultations 
only 57% of the cost of these has been attributed to NAA.  Since the cost of the 
short consultation (Level B) has already been included, these long 
consultations add a further $14.6 million towards the total GP cost of NAA. 
                                               
19
 All bulk-billing percentages are from Medicare Online Statistics for the last quarter covered by the BEACH 
report (March 2006) - http://www.health.gov.au/internet/wcms/publishing.nsf/Content/medstat-mar06-tables-b.   
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Procedures provided by GPs 
There were also 1,148 procedural treatments provided by GPs (4.1% of all NAA encounters).  
The five most common of these (listed below) accounted for 91% of procedural treatments 
given: 
 sensitivity test; 
 excision/removal tissue/biopsy/destruction/debridement/cauterisation; 
 local injection/infiltration; 
 dressing/pressure/compression/tamponade; and 
 other therapeutic procedures/surgery not elsewhere classified. 
The model uses a sensitivity test (MBS item 12000) - which appears to be the only allergy-
specific treatment in the top five - as a cost proxy for these procedural treatments.  The MBS 
fee for this service is $34.00 and the AMA fee $75.00, which on a bulk-billing rate of 77% 
yields an average fee of $43.74. 
In total, there were an estimated 178,215 procedural treatments supplied by 
GPs for people with NAA as their main condition.  As with all other GP 
encounters, 43% of the fees for these services are allocated to non-NAA 
complaints, leaving a total cost of $4.6 million for NAA GP procedures.  This 
brings the total GP costs to $113.5 million in 2007. 
3.2.2 PHARMACEUTICAL COSTS 
The most common action taken by GPs to treat NAA is to give medication.  In fact there were 
more medication treatments than there were encounters in the BEACH sample.  Including 
over-the-counter, GP-supplied and prescriptions, the 27,916 encounters resulted in 31,332 
medication treatments.  Of those patients given prescriptions, 24% were for more than one 
medicine.  Based on the top ten categories of medication (which account for the majority of 
all scripts), the average cost of medicines (if prescribed) was $12.22 (Table 3-3). 
TABLE 3-3:  NAA PHARMACEUTICAL COSTS 
Generic category % Pharmacy 
direct prices 
Most common branded 
medicine 
Betamethasone  topical 9.6% $6.99 Diprosone cream/ointment 0.5 mg  
Mometasone 8.2% $9.95 Elocon cream/ointment/lotion      
Hydrocortisone topical 6.3% $5.95 Egocort cream  
Budesonide  topical nasal 6.3% $31.95 Rhinocort nasal spray 100 mcg      
Amoxycillin/potass.clavulanate 5.0% $16.95 Augmentin duo forte tablets 875 mg  
Amoxycillin 4.7% $9.95 Amoxil  capsules 500 mg 
Loratadine 4.0% $9.95 Claratyne  tablets 10 mg 
Methylprednisolone aceponate 4.0% $8.95 Advantan  cream 1 mg 7 
Triamcinolone topical  3.5% $9.65 Aristocort cream/ointment    
Roxithromycin 3.4% $12.95 Rulide  tablets 300 mg  
Total 55.0% $12.22 Weighted average 
Source: AGPSCC (2007) and Pharmacy Direct – www.pharmacydirect.com.au, accessed 28 September 2007. 
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An estimated 4.86 million medications were prescribed for NAA in 2007, 
directly supplied or recommended (OTC), at a total cost of $59.4 million. 
These estimates may be conservative as they may understate the extent of pharmaceuticals 
used by people with NAA who self-medicate with across the counter antihistamines and 
nasal steroid sprays and low dose topical cortisone creams and those paying retail prices 
greater than discount prices quoted above.  Self-prescribed asthma puffers, however, would 
be counted in the pharmaceutical cost of asthma. 
 Private correspondence with Synovate-Aztec (a market research firm) indicates that 
Australians annually purchase around $125 million worth of OTC antihistamines and 
intranasal corticosteroids for allergy treatment.  BEACH data does not separately 
identify OTC medicines that GPs recommend patients purchase.  However, prescribed 
(as opposed to GP supplied or OTC) medications accounted for 77% of the total 
number of scripts.  Assuming OTC and GP-supplied medications had equal shares of 
the remainder, and that OTC medications had the same average cost as all 
medications from costs above ($12.22) indicates that only some $6.8 million of OTC 
medications are purchased as a result of GP recommendations.  Thus, including this 
marketing data would increase total medication costs by $118 million (or, averaged 
across all 4.1 million allergy sufferers, an extra $29 per person per year).  However, 
due to data uncertainties, and erring on the side of caution, these costs have not been 
included in the model.   
3.2.3 PATHOLOGY COSTS 
The BEACH data show a total of 1,556 pathology tests ordered by GPs (5.6% of encounters) 
for NAA.  The top four categories of MBS pathology groups accounted for 95% of these tests 
(Table 3-4), with blood allergy testing (RAST, ImmunoCap) being a common order of GPs.  
Proxy items have been chosen for each category according to either specificity to allergies, 
or else their overall frequency according to general Medicare statistics.  Using a standard 
pathology bulk-billing rate of 86.3%, where a GP orders a pathology test for a patient, the 
average cost is estimated as $20.04. 
TABLE 3-4:  NAA PATHOLOGY COSTS 
Category Percent Typical 
MBS# 
MBS 
fee 
Private 
fee 
Average 
fee 
Description 
Chemistry 29% 66500 $9.75 $18.60 $10.96 Quantitation in serum, plasma, urine 
or other body fluid (except amniotic 
fluid), by any method except 
reagent tablet or reagent  – 1 test 
Immunology 25% 71075 $23.40 $52.00 $27.32 Quantitation of immunoglobulin E 
(total), 1 test 
Haematology 22% 65070 $17.20 $32.50 $19.30 Erythrocyte, haematocrit, or 
haemoglobin count, calculation of 
red cell index, platelet or leucocyte 
count and manual or instrument 
generated differential count 
Microbiology  19% 69303 $22.15 $42.00 $24.87 Culture or microscopy to detect 
pathogenic micro-organisms from 
nasal, throat, eye or ear swabs  
Total 95%    $20.04 
 
Source: MBS Online and AGPSCC (2007). 
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Some 241,553 pathology tests were ordered by GPs in relation to NAA in 
2007, at an estimated total cost of $4.84 million. 
3.2.4 SPECIALIST COSTS 
GPs referred patients to specialists in 1,275 cases (4.6% of encounters)20.  The majority of 
these referrals were to organ-specialists, with only 21% of patients being referred to 
allergists.  For costing purposes, most specialist referrals are assumed to be MBS item 104 
(Specialist Consultation) for which the MBS fee is $75.60, the AMA fee is $132.00, and the 
bulk-billing rate is 25.5%, yielding an average fee of $117.62.21  However, allergists, 
immunologists22 and respiratory physicians are assumed to use MBS item 11023 (extended 
consultation), for which the MBS fee is $133.35 and the AMA fee $240.00, making an 
average of $212.80.  This brings the total average specialist fee to $141.93, and the total 
cost to $28.1 million in 2007.24 
TABLE 3-5:  NAA SPECIALIST REFERRALS BY TYPE 
  % Fee 
dermatologist 455 37% $117.62 
ENT 348 28% $117.62 
allergist 263 21% $212.80 
ophthalmologist 60 5% $117.62 
immunologist 48 4% $212.80 
paediatrician 37 3% $117.62 
respiratory physician 7 1% $212.80 
other specialist 27 2% $117.62 
 1245 100% $141.93 
Source: AGPSCC (2007). 
GPs referred 197,930 of their patients to specialists in 2007 to provide 
advanced allergy treatment, at a cost of $28.1 million. 
3.2.5 IMAGING COSTS 
Finally, GP ordered an imaging test for 1.5% of their allergy patients (424 encounters).  The 
top five imaging services (Table 3-6) accounted for over 90% of all imaging services.  Using 
a bulk-billing rate of 60.2%, the average cost of such imaging services was $252.92. 
                                               
20
 Referrals to allied health services, emergency departments and ‘other’ were also made in a 0.25% of 
encounters. 
21
 Fees are higher for these three classes as advised by ASCIA, bulk billing rates are the same.  Adding in the 
MBS 110 increases the average specialist fee to $141.93 (from $117.62) and total specialist 
expenditure to $28.1m from $23.3m.  
22
 While allergist and immunologist can be considered synonymous terms, they are reported separately in BEACH 
data. 
23
 Consultant physicians, as a class, have significantly longer appointments than other specialists. 
24
 The costs quoted in the table may be an underestimate, as allergy skin prick testing, patch testing and 
measurements of lung function are used by several specialities as well as some GP’s and pathology laboratories, 
which would result in higher Medicare-related and private (out of pocket) costs. 
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TABLE 3-6:  ESTIMATED NAA IMAGING COSTS 
Type % MBS 
Item 
MBS 
Fee 
AMA Fee Average Fee 
CT Sinus /facial 
bones 
59.4% 56022 $225.00 $520.00 $342.41 
X-ray Sinus 23.3% 57903 $47.30 $120.00 $76.23 
X-ray Chest 5.7% 58500 $35.35 $90.00 $57.10 
CT Brain 2.8% 56001 $195.05 $450.00 $296.52 
X-ray Facial bones 1.2% 57912 $47.15 $120.00 $76.14 
Total 92.5%    $252.92 
Source: AGPSCC (2007) and MBS Online. 
A total of 65,822 diagnostic imaging services were requested by GPs in 2007 
in support of their patients with NAA, at a cost of $16.6 million.  This estimate is 
conservative, as BEACH data do not include imaging services ordered by 
specialists.) 
3.2.6 HOSPITAL INPATIENT COSTS 
The National Hospital Cost Data Collection25 provides top-down data for the treatment of 
‘Allergic Reactions’ (AR-DRG X61Z) in 200526.  The average cost per separation was $1,235 
with almost half of this (46.5%) being for emergency and critical care (Table 3-7).  Data from 
2005 do not include private hospitals, although 2003 data show that average private hospital 
costs were 19% lower than their public counterparts, yielding a cost per private separation of 
$1,002.  In 2005 there were 4,405 separations (92% of which were in public hospitals) for a 
total cost of $5.36 million.  Assuming that admissions for allergic reactions rises in line with 
the general population, in 2007 there would have been 4,532 separations, which in current 
prices (using health inflation of 3.7%) brings the inpatient cost to $5.9 million. 
                                               
25
 http://www.health.gov.au/internet/wcms/publishing.nsf/Content/88F4E78E15620A80CA2571CB0004DDAA 
26
 X61Z includes anaphylactic shock due to food, anaphylactic shock due to drugs, other serum reactions, 
angioneurotic oedema, and “unspecified allergies” 
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TABLE 3-7:  COST PER SEPARATION FOR ‘ALLERGIC REACTIONS’, PUBLIC HOSPITALS, 2005 
Category Direct Overhead Total % 
Emergency Depts $323 $92 $415 33.6% 
Ward Nursing $139 $34 $173 14.0% 
Critical Care $122 $37 $159 12.9% 
Ward Medical  $112 $14 $126 10.2% 
On-costs  $63 $63 5.1% 
Hotel  $56 $56 4.5% 
Non clinical salaries  $45 $45 3.6% 
Supplies $19 $25 $44 3.6% 
Pathology $34 $8 $42 3.4% 
Pharmacy $37 $5 $42 3.4% 
Depreciation  $26 $26 2.1% 
Imaging $19 $3 $22 1.8% 
Allied $12 $3 $15 1.2% 
Operating Rooms $4 $1 $5 0.4% 
Specialist Procedure Suites $1 $0 $1 0.1% 
Prosthetics  $1 $1 0.1% 
Total  $822 $412 $1,235 100% 
While the National Hospital Data Collection does not provide specific cost estimates for other 
allergic conditions, approximations can be used.  Hence for allergic respiratory conditions, 
this report uses DRG E02C “Other respiratory procedures (without complications); and for 
allergic skin conditions, the DRG J67A “Minor skin disorders”.27 
The AIHW records that in 2004-05, there were 2,525 hospitalisations for skin allergies (see 
Table 3-8).  Allowing for growth in line with population indicates 2,598 separations in 2007.  
The average cost in public hospitals (81% of separations) was $3,194 per separation in 
2004-05.  Assuming private hospitals are 19% cheaper, the average price was $2,592.  
Allowing for health inflation brings the average cost per separation in 2007 to $3,311.  
Multiplying this by the 2,598 separations in 2007 gives a total hospital cost of $8.60 
million. 
TABLE 3-8:  SKIN ALLERGY SEPARATIONS, 2004-05 
ICD-10 Category Number of separations 
L50.0 Allergic urticaria 1,369 
L20 Atopic dermatitis 956 
L23 Allergic contact dermatitis 200 
Total 2,525 
Source: AIHW Hospital Morbidity Database http://www.aihw.gov.au/hospitals/inhm_datab.cfm. 
Similarly, the AIHW records that there were 5,388 separations for allergic respiratory 
conditions in 2004-05 (see Table 3-9 below).  Allowing for growth in population indicates 
5,544 separations in 2007.  The average cost in public hospitals (56% of hospitalisations) 
was $3,240, and private hospitals $2,624.  Allowing for health inflation brings the average 
                                               
27
 In 2004-05 the AIHW records that there were 88 hospitalisations for “allergic and dietetic gastroenteritis and 
colitis” and 35 hospitalisations for “acute atopic conjunctivitis”.  These have not been costed. 
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cost per separation in 2007 to $3,193.  Multiplying this by the 5,544 separations in 2007 
gives a total hospital cost of $17.70 million. 
TABLE 3-9:  ALLERGIC RESPIRATORY SEPARATIONS, 2004-05 
ICD-10 Category No. 
Allergic Rhinitis 427 
Allergic Sinusitis (=49.4% of chronic sinusitis) 4,961 
Total Allergic Respiratory hospitalisations 5,388 
Source: AIHW Hospital Morbidity Database http://www.aihw.gov.au/hospitals/inhm_datab.cfm. 
There were a total of 12,674 hospital separations for (non-asthma) allergic 
conditions 2007, at a cost of $32.2 million.   
 
3.2.7 SUMMARY OF NAA COSTS, 2007 
For health expenditure to be presented on the same basis as asthma costs, allowances are 
made for hospital outpatients (non-admitted), aged care homes, allied health, research and 
non-allocated health costs using similar proportions relative to the total as those for asthma 
(Table 3-10).  Total health expenditure for NAA in 2007 was thus estimated as 
$349.3 million.  Dividing this by the estimated 4.08 million people with allergies in 2007 yields 
health expenditure per person of $85.63 per annum28. 
TABLE 3-10:  TOTAL HEALTH SYSTEM EXPENDITURE, NON-ASTHMA ALLERGIES, 2007 
Category $m % 
GP visit $113.5 32.5% 
Medication $59.4 17.0% 
Specialists $28.1 8.0% 
Pathology $4.8 1.4% 
Imaging $16.6 4.8% 
Hospital inpatients $32.2 9.2% 
Hospital outpatients $31.9 9.1% 
Aged care homes $7.3 2.1% 
Research $2.7 0.8% 
Allied health $9.1 2.6% 
Non-allocated health costs $43.7 12.5% 
TOTAL $349.3 100% 
 
                                               
28
 The individual cost burden varies widely, and falls more heavily on those with severe and chronic disease. 
Costs of antihistamines are approximately $24/month, nasal corticosteroids approximately $25/month, and the 
PBS patient contribution to a single asthma medication or eczema topical corticosteroid at around $33/month. It is 
therefore not difficult for a patient with chronic urticaria to spend $288/year, a patient with severe allergic rhinitis 
$588/year (on antihistamines and a nasal steroid, and even more if they need eyedrops as well), or a patient with 
allergic rhinitis, asthma and atopic eczema needing all medications approximately $984/year out of pocket. These 
costs are not subsidised by the PBS nor do they count towards the Medicare safety net. 
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3.3 TOTAL HEALTH SYSTEM EXPENDITURE BY BEARER 
Adding the 2007 total expenditures for asthma ($808.0 million) and other allergies 
($306.8 million) yields a total expenditure for that year of $1.16 billion.  Dividing this by the 
number of persons with allergies (4.08 million) produces an annual expenditure per person of 
$283.71. 
Based on the average distribution of who bears total health expenditure costs derived from 
AIHW (2007), the burden of this cost is apportioned as shown in Table 3-11.  The largest 
shares are borne by the Federal Government (eg, Medicare and Pharmaceutical Benefits 
subsidies) and State Governments (eg, hospital costs). 
TABLE 3-11:  DISTRIBUTION OF ALLERGY HEALTH COSTS, 2007 
Health Costs $m % 
Individuals $163.9 14.2% 
Family/Friends $37.5 3.2% 
Federal Government $496.5 42.9% 
State Government $288.2 24.9% 
Society/Other $171.3 14.8% 
Total $1,157.4 100% 
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4. OTHER FINANCIAL COSTS 
In addition to health system costs, allergy also imposes a number of other important financial 
costs on society and the economy, including the following. 
 Productivity losses of people with allergic disease comprise those from employment 
impacts, absenteeism and/or premature mortality. 
 Carer costs comprise the value of care services provided in the community primarily 
by informal carers and not captured in health system costs. 
 Other costs comprise the cost of aids, home modifications and other pertinent 
financial costs not captured elsewhere. 
 Transfer costs comprise the DWL associated with government transfers such as 
taxation revenue foregone, welfare and disability payments. 
It is important to make the economic distinction between real and transfer costs. 
 Real costs use up real resources, such as capital or labour, or reduce the economy’s 
overall capacity to produce goods and services. 
 Transfer payments involve payments from one economic agent to another that do not 
use up real resources, for example, a disability support pension, or taxation revenue. 
Data on other financial costs are drawn from a variety of sources – for example, the literature 
(focusing on Australian literature but sometimes supplemented by international material), 
data from the ABS Survey of Disability, Ageing and Carers (SDAC), ABS data on Average 
Weekly Earnings (AWE) and so on. 
4.1 PRODUCTIVITY LOSSES 
Productivity losses are the cost of production that is lost when people with allergy are unable 
to work because of the condition.  They may work less than they otherwise would (either 
being employed less, being absent more often or being less productive while at work) or they 
may die prematurely.  Access Economics adopts a human capital approach to measurement 
of productivity losses in developed countries. 
4.1.1 EMPLOYMENT IMPACTS 
Allergy can affect a person’s ability to work.  If employment rates are lower for people with 
allergy, this loss in productivity represents a real cost to the economy.  Data for the reduction 
in employment due to allergy was sourced from the ABS SDAC, which reported the likelihood 
of being employed if persons experienced allergy (72.9%) compared with the likelihood of 
being employed if they were in the general population (73.9%). Therefore, people with allergy 
had an overall employment reduction of around 1%. This data was then combined with 
average weekly earnings (AWE) and employment rates for each respective age-gender 
group to calculate the lost earnings due to reduced employment.  
The annual cost of lost earnings due to reduced employment is estimated at 
around $1.1 billion in 2007.  
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4.1.2 ABSENTEEISM AND LOST HOUSEHOLD PRODUCTIVITY 
Allergy can adversely affect work performance through absence from work due to the allergy 
(‘absenteeism’).  Absenteeism is measured by looking at the number of work days missed by 
people with allergy.  Data for absenteeism were obtained from the ABS NHS, which reported 
that there were 3,209,200 people with allergy taking 1,083,200 days away per year due to 
their own illness29.  This meant there were 0.34 days per person per year of absenteeism due 
to allergy.  The same number of days is estimated to be lost, for those who do not work, from 
their household productivity, which is valued at 30% of the average wage rate. 
Based on these parameters and the AWE for each age-gender group, Access 
Economics estimates that in 2007, the total cost of absenteeism due to allergy 
is $196 million. This includes around $166 million due to absenteeism for people 
in paid work and around $31 million in lost household productivity for those in 
unpaid work. 
4.1.3 PRESENTEEISM 
Allergy can also affect a person’s ability to work effectively while at work (‘presenteeism’).  
Presenteeism can be estimated by multiplying the number of days worked with allergy by the 
percentage reduction in effectiveness on days worked with allergy.  For example, four days 
worked with allergy with a 50% decrease in work effectiveness would result in an estimate of 
two reduced effectiveness work days.  
Lamb et al (2006), studying a broad cross section of 8,267 employees at 47 employer 
locations across the US between 2001 and 2002, found that employees who experienced 
allergic rhinitis did so for 52.5 days per year, and were unproductive for 2.3 hours per typical 
8-hour work day while they were symptomatic.  Given the lack of data and the relative 
similarities between the populations, these results have been applied to Australia.  This 
allows us to isolate the days with lower productivity at 48.9 days per year and calculate a 
reduction of productivity of 3.9% per year for those with allergy.  Using this proportion and 
the AWE for each age-gender group, the lost work effectiveness (or lost productivity) can 
then be calculated. 
Access Economics estimates that in 2007, the total cost of presenteeism due 
to allergy is $4.2 billion. 
4.1.4 PREMATURE DEATH 
Section 1.4 estimated 586 deaths due to allergy in 2007 (298 males and 289 females).  
Based on this case mortality risk, and incorporating employment rates and estimates of 
average lifetime earnings for different age groups, the present value of lost earnings due to 
mortality among those who would otherwise have been employed is shown in Figure 4-1. 
                                               
29
 That is, as opposed to taking time off to care for someone else’s illness 
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The estimated annual cost due to lost productivity from premature death 
due to allergy is $83.6 million in 2007. 
FIGURE 4-1:  ALLERGY, COSTS OF PREMATURE MORTALITY BY AGE AND GENDER ($ MILLION) 
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Source: Access Economics based a RR of mortality of 1.02 for allergy across all ages. 
Premature death also leads to additional search and hiring costs for replacement workers.  
These are estimated as the number of people with allergy who die prematurely (by age and 
gender) multiplied by their chance of being employed multiplied by the search and hiring cost 
brought forward three years (the search and hiring cost is estimated as 26 weeks at AWE 
and the three year bring forward reflects average staff turnover rates in Australia).  
In 2007, additional search and hiring costs are estimated as $118,172 for 
people with allergy, based on the present value of bringing forward three years 
of average cost of staff turnover (26 weeks at AWE). 
4.1.5 LOST TAXATION REVENUE 
Reduced earnings due to reduced workforce participation, absenteeism and premature death 
also have an effect on taxation revenue collected by the Government.  As well as forgone 
income (personal) taxation, there will also be a fall in indirect (consumption) tax, as those 
with lower incomes spend less on the consumption of goods and services. 
Personal income tax forgone is a product of the average personal income tax rate (18.3%) 
and the forgone income.  With allergy and lower income, there will be less consumption of 
goods and services, with the indirect taxation rate estimated as 15.1%.  These average 
taxation rates are derived for 2007 from the Access Economics macroeconomic model 
(AEM).  
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Around $1.9 billion in lost potential tax revenue is estimated to be incurred 
in 2007, due to the reduced productivity of people with allergy. 
Lost taxation revenue is considered a transfer payment, rather than an economic cost per se. 
However, raising additional taxation revenues does impose real efficiency costs on the 
Australian economy, known as deadweight losses (DWLs).  Administration of the taxation 
system costs around 1.25% of revenue raised (derived from total amounts spent and 
revenue raised in 2000-01, relative to Commonwealth department running costs).  Even 
larger DWLs arise from the distortionary impact of taxes on workers’ work and consumption 
choices.  These distortionary impacts are estimated to be 27.5% of each tax dollar collected 
(Lattimore, 1997 and used in Productivity Commission, 2003:6.15-6.16, with rationale).  
Altogether the DWL is 28.75% of the value of the taxation forgone (Section 4.5).  
Access Economics estimates that around $0.7 billion in deadweight loss is 
incurred in 2007, due to the additional taxation required to replace that forgone 
due to lost productivity of people with allergy (Table 4-1). 
TABLE 4-1:  LOST EARNINGS AND TAXATION DUE TO ALLERGY, 2007 
Average personal income tax rate* 18.3% 
Potential personal income tax lost $1.1 billion 
Average indirect tax rate* 15.1% 
Potential indirect tax lost $0.8 billion 
Total potential tax revenue lost  $1.9 billion 
Deadweight loss from additional taxation $0.5 billion 
* Source: Access Economics macroeconomic model (2007). 
Welfare payments made to people who are no longer working must, in a budget-neutral 
setting, also be funded by additional taxation.  The DWLs associated with welfare transfers 
are calculated in Section 4.5, where the nature of DWLs is explained in more detail. 
4.2 CARER COSTS 
Carers are people who provide informal care to others in need of assistance or support. Most 
informal carers are family or friends of the person receiving care.  Carers may take time off 
work to accompany people with allergy to medical appointments, stay with them in hospital, 
or care for them at home. Carers may also take time off work to undertake many of the 
unpaid tasks that the person with allergy would do if they did not have allergy and were able 
to do these tasks. 
Data from the 2003 SDAC sourced specifically for this report identified around 81,500 
primary carers who cared for people with allergy as their main condition.  
However, it is important to avoid double counting the people with allergy who would have 
received care anyway. As such it is necessary to identify the ‘excess’ amount of care 
provided to people with allergy by calculating the usage rates of informal care for people with 
allergy (2.1% of people with allergies have a primary carer, where allergy is the main 
condition) and comparing them to informal care usage rates for the general Australian 
population (2.4% of the general population have a primary carer, with very little difference in 
the age-gender distribution of the respective populations).  In summary, SDAC data show 
that the use of carers is neither significantly lower nor higher by age and gender than for the 
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general population. Hence, it was concluded that no additional costs (attributable to 
allergy) were incurred due to the use of informal carers.  
 This is not to say that there are no additional costs imposed on people who care for 
people with allergies even where they would still have cared for them in the absence of 
the allergy.  Parents, for example, may spend considerable time moisturising a child 
with severe atopic dermatitis, undertaking allergen avoidance measures, taking them to 
medical appointments, or in extra time required to shop or prepare special meals for a 
child with food allergy.   However, in the absence of solid data, no attempt has been 
made to quantify these costs. 
4.3 AIDS AND HOME MODIFICATIONS 
People with allergies use aids such as dust mite covers, asthma medication spacers, asthma 
nebulisers, wet dressings for eczema, special vacuum cleaners, HEPA filters and allergen 
avoidance measures.  However, in the absence of allergy-specific studies, cost estimates for 
aids and home modifications are derived from previously estimated average costs for all 
persons with disabilities. 
Aids and home modifications are those not captured in formal health sector or disability 
services costs that include equipment and technology in order to assist with daily living.  
Estimates of aids and modifications costs are based on data from the ABS SDAC for people 
with allergy as their main condition. These data are then compared to utilisation rates of aids 
and modifications for the rest of the SDAC survey population to estimate the ‘excess’ aids 
and modifications used by people with allergy, relative to people without allergy. 
Results from SDAC show that of those who reported allergy as their main condition: 
 66.9% used at least one type of self care aid compared to 48.3% without; 
 15.8% used mobility aids compared to 12.8% without; and 
 11.5% made modifications to their home compared to 10.9% without. 
Costs for various products are based on prices provided by the Independent Living Centre 
NSW, the Victorian Aids and Equipment Program and previous studies undertaken by 
Access Economics, inflated to 2007 prices. While some equipment and modifications require 
large outlays but should last a number of years (eg, nebuliser machines), other devices need 
to be replaced more regularly (eg, plastic spacers crack in dishwashers).. 
Overall, the cost for aids and equipment for people with allergy was 
estimated at around $259.1 million in 2007 – or $64 per person with allergy.  
As it is not known how much of this cost is subsidised by governments, paid for by the 
person with allergy or their family and friends, or paid for through community programs, the 
amount is allocated in four equal portions to the Federal Government, State and Territory 
governments, family and friends and society/other. 
4.4 FUNERAL COSTS 
The ‘additional’ cost of funerals borne by family and friends of people with allergy is based on 
the additional likelihood of death associated with allergy (Section 1.4) in the period that the 
person experiences it.  However, some patients (particularly older patients) would have died 
during this time anyway.  Eventually everyone must die and thus incur funeral expenses – so 
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the true cost is the cost brought forward (adjusted for the likelihood of dying anyway in a 
given year).  The BTRE (2000) calculated a weighted average cost of a funeral across all 
States and Territories, to estimate an Australian total average cost of $3,200 per person for 
1996, or $4,154 per person who died in 2007. 
The bring forward of funeral costs associated with premature death for people 
with allergy is estimated at around $2.4 million in 2007. 
 
4.5 DEADWEIGHT LOSSES FROM TRANSFERS 
4.5.1 WELFARE AND INCOME SUPPORT PAYMENTS 
Transfer payments represent a shift of resources from one economic entity to another. The 
act of taxation and redistribution creates distortions and inefficiencies in the economy, so 
transfers also involve real net costs to the economy. 
Data regarding the number of people on income support payments was sourced from 
Centrelink Australia, specially for this report.  It was difficult to specifically identify individuals 
on income support due to allergy as this condition is not separately isolated in the Centrelink 
data.  Instead, data from available allergy-related conditions such as asthma and eczema 
were used and combined with allergy-related attributable fractions to conservatively estimate 
the number of income support recipients due to allergy.  The most commonly received 
Centrelink work related benefit was the Disability Support Pension (DSP), which Access 
Economics conservatively estimates 5,726 people living with allergy were receiving due to 
their allergies in June 2007.  There were also an estimated 1,962 people with allergy 
receiving Newstart Allowance (NA) and 37 people receiving Sickness Allowance (SA), due to 
their allergies. 
The value of these payments in 2007 is estimated to be around $89 million30. However, some 
of these people would have ordinarily received welfare payments which must be netted out to 
estimate the additional welfare payments due to allergy, using a Melbourne University study 
(Tseng and Wilkins, 2002) about the ‘reliance’ of the general population (aged 15-64 years) 
on income support of around 12%.  Factoring down the $89 million by this 12% gives a cost 
of welfare reliance on DSP, NA and SA due to allergy of around $78 million per annum 
in 2007. 
4.5.2 DEADWEIGHT LOSSES 
The welfare payments calculated immediately above are, like taxation revenue losses, not 
themselves economic costs but, rather, a financial transfer from taxpayers to the income 
support recipients.  The real resource cost of these transfer payments is only the associated 
DWL. 
DWLs refer to the costs of administering welfare pensions and raising additional taxation 
revenues.  Although invalid and sickness benefits and forgone taxation are transfers, not real 
costs (so should not be included in the estimation of total costs) it is still worthwhile 
                                               
30
 Based on a payment of $446.60 per fortnight for DSP; and $429.80 for NSA and SA. 
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estimating them as that helps us understand how the total costs of allergy are shared 
between the taxpayer, the individual and other financiers.   
There are two sources of lost tax revenue that result from the lower earnings – the potential 
income tax forgone and the potential indirect (consumption) tax forgone.  The latter is lost 
because, as income falls, so does consumption of goods and services.  The average 
personal income tax rate used is 18.3% and the average indirect taxation rate used is 15.1%, 
based on parameters for 2007 from the Access Economics macroeconomic model. 
Transfer payments (Government payments/services and taxes) are not a net cost to society 
as they represent a shift of consumption power from one group of individuals to another in 
society.  If the act of taxation did not create distortions and inefficiencies in the economy, 
then transfers could be made without a net cost to society.  However, through these 
distortions, taxation does impose a DWL on the economy. 
DWL is the loss of consumer and producer surplus, as a result of the imposition of a 
distortion to the equilibrium (society preferred) level of output and prices.  Taxes alter the 
price and quantity of goods sold compared to what they would be if the market were not 
distorted, and thus lead to some diminution in the value of trade between buyers and sellers 
that would otherwise be enjoyed (Figure 4-5). 
FIGURE 4-2:  DWL OF TAXATION 
Price ($)
Output
Supply
Demand
Price plus Tax
Price
Taxation Revenue
Actual Quantity 
Supplied
Potential Quantity 
Supplied
Deadweight Loss (cost 
of raising taxation 
revenue)
 
The rate of DWL used in this report is 27.5 cents per $1 of tax revenue raised plus 1.25 cents 
per $1 of tax revenue raised for Australian Taxation Office administration, based on 
Productivity Commission (2003) in turn derived from Lattimore (1997), ie, 28.75% overall.  
The total extra tax dollars required to be collected include: 
 the taxation revenue lost as a result of allergy and its impacts (with $0.5 billion of DWL 
in the case of allergy); 
 the value of government services provided (including the Government-funded 
component of health system costs, with $0.2 billion of DWL); and 
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 the additional induced social welfare payments required to be paid (with $22 million of 
DWL). 
Thus the DWL for people with allergy in 2007 is estimated at around 
$0.8 billion.  
 
4.6 SUMMARY OF OTHER FINANCIAL COSTS 
In total, the non-health related financial costs of allergy pain are estimated 
to be around $6.6 billion in 2007. 
TABLE 4-2:  SUMMARY OF OTHER FINANCIAL COSTS OF ALLERGY, 2007 
$ million
Productivity costs 5,598.1
Lower productivity 4,192.9
Absenteeism 195.9
Lower employment 1,125.5
Premature death 83.6
Search and hiring costs 0.1
Carer costs 0.0
Aids and modifications 259.1
Funeral costs 2.4
Deadweight loss 782.7
Total other financial costs 6,642.3
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5. BURDEN OF DISEASE 
The disability, loss of wellbeing and premature death that result from allergic disease are 
more difficult to measure, but have been analysed in this chapter in terms of the years of 
healthy life lost, both quantitatively and qualitatively, known as the ‘burden of disease’, with 
an imputed value of a statistical life year (VSLY) so as to compare these costs with financial 
costs of allergy. 
5.1 METHODOLOGY – VALUING LIFE AND HEALTH 
Since Schelling’s (1968) discussion of the economics of life saving, the economic literature 
has properly focused on willingness to pay (willingness to accept) measures of mortality 
and morbidity risk.  Using evidence of market trade-offs between risk and money, including 
numerous labour market and other studies (such as installing smoke detectors, wearing 
seatbelts or bike helmets etc), economists have developed estimates of the Value of a 
‘Statistical’ Life (VSL). 
The willingness to pay approach estimates the value of life in terms of the 
amounts that individuals are prepared to pay to reduce risks to their lives.  It uses 
stated or revealed preferences to ascertain the value people place on reducing 
risk to life and reflects the value of intangible elements such as quality of life, 
health and leisure.  While it overcomes the theoretical difficulties of the human 
capital approach, it involves more empirical difficulties in measurement (BTE, 
2000:20-21). 
Viscusi and Aldy (2002) summarise the extensive literature in this field, most of which has 
used econometric analysis to value mortality risk and the ‘hedonic wage’ by estimating 
compensating differentials for on-the-job risk exposure in labour markets, in other words, 
determining what dollar amount would be accepted by an individual to induce him/her to 
increase the possibility of death or morbidity by a given percentage.  They find the VSL 
ranges between US$4 million and US$9 million with a median of US$7 million (in year 2000 
US dollars), similar but marginally higher than the VSL derived from US product and housing 
markets, and also marginally higher than non-US studies, although all in the same order of 
magnitude.  They also review a parallel literature on the implicit value of the risk of non-fatal 
injuries. 
A particular life may be regarded as priceless, yet relatively low implicit values 
may be assigned to life because of the distinction between identified and 
anonymous (or ‘statistical’) lives.  When a ‘value of life’ estimate is derived, it is 
not any particular person’s life that is valued, but that of an unknown or statistical 
individual (Bureau of Transport and Regional Economics, 2002:19). 
Weaknesses in this approach, as with human capital, are that there can be substantial 
variation between individuals.  Extraneous influences in labour markets such as imperfect 
information, income/wealth or power asymmetries can cause difficulty in correctly perceiving 
the risk or in negotiating an acceptably higher wage. 
Viscusi and Aldy (2002) include some Australian studies in their meta-analysis, notably 
Kniesner and Leeth (1991) of the ABS with VSL of US2000 $4.2 million and Miller et al 
(1997) of the National Occupational Health and Safety Commission (NOHSC) with quite a 
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high VSL of US2000$11.3m-19.1 million (Viscusi and Aldy, 2002, Table 4, pp92-93).  Since 
there are relatively few Australian studies, there is also the issue of converting foreign (US) 
data to Australian dollars using either exchange rates or purchasing power parity and 
choosing a period. 
Access Economics (2003) presents outcomes of studies from Yale University (Nordhaus, 
1999) – where VSL is estimated as $US2.66m; University of Chicago (Murphy and Topel, 
1999) – US$5m; Cutler and Richardson (1998) – who model a common range from US$3m 
to US$7m, noting a literature range of $US0.6m to $US13.5m per fatality prevented (1998 
US dollars).  These eminent researchers apply discount rates of 0% and 3% (favouring 3%) 
to the common range to derive an equivalent of $US 75,000 to $US 150,000 for a year of life 
gained. 
5.1.1 DISABILITY ADJUSTED LIFE YEARS (DALYS) AND QUALITY 
ADJUSTED LIFE YEARS (QALYS) 
In an attempt to overcome some of the issues in relation to placing a dollar value on a human 
life, in the last decade an alternative approach to valuing human life has been derived.  The 
approach is non-financial, where allergy, suffering and premature mortality are measured in 
terms of DALYs, with 0 representing a year of perfect health and 1 representing death (the 
converse of a QALY where 1 represents perfect health).  This approach was developed by 
the World Health Organization, the World Bank and Harvard University and provides a 
comprehensive assessment of mortality and disability from diseases, injuries and risk factors 
in 1990, projected to 2020 (Murray and Lopez, 1996).  Methods and data sources are 
detailed further in Murray et al (2001). 
The DALY approach has been adopted and applied in Australia by the AIHW with a separate 
comprehensive application in Victoria.  Mathers et al (1999) from the AIHW estimate the BoD 
and injury in 1996, including separate identification of premature mortality; Years of Life Lost 
due to Premature Mortality (YLL), and morbidity; Years of Healthy Life Lost due to Disability 
(YLD) components.  In any year, the disability weight of a disease (for example, 0.18 for a 
broken wrist) reflects a relative health state.  In this example, 0.18 would represent losing 
18% of a year of healthy life because of the inflicted injury. 
The DALY approach has been successful in avoiding the subjectivity of individual valuation 
and is capable of overcoming the problem of comparability between individuals and between 
nations, although nations have subsequently adopted variations in weighting systems.  For 
example, in some countries DALYs are age-weighted for older people although in Australia 
the minority approach is adopted – valuing a DALY equally for people of all ages. 
The main problem with the DALY approach is that it is not financial and is thus not directly 
comparable with most other cost measures.  In public policy making, therefore, there is 
always the temptation to re-apply a financial measure conversion to ascertain the cost of an 
injury or fatality or the value of a preventive health intervention.  Such financial conversions 
tend to utilise ‘willingness to pay’ or risk-based labour market studies described above. 
The Department of Health and Ageing (based on work by Applied Economics) adopted a 
very conservative approach to this issue, placing the value of a human life year at around 
A$60,000 per annum, which is lower than most international lower bounds on the estimate. 
“In order to convert DALYs into economic benefits, a dollar value per DALY is 
required.  In this study, we follow the standard approach in the economics 
literature and derive the value of a healthy year from the value of life.  For 
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example, if the estimated value of life is A$2 million, the average loss of healthy 
life is 40 years, and the discount rate is 5% per annum, the value of a healthy 
year would be $118,000.31 Tolley, Kenkel and Fabian (1994) review the literature 
on valuing life and life years and conclude that a range of US$70,000 to 
US$175,000 per life year is reasonable.  In a major study of the value of health of 
the US population, Cutler and Richardson (1997) adopt an average value of 
US$100,000 in 1990 dollars for a healthy year. 
Although there is an extensive international literature on the value of life (Viscusi, 
1993), there is little Australian research on this subject.  As the Bureau of 
Transport Economics (BTE) (in BTE, 2000) notes, international research using 
willingness to pay values usually places the value of life at somewhere between 
A$1.8 and A$4.3 million.  On the other hand, values of life that reflect the present 
value of output lost (the human capital approach) are usually under $1 million. 
The BTE (2000) adopts estimates of $1 million to $1.4 million per fatality, 
reflecting a 7% and 4% discount rate respectively.  The higher figure of $1.4 
million is made up of loss of workforce productivity of $540,000, loss of 
household productivity of $500,000 and loss of quality of life of $319,000.  This is 
an unusual approach that combines human capital and willingness to pay 
concepts and adds household output to workforce output. 
For this study, a value of $1 million and an equivalent value of $60,000 for a 
healthy year are assumed.32 In other words, the cost of a DALY is $60,000.  This 
represents a conservative valuation of the estimated willingness to pay values for 
human life that are used most often in similar studies.33” (DoHA, 2003, pp11-12).” 
As the citation concludes, the estimate of $60,000 per DALY is very low.  The Viscusi (1993) 
meta-analysis referred to reviewed 24 studies with values of a human life ranging between 
$US 0.5 million and $US 16m, all in pre-1993 US dollars.  Even the lowest of these 
converted to 2003 Australian dollars at current exchange rates, exceeds the estimate 
adopted ($1m) by nearly 25%.  The BTE study tends to disregard the literature at the higher 
end and also adopts a range (A$1-$1.4m) below the lower bound of the international range 
that it identifies (A$1.8-$4.3m). 
The rationale for adopting these very low estimates is not provided explicitly.  Certainly it is in 
the interests of fiscal restraint to present as low an estimate as possible. 
In contrast, the majority of the literature as detailed above appears to support a higher 
estimate for VSL, as presented in Table 5-1, which Access Economics believes is important 
to consider in disease costing applications and decisions.  The US dollar values of the lower 
bound, midrange and upper bound are shown.  The ‘average’ estimate is the average of the 
range excluding the high NOHSC outlier.  Equal weightings are used for each study as the: 
 Viscusi and Aldy meta-analysis summarises 60 recent studies; 
                                               
31
 In round numbers, $2,000,000 = $118,000/1.05 + $118,000/(1.05)2 + … + $118,000/(1.05).40 [Access 
Economics comment: The actual value should be $116,556, not $118,000 even in round numbers.] 
32
 The equivalent value of $60,000 assumes, in broad terms, 40 years of lost life and a discount rate of 5%. 
[Access Economics comment: More accurately the figure should be $58,278.] 
33
 In addition to the cited references in the text, see for example Murphy and Topel’s study (1999) on the 
economic value of medical research. [Access Economics comment. Identical reference to our Murphy and Topel 
(1999).] 
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 ABS study is Australian; and 
 Yale and Harvard studies are based on the conclusions of eminent researchers in the 
field after conducting literature analysis. 
Where there is no low or high US dollar estimate for a study, the midrange estimate is used 
to calculate the average.  The midrange estimates are converted to Australian dollars at 
purchasing power parity (as this is less volatile than exchange rates) of USD=0.7281AUD for 
2003 as estimated by the OECD. 
Access Economics concludes the VSL range in Australia lies between $3.7m and $9.6m34, 
with a mid-range estimate of $6.5m. These estimates have conservatively not been inflated 
to 2007 prices, given the uncertainty levels. 
TABLE 5-1:  INTERNATIONAL ESTIMATES OF VSL, VARIOUS YEARS 
 
US$m A$m 
 
Lower Midrange Upper 0.7281 
Viscusi and Aldy meta-
analysis 2002 
4 7 9 9.6 
Australian: ABS 1991  4.2  5.8 
 NOHSC 1997 11.3  19.1  
Yale (Nordhaus) 1999  2.66  3.7 
Harvard (Cutler and 
Richardson) 1998 
0.6 5 13.7 6.9 
Average*  2.9 4.7 7.4 6.5 
* Average of range excluding high NOHSC outlier, using midrange if no data; conservatively not inflated 
A$m conversions are at the OECD 2003 PPP rate 
5.1.2 DISCOUNT RATES 
A discount rate is used to convert future income or a cost stream into the equivalent value in 
today’s dollars. 
Choosing an appropriate discount rate for present valuations in cost analysis is a subject of 
some debate, and can vary depending on what type of future income or cost stream is being 
considered.  There is a substantial body of literature, which often provides conflicting advice, 
on the appropriate mechanism by which costs should be discounted over time, properly 
taking into account risks, inflation, positive time preference and expected productivity gains. 
The absolute minimum option that one can adopt in discounting future income and costs is to 
set future values in current day dollar terms on the basis of a risk free assessment about the 
future (that is, assume the future flows are similar to the certain flows attaching to a long term 
Government bond). 
Wages should be assumed to grow in dollar terms according to best estimates for inflation 
and productivity growth.  In selecting discount rates for this project, we have thus settled 
upon the following as the preferred approach. 
                                               
34
 Calculated from the non-indexed studies themselves. Converting the Access Economics average estimates 
from USD to AUD at purchasing power parity (PPP) would provide slightly higher estimates - $3.9 million and 
$10.2m, with the same midrange estimate. 
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 Positive time preference:  Access Economics uses the long term nominal bond rate 
of 5.8% pa (from recent history) as the parameter for this aspect of the discount rate (If 
there were no positive time preference, people would be indifferent between having 
something now or a long way off in the future, so this applies to all flows of goods and 
services). 
 Inflation:  The Reserve Bank has a clear mandate to pursue a monetary policy that 
delivers 2% to 3% inflation over the course of the economic cycle.  This is a realistic 
longer run goal and we therefore use a value of 2.5% pa for this variable (It is important 
to allow for inflation in order to derive a real (rather than nominal) rate).  Health inflation 
over recent years has been somewhat higher, at around 3.2%. 
 Productivity growth: The Commonwealth Government's Intergenerational 
Report 2007 assumed productivity growth of 1.5% in the decade to 2010 and 1.75% 
thereafter.  We suggest 1.75% for the purposes of this analysis as many of the 
productivity costs extend past 2010. 
There are then three different real discount rates that should be applied: 
 To discount income streams of future earnings, the discount rate is: 
5.8 - 2.5 - 1.75 = 1.55%. 
 To discount health costs, the discount rate is: 
5.8 - (3.2 - 1.75) - 1.75 = 2.6%. 
 To discount other future streams (healthy life) the discount rate is: 
5.8 – 2.5 = 3.3% 
While there may be sensible debate about whether health services (or other costs with a high 
labour component in their costs) should also deduct productivity growth from their discount 
rate, we argue that these costs grow in real terms over time significantly as a result of other 
factors such as new technologies and improved quality, and we could reasonably expect this 
to continue in the future. 
Discounting the VSL of $3.7m from Table 5-1 by the discount rate of 3.3% over an average 
40 years expected life span (the average from the meta-analysis of wage-risk studies) 
provides an estimate of the Value of a Statistical Life Year (VSLY) of $162,561. 
5.2 BURDEN OF DISEASE DUE TO ALLERGY 
5.2.1 DISABILITY WEIGHTS 
One of the main costs of allergy is the loss of wellbeing and quality of life that it entails.  This 
can be estimated by initially allocating a disability weight to allergy. 
The disability35 weights used in this study are based originally on those available from the 
AIHW (Mathers et al, 1999). 
 The available disability weight of 0.03 for people with asthma and the disability weight 
of 0.061 for people with sinusitis were used to conservatively estimate an overall 
disability weight for people with allergy of 0.037. This (weighted average) estimate was 
                                               
35
 The disability weights used in DALYs are objectively assessed by experts, and are preferred over the various 
subjective health utility indexes used in QALYs.  QALYs also do not incorporate mortality. 
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obtained by applying the attributable fractions of asthma and sinusitis to allergy 
outlined in Section 2.1 to estimate an overall disability weight for all allergies. 
5.2.2 YEARS OF LIFE LOST DUE TO DISABILITY 
Based on the disability weight outlined above and the total number of people experiencing 
allergy, the YLD for allergy has been calculated by gender (Table 5-2), for the year 2007.   
In total, YLD for allergy was an estimated 150,313 DALYs in 2007. 
TABLE 5-2:  ESTIMATED YEARS OF HEALTHY LIFE LOST DUE TO DISABILITY (YLD), 2007 (DALYS) 
Estimated disability 
weight
Prevalence YLD
Males 0.037                         1,852,455    68,257         
Females 0.037                         2,226,961    82,056         
 
5.2.3 YEARS OF LIFE DUE TO PREMATURE DEATH 
Based on the relative risk of mortality due to allergy outlined above in Section 1.4, it is 
estimated that there are around 586 deaths per year due to allergy.  The years of life lost 
due to premature death (YLL) have been estimated from the age-gender distribution of 
deaths by the corresponding YLL for the age of death in the Standard Life Expectancy Table 
(West Level 26) with a discount rate of 3.3% and no age weighting (Table 5-3).   
In total, YLL for allergy was an estimated 5,831 DALYs in 2007. 
TABLE 5-3:  YEARS OF LIFE LOST DUE TO PREMATURE DEATH (YLL) DUE TO ALLERGY, 2007 
15-29 30-39 40-49 50-59 60-69 70-79 80+ Total
Males 298         245         310         455         567         632         559         3,066      
Females 133         141         268         402         481         561         779         2,765      
Persons 431         386         578         857         1,048      1,193      1,338      5,831      
 
5.2.4 TOTAL DALYS DUE TO ALLERGY 
The overall loss of wellbeing due to allergy is estimated as 156,144 DALYs.  
Figure 5-1 illustrates the YLD and YLL components by age and gender.  The greatest impact 
of allergy is in young adulthood to middle age, reflecting the physiology of allergy and higher 
YLD due to the large number of Australians with allergy in this cohort.  
 77% of DALYs occur in the 15-64 age group – demonstrating that allergy has a 
significant impact on the workforce age population.  
Indicative of the greater prevalence and hence greater YLD, it can also be seen that the 
largest loss of wellbeing due to allergy in Australia is among women (54% of total DALYs). 
 The economic impact of allergic disease 
 
 
 
67 
FIGURE 5-1:  LOSS OF WELLBEING DUE TO ALLERGY (DALYS), BY AGE AND GENDER, 2007 
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Multiplying the number of DALYs by the VSLY ($162,561) provides an estimate of the gross 
dollar value of the loss of wellbeing due to allergy. 
The estimated gross cost of lost wellbeing from allergy is $25.4 billion 
in 2007. This reflects the relatively high prevalence of allergy in the 
community and its disability weight of 0.037. 
5.2.5 NET VALUE OF A HEALTHY LIFE LOST 
Bearing in mind that the wage-risk studies underlying the calculation of the VSL take into 
account all known personal impacts – suffering and premature death, lost wages/income, 
out-of-pocket personal health costs and so on – the estimate of $25.4 billion should be 
treated as a ‘gross’ figure.  However, costs specific to allergy that are unlikely to have 
entered into the thinking of people in the source wage/risk studies should not be netted out 
(eg, publicly financed health spending, care provided voluntarily).  The results after netting 
out are presented in Table 5-4. 
TABLE 5-4:  NET COST OF LOST WELLBEING, $MILLION, 2007 
Gross cost of wellbeing 25,383
Less production losses net of tax 3,646
Less health costs borne out-of-pocket 164
Net cost of lost wellbeing 21,573
 
The net cost of lost wellbeing due to allergy is estimated to be $21.6 billion 
in 2007. 
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6. SUMMARY OF ECONOMIC IMPACTS 
The economic cost of allergy in 2007 is summarised in Table 6-1. 
 The total cost of allergy was estimated at $29.4 billion – or $7,200 per person with 
allergy.  
 The total financial cost of allergy was $7.8 billion in 2007. This excludes the burden 
of disease component (the economic value of disability and premature mortality). 
 These are real economic costs that include productivity losses (72%), health 
system costs (15%), deadweight losses (DWLs) (10%), and other indirect 
costs (3%). 
 
TABLE 6-1:  ALLERGY COST SUMMARY, 2007 
Individuals Family/Friends
Federal 
Government
State and 
Territory 
Governments
Employers Society/Other Total
Burden of disease 21,573 0 0 0 0 0 21,573
Health system costs 164 38 497 288 0 171 1,157
Productivity costs 3,646 0 1,860 0 93 0 5,598
Carer costs 0 0 0 0 0 0 0
Other Indirect costs 0 67 65 65 0 65 262
Deadweight losses 0 0 0 0 0 783 783
Transfers -78 0 78 0 0 0 0
Total financial costs 3,732 105 2,499 353 93 1,019 7,800
Total costs including 
burden of disease 25,305 105 2,499 353 93 1,019 29,373
Burden of disease 5,288 0 0 0 0 0 5,288
Health system costs 40 9 122 71 0 42 284
Productivity costs 894 0 456 0 23 0 1,372
Carer costs 0 0 0 0 0 0 0
Other Indirect costs 0 16 16 16 0 16 64
Deadweight losses 0 0 0 0 0 192 192
Transfers -19 0 19 0 0 0 0
Total financial costs 915 26 613 87 23 250 1,912
Total costs including 
burden of disease 6,203 26 613 87 23 250 7,200
Total cost ($ million)
Cost per person with allergy ($)
 
When analysing the total costs of allergy in 2007, the BoD accounts by far for the largest 
share (at 73%).  Productivity costs are the next largest component, making up 19% and 
reflecting the relatively high prevalence and productivity impact of allergy among the working 
age population.  Health system costs represent a further 4%, while DWLs and other indirect 
costs make up the remaining 4% (Figure 6-1).  
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FIGURE 6-1:  TOTAL COSTS OF ALLERGY BY TYPE, 2007 
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The largest share of allergy costs is borne by people with allergy themselves who, principally 
due to the large BoD costs, bear 86% of total costs; 9% of total costs are borne by the 
Federal Government, due primarily to their share of health system and productivity costs. 
State and Territory governments 1%, Employers bear less than 1%, while the remaining 3% 
is borne by society and family and friends. 
FIGURE 6-2:  TOTAL COSTS OF ALLERGY BY BEARER, 2007 
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If just the financial costs are considered, the relative shares by bearer are shown in Figure 
6-3, with individuals bearing the largest share owing to the productivity impacts (48%), 
followed by the Federal Government (32%). 
FIGURE 6-3:  FINANCIAL COSTS OF ALLERGY BY BEARER, 2007 
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The costs of allergies can be compared to other diseases that Access Economics has 
evaluated using the same methodology.  For example, the burden of disease from allergies 
($21.5 billion) is almost twice as large as those estimated for arthritis ($11.7 billion) or 
hearing loss ($11.7 billion).36  Similarly, the financial cost of allergies ($7.8 billion) is greater 
than that for schizophrenia ($1.8 billion) and bipolar disorder ($1.6 billion) combined.37 
                                               
36
 Access Economics (2005) and (2007).  
37
 Access Economics (2002) and (2003) 
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7. ALLERGY/IMMUNOLOGY SPECIALIST WORKFORCE 
This chapter examines the distribution of specialist allergy/immunology services across 
Australia, including projections for future requirements.  An allergy/immunology specialist is 
defined as a registered medical practitioner with recognised specialist qualifications in 
allergy/immunology whose work is principally concerned with the discipline of 
allergy/immunology, including patient consultations, medical research, administration, 
teaching and medico legal consultations.  The positions may be based in private practice, or 
may be salaried hospital or university positions.  It does not include other practitioners who 
are not registered as allergy/immunology specialists (but who practise in this area as part of 
their work), nor speciality trainees. 
The analysis in the chapter is qualitative in nature, and it is recommended that a more 
rigorous quantitative analysis is undertaken to more thoroughly assess need (demand) and 
supply for services.  Recommended modelling would utilise Medicare data to assess service 
utilisation by age and gender of the patient and would project this demand over future years 
based on different prevalence scenarios.  Factors such as workplace feminisation impacts 
and changing work preferences should be incorporated with sensitivity analysis conducted 
on these key parameters, to accurately determine areas of shortfall and to plan future 
training and placement needs.  However, for the purposes of this report, some very basic 
analysis is undertaken here that, nonetheless, reveals a potentially important policy 
challenge. 
7.1 DATA SOURCES AND ASSUMPTIONS 
A prime data source for the analysis was an internal anonymous workforce survey of ASCIA 
members performed in the first quarter of 2007.  There were 84 respondents from 112 active 
clinicians (of a total 130 Australian members) ie, a response rate of 75% of the active 
workforce.  Age of planned retirement and number of retirees were calculated from survey 
data.  Of the replies, 25% were from females, similar to the 20% overall female proportion of 
ASCIA specialist members.  The AMWAC/AIHW report Female Participation in the Australian 
Medical Workforce, reported that the proportion of female specialists (on average) work 
shorter hours, retire on average at least five years earlier than male specialists and 
contribute fewer FTE.  However, for the purposes of this chapter, data were not adjusted 
based on gender, which has the effect of making any projected workforce shortages more 
conservative than if feminisation impacts were included. 
Additional data examined included AIHW workforce data and data on trainees and recent 
graduates provided by the Royal Australasian College of Physicians.  Population data were 
derived from ABS population estimates for 2007 using the Access Economics 
Macroeconomic Model.  For each jurisdiction, the number of clinicians known to be practising 
in a State/Territory was used.  Since ACT and NSW clinicians serve an overlapping patient 
population, ACT and NSW data were pooled.  ASCIA is not aware of any qualified 
allergy/immunology specialists who have not been identified by this data.  For the purposes 
of discussion, one Full Time Equivalent (FTE) is defined as a clinician providing 25 hours of 
clinical patient care per week which, based on the current working hours relative 
characteristics from the survey (22.7 clinical of 43.1 total, Section 7.2), would imply a 47.5-
hour full-time week for all activities (ie, including administration, pathology and teaching).  
Sensitivity analysis would be recommended around this parameter in more detailed 
modelling.  
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7.2 CURRENT WORKFORCE  
Number and distribution:  There are currently 112 clinically active allergy/immunology 
specialists involved in patient care who are ASCIA members practising in six States and 
Territories; there are currently no allergy/immunology specialists in Tasmania or the Northern 
Territory.  All specialists are based in or near capital cities, although some undertake rural 
clinics.  There is approximately one allergy/immunology specialist per 185,600 people in 
Australia, and one FTE allergy/immunology specialist per 202,200 people in Australia, with 
significant regional variation.  In Queensland there are relatively few specialists overall, and 
no public paediatric allergy/immunology services in Queensland hospitals, although plans to 
establish such a service in 2008 were announced by the Queensland Health Minister in May 
2007.  Recent announcements to enhance allergy services in Western Australia were also 
announced in September 2007. 
TABLE 7-1:  ALLERGY/IMMUNOLOGY SPECIALISTS, BY JURISDICTION, 2007 
State No. of 
specialists 
Average 
clinical 
hrs/week 
FTE Population* 
(ABS 2004) 
No./100,000 FTE/100,000 
National 112 22.7 102 20,793,375 0.54 0.49 
ACT/NSW 53 22.1 47 7,214,104 0.73 0.65 
VIC 23 26.2 24 5,128,000 0.45 0.47 
QLD 9 23.5 8 4,117,746 0.22 0.21 
WA 14 20.8 12 2,075,025 0.67 0.56 
SA 13 22.6 12 1,555,703 0.84 0.76 
NT 0 0 - 209,791 - - 
TAS 0 0 - 490,297 - - 
Source: ASCIA survey data and AEM.  * Population is not the sum of the states because of small population in 
Territories (eg, Christmas Island). 
Note:  There is substantial variation in the clinical hours worked/week in various jurisdictions. While the sample 
size is too small to assume that these differences are statistically significant, in reality relatively minor regional 
variations in clinical hours worked (eg. in states with major research institutes such as WA) may have a major 
impact on clinical service availability and waiting times that may not be reflected in simple FTE/100,000 data, as 
reflected in Table 7.4. 
Age and Gender:  The mean and median age of specialists in the survey was 51 and 47 
years respectively (range 28-70 years).  The largest ten-year cohort of those surveyed was 
aged between 61 and 70 years (25%).  The proportion of female specialists and trainees was 
20% and 57% respectively. Around 25 specialists are expected to retire in the five years 
following 2007, and 45 in the following ten years (based on a survey question asking when 
they expected to retire).   
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FIGURE 7-1:  AGE DISTRIBUTION OF ALLERGY/IMMUNOLOGY SPECIALISTS, AUSTRALIA (YEAR) 
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Source: ASCIA survey data. 
Working hours and characteristics:  The mean number of hours worked was found in the 
survey to be 43.1 per week (median 43.0; range 12-70).  Approximately 22.7 hours per week 
are spent in direct patient care of children (36.1%) and adults (63.9%).  Between the ages of 
35 and 64 years, most specialists work 40 hours or more per week, while those over the age 
of 65 years tend to work part time.  Other duties include immunopathology (4.3 hours per 
week) and administration and teaching (15.9 hours/week).   
FIGURE 7-2:  HOURS WORKED, CLINICAL PRACTICE AND OTHER ACTIVITIES 
Clinical (adult)
Clinical (Paediatric)
Pathology
Admin/ Teaching
 
Source: ASCIA survey data  
Training Arrangements:  All training programs are based in large city teaching hospitals, 
most full time, and last between three to five years depending on the mixture of 
immunopathology, clinical, research or combined training programs chosen. Information from 
Dr M Cook and Dr R Wong from the Joint Immunology and Allergy training program run by 
the Royal Australasian College of Physicians and Royal College of Pathologists of 
Australasia estimate that, as of July 2007, there were 27 approved allergy/immunology 
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training positions and 28 trainees in Australia, with four expected to graduate with specialist 
qualifications by the end of 2007, and around six per year thereafter.  The age of current 
trainees ranges from 28 to 42 years (median 31.5 years) and 16 of current trainees (57%) 
are women.  In the years 2002 to 2007, the median age of graduation with full specialist 
qualifications was 35 years (range 33 to 47 years).  This may increase with the impact of 
graduate medical programs on the age of entry to specialist training schemes.  The training 
centres are shown in Table 7-2. 
TABLE 7-2:  AUSTRALIAN ALLERGY/IMMUNOLOGY TRAINING CENTRES (2007)* 
Centre Jurisdiction 
Canberra Hospital / ACT Pathology ACT 
Campbelltown Hospital NSW 
Children's Hospital, Westmead (CHW - paediatrics) NSW 
Concord Repatriation General Hospital NSW 
Liverpool Hospital / SWAPS Liverpool Hospital NSW 
SSWAPS/ Royal Prince Alfred (RPA) NSW 
SEALS / Sutherland (Pathology) NSW 
HAPS / John Hunter Hospital NSW 
St Vincent's Hospital NSW 
Sydney Children's Hospital (paediatrics) NSW 
Westmead Hospital/ICPMR NSW 
Princess Alexandra Hospital (subject to availability) QLD 
Queensland Health Pathology Service at Royal Brisbane & Womens 
Hospital (Pathology) 
QLD 
Flinders Medical Centre SA 
Royal Adelaide Hospital SA 
IMVS: Institute for Molecular & Veterinary Sciences / Royal Adelaide 
Hospital (Pathology) 
SA 
Women's & Children's Hospital (paediatrics) SA 
Alfred Hospital VIC 
Women’s and Children’s Health, Royal Children's Hospital, VIC 
(paediatrics) 
VIC 
Royal Melbourne Hospital / MHSPS VIC 
Fremantle Hospital / Pathwest WA 
Princess Margaret Hospital for Children / Pathwest (paediatrics) WA 
Royal Perth Hospital / Pathwest WA 
Sir Charles Gairdner Hospital / Pathwest QEII Medical Centre WA 
Source:  * As of 10 July 2007.  
7.3 ADEQUACY OF THE CURRENT ALLERGY/IMMUNOLOGY 
WORKFORCE  
Assessing the adequacy of the current workforce:  In the absence of a thorough 
modelled workforce analysis, there are a number of qualitative indicators of the adequacy of 
a medical workforce.  Although no single measure can provide a definitive assessment, by 
examining each of the following metrics it is possible to gain a qualitative indication of 
whether the workforce is meeting current demand or if there is a significant shortfall or 
oversupply: 
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 regional variations in specialist: population ratio (SPR) and access to care; 
 comparisons with other specialities; 
 waiting times for consultations; and  
 perceptions of allergy/immunology specialists of the adequacy of the current workforce.  
Regional variation in allergy/immunology services:  The regional variation in SPR 
suggests that the workforce is inadequate in Tasmania and the Northern Territory where 
there are no specialists and in Queensland were there are relatively few specialists overall 
and no public hospital paediatric allergy/immunology services.  Access to services in rural 
areas is likely to be lower across all jurisdictions, as almost all services are based in major 
regional or capital cities. 
International comparisons:  Australia has approximately 0.65 allergy/immunology 
specialists per 100,000 population (130 Fellows in a population of 20 million) positions, about 
the same as Canada (213 Fellows in a population of 33 million) and is low compared to the 
USA (1.05 per 100,000)38.  Comparable data are not available for Europe (where most 
allergy/immunology services are provided by a variety of non-vocationally trained speciality 
physicians), nor for the UK (where allergy care is similarly fragmented and in short supply). 
Comparison with other specialties:  Allergy/immunology is a relatively small specialty, 
comprising only 112 clinically active individuals, which is only 0.65% of an estimated 17,134 
practising specialists in Australia (AMWAC, 2004).  The number of FTE per population 
allergy/immunology specialists is substantially less than that of thoracic medicine, 
dermatology, ENT surgery and paediatrics, even though allergy/immunology specialists 
consult in each of these areas as well as specialty-specific conditions such as anaphylaxis, 
food allergy, autoimmune disease and immunodeficiency.  
TABLE 7-3:  SPECIALIST POPULATION RATIO, SELECTED SPECIALTIES, FTE PER 100,000 
Speciality FTE per 100,000 
Paediatric surgery 0.30  
Cardiothoracic surgery 0.50 
Neurosurgery 0.60 
Infectious disease 0.60 
Intensive Care 0.60 
Vascular surgery 0.60 
Allergy/Immunology 0.65  
Haematology 0.80 
Rheumatology 1.2 
Endocrinology 1.3 
Thoracic Medicine 1.4 
ENT Surgery 1.5 
Dermatology 1.7 
Paediatrics 3.8 
Source:  Data derived from AMWAC Report 2004.4. 
                                               
38
 Marshall (2007) and Dr D Fischer, personal communication, 25 June 2007. 
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Consultation waiting times:  For non-urgent conditions, mean waiting times for initial 
consultations from the survey are estimated as 13 weeks in private consulting rooms and 18 
weeks for public hospital clinics (where available), with urgent cases given priority.  The 
waiting time in Queensland for a standard first consultation is well above the average for both 
private and public patients.  The range of waiting times, however, is much longer; up to 48 
weeks in some States and almost double that time in Queensland. 
TABLE 7-4:  AVERAGE CONSULTATION WAITING TIMES (WEEKS), PRIVATE AND PUBLIC CLINICS 
 Urgent Non-urgent 
Location Public  Private  Public Private 
Range 
Overall 
ACT 3 2 18 6 2-24 
NSW 1 1 15 11 1-36 
VIC 1 1 12 8 1-24 
QLD 5 5 29 32 5-84 
WA 2 2 11 10 2-36 
SA 9 3 22 12 3-48 
Source:  ASCIA Survey39. 
Conclusions:  Overall, qualitative indicators suggest potential undersupply of 
allergy/immunology specialists with serious shortages in some States and in rural areas.  
Further, specialists working in the field40 report that health care system changes have 
resulted in public hospitals becoming less willing to resource training positions or provide 
unfunded outpatient clinical services.  This impacts not only on the provision of some 
essential clinical services that cannot be provided in private practice, but also hampers the 
training of undergraduates, general practitioners, other specialities and nursing staff. 
7.4 PROJECTIONS OF SUPPLY AND DEMAND 
Supply Trends:  Based on the retirement intentions of respondents to the ASCIA survey, a 
retirement age of 66 years was used for projection purposes.  The representation of women 
in the workforce is currently 20% and it is expected that the proportion of women in the 
workforce will increase, as the number of female trainees continues to increase (currently 
57%) and the large, predominantly male, cohort of specialists aged 55 years and over 
proceeds through to retirement.  Based on recent graduates from the program and the 
number and stage of current trainees, an estimated four specialists will qualify by the end of 
2007 and six specialists per year will graduate into the workforce over the next 5-10 
years.  The entry of these individuals into specialist clinical work may be delayed if they 
undertake a period of additional research or clinical training abroad (as many do).  It is 
anticipated that at least 41% of current allergy/immunology specialists will retire in the next 
ten years (although 55% of respondents indicated their plans to do so over the same period).  
Over the past five years 2002-2007, 14 new allergy/immunology specialists graduated with 
specialist qualifications at a median age of 35 years (range 33-47 years).  Current retirement 
projections are shown below.  It should be noted that these are minimum numbers, based on 
                                               
39
 Since the completion of the survey, non-urgent waiting times in the ACT have increased ACT to 3 months 
(private clinics), 6 months (adult public clinics) and 9 months (paediatric public clinics; Dr Carolyn Hawkins, 
personal communication). Public hospital waiting times in WA are currently 7 weeks (urgent cases) and 22 weeks 
(non urgent; Dr Richard Loh, personal communication). ASCIA plans to repeat a more detailed workforce and 
patient access survey at the end of 2007. 
40
 R Mullins personal communication 15 October. 
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those who responded to the 2007 workforce survey, and no data on planned retirements are 
available from the 28 active members who did not respond to the survey.  If additional 
specialists from this group also retire (as is likely), then workforce shortages are likely to be 
substantially greater than the data indicated in Table 7-5 and Table 7-6. Indeed, factoring up 
by 1/75% to allow for the retirements from this group, would suggest the same number of 
specialists (115) at the end of 2017 as in 2007.  Trainees may not ultimately undertake 
clinical work, in which case specialist numbers may actually contract over the next decade. 
TABLE 7-5:  PLANNED WORKFORCE RETIREMENT 2007-2017 
Year Planned Retirement Cumulative Total 
2007 1 1 
2008 3 4 
2009 9 13 
2010 4 17 
2011 4 21 
2012 5 26 
2013 1 27 
2014 4 31 
2015 10 41 
2016 1 42 
2017 4 46 
Source:  ASCIA Survey. 
TABLE 7-6:  ENTRY AND EXIT FROM THE WORKFORCE, BEST CASE WITH CURRENT POLICY 
Year Cumulative 
retirements 
Cumulative 
new 
specialists*  
End-year 
balance  
Population 
(est; AEM) 
Specialist/ 
100,000 
FTE/ 
100,000** 
2007 1 4 115 20,790,666 0.55 0.50 
2012 26 34 119 21,965,001 0.54 0.49 
2017 46 64 129 23,105,185 0.56 0.51 
Source:  ASCIA survey for retirements Dr M Cook and Dr R Wong re trainee numbers and ABS re population 
projections.  * Calculated on the basis of six new graduates per year.  ** Calculated based on FTE representing 
25 hours patient care/week and no gender-related adjustments to FTE. 
TABLE 7-7:  ENTRY AND EXIT FROM THE WORKFORCE, LIKELY CASE WITH CURRENT POLICY 
Year Cumulative 
retirements* 
Cumulative 
new 
specialists*  
End-year 
balance  
Population 
(est; AEM) 
Specialist/ 
100,000 
FTE/ 
100,000** 
2007 1 4 115 20,790,666 0.55 0.50 
2012 35 34 111 21,965,001 0.51 0.45 
2017 61 64 115 23,105,185 0.50 0.43 
Source:  ASCIA survey for retirements Dr M Cook and Dr R Wong re trainee numbers and ABS re population 
projections.  * Factored up by 1/75% compared to best case.  ** Calculated on the basis of six new graduates per 
year.  ** Calculated based on FTE representing 25 hours patient care/week initially and with gender-related 
adjustments to FTE from 1.10 (2007) to 1.12 (2012) to 1.15 (2017). 
Addressing current regional shortfalls:  Using a benchmark approach, to bring all 
jurisdictions into line with the levels of service availability in NSW and the ACT (one 
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allergy/immunology specialist per 136,000 population) would require the provision of 41 
additional specialists – 21 extra in Queensland, 15 extra in Victoria, 4 in Tasmania and 1 
extra in WA, while relocating a SA specialist to the NT (Table 7-8). 
TABLE 7-8:  GEOGRAPHICAL RE-DISTRIBUTION OF SPECIALISTS TO MEET NSW/ACT BENCHMARK, 
2007 
State Current  
no. of specialists 
Current No./ 
100,000 
Benchmark 
No. 
Change Shortage 
(change cf. 
actual) 
National 112 0.54 152.7 40.7 36% 
ACT/NSW 53 0.73 53.0 - 0% 
VIC 23 0.45 37.7 14.7 64% 
QLD 9 0.22 30.3 21.3 236% 
WA 14 0.67 15.2 1.2 9% 
SA 13 0.84 11.4 -1.6 -12% 
NT 0 - 1.5 1.5 total 
TAS 0 - 3.6 3.6 total 
Source: Access Economics based on ASCIA survey data.   
Estimating future growth and needs:  Australia’s population is estimated to be growing at 
a rate of 1.3% per annum net, taking into account birth and death rates and net migration. 
Assuming the maintenance of the same SPR, population growth alone of an additional 
2.3 million over the next ten years would require an additional 17 specialists over the same 
period.  These estimates do not take into account the potential for increased service demand 
driven by changing epidemiology of allergic disorders (allergic rhinitis, food allergy and 
anaphylaxis in particular) in Australia over the last ten years.  
Taking into account extra retirements, the training lag (such that new entrants in 2007 would 
be graduates at end-2010), feminisation impacts (increasing the FTE ratio from 1.10 to 1.15) 
and population growth, to correct the maldistribution and achieve the NSW/ACT benchmark 
over the ten-year period in a manner believed to be achievable given training capacity would 
require increasing the number of graduates from six per year to 12 per year (Table 7-9).  
There is no allowance for attrition of students, mortality of students or specialists, other non-
retirement workforce exits or higher allergy prevalence. 
TABLE 7-9:  ENTRY AND EXIT FROM THE WORKFORCE, POLICY TO INCREASE TRAINING PLACES BY 
3 PER ANNUM FROM 2008 
Year Cumulative 
retirements* 
Cumulative 
new 
specialists*  
End-year 
balance  
Compared 
to likely 
case 
Specialist/ 
100,000 
FTE/ 
100,000** 
2007 1 4 115 115 0.55 0.50 
2012 35 37 114 111 0.52 0.46 
2017 61 127 178 115 0.77 0.67 
Source:  ASCIA survey for retirements Dr M Cook and Dr R Wong re trainee numbers and ABS re population 
projections. * Factored up by 1/75% compared to best case.  ** Calculated on the basis of 6 graduates in 2008 
increasing to 33 in 2017.  ** Calculated based on FTE representing 25 hours patient care/week initially and with 
gender-related adjustments to FTE from 1.10 (2007) to 1.12 (2012) to 1.15 (2017). 
Australia would need 178 allergy/immunology specialists by 2017 to correct the 
maldistribution and achieve the NSW/ACT benchmark over the ten-year period. This 
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contrasts with the likely 115 specialists who would be available if training places were kept at 
six per year.  The additional 63 specialists could be achieved by training 127 over the period 
rather than 64, given the simple assumptions of this basic modelling.  There would not be 
much impact by 2012, with the SPR only 0.52 compared to 0.51 in the likely case; however, 
the benefits would start to emerge from 2013 onwards. 
7.5 WORKFORCE CHALLENGES 
The analysis suggests that there are significant regional and rural difficulties in accessing 
specialist care and that the overall supply of allergy/immunology specialists may be 
inadequate to meet growing demand.  Not only is there a current (and anticipated) shortage 
of trained allergy/immunology specialists, but there is little skilled capacity in primary medical 
care to manage many of these disorders.  Contributing factors to this have been the relatively 
limited allergy/immunology content in medical school curricula and privatisation of many 
hospital-based allergy/immunology services over the last 20 years, which together have 
constrained clinical exposure to the speciality by medical students and doctors in training, 
including by other relevant specialities such as paediatrics.  Low levels of exposure and 
training can result in poor diagnosis and management of allergic/immune disease that, in 
turn, can contribute to suboptimal patient outcomes, patient disillusionment with conventional 
medicine and increased uptake of unproven allergy testing and therapies (Mullins et al, 2005; 
MacLennan et al, 2002; Goldrosen and Straus, 2004). 
Training places:  A balance in supply to match a continued minimum growth rate in demand 
could be achieved by increasing the number of allergy/immunology training places, in a 
staged manner (by three extra per year), from 6 in 2008 to 9 in 2009, 12 in 2010 and so on, 
to reach 33 in 2017.  Given the 4-5 year training program, there would be delays in flow on 
effects to the number of available specialists, but this training trajectory would be achievable 
in the medium term, with the projected trend in requirements able to be further monitored and 
recommended increases in training positions adjusted if necessary. 
Ideally, training positions should be increased proportionately more in the comparatively less 
well endowed State of Queensland, as well as in South Australia and Victoria, to allow for 
outreach services or rotations through the Northern Territory and Tasmania, respectively.  In 
the short term it is likely that expanded services in allergy/immunology in under serviced 
areas will require recruitment of specialists from other areas to establish units and train future 
specialists.  This may initially require outreach programs and specialist and trainee rotations 
to be negotiated across State borders.  Given recent changes in epidemiology, particular 
emphasis should be given to increasing the number of paediatric allergy/immunology 
trainees. 
Gender issues:  With workforce feminisation, each specialist on average is likely to 
contribute fewer lifetime hours in the future relative to the past (females lifetime hours are 
estimated as around 75% of male hours across all specialties), which needs to be taken into 
account when considering calculating the number of training places required to meet future 
needs (AMWAC & AIHW 1996b).  More detailed modelling of the allergy/immunology 
workforce by age and gender would help improve the projections to more accurately account 
for feminisation than the approximations utilised here. 
Funding of training places and specialist units:  The changes that are occurring in 
allergy/immunology practice are likely to continue and, as a result, the trend away from public 
hospital practice may lead to a decline in support for the funding of traditional hospital-based 
allergy/immunology training positions, normally funded by State governments. While 
opportunities exist for novel methods of training, such as the piloting of private/public training 
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facilities in the future, hospital-based allergy/immunology services are essential for the 
provision of some essential clinical services (such as potentially dangerous drug and food 
challenges).  They can serve as a resource for community education as well as research. 
The existence of allergy/immunology departments in public hospitals provides a crucial 
recruitment tool for future specialists and is also an opportunity to increase exposure and 
skills for those entering primary care or other specialties at a later date.  
A number of current training places in Australia are dependent on the availability of funding, 
which is not always guaranteed.  Some are funded on a temporary basis from hospital 
fellowships, or from a combination of one or more of university, hospital discretionary and 
pathology laboratory-derived funds.  New allergy/immunology training positions may need to 
be specifically and fully funded because most allergy/immunology services (being provided 
on an outpatient basis) do not attract resources under the current Commonwealth funding 
arrangements to hospitals.  Consideration to guaranteed funding of current positions is thus 
also a priority. 
Changes to the training program are likely to require a financial commitment from both the 
Commonwealth and State/Territory governments, including funding specifically designated to 
take into account the funding of registrar positions and either VMO or staff specialist 
supervisors, together with the ancillary services required to maintain a fully functioning 
hospital-based service.   
It is recommended that Commonwealth, State and Territory health departments undertake 
negotiations with the Royal Australasian College of Physicians, the Royal College of 
Pathologists of Australasia and the Australasian Society for Clinical Immunology and Allergy 
for the establishment of additional training positions; with the additional positions to be 
introduced gradually where suitable support and training programs are available.  
Introduction of short-term measures to meet localised service shortfalls may be required, 
given that the increased number of graduates will not make an effective contribution to the 
workforce until 2012 at the earliest. 
Structure of training:  The increase in the number of trainees may require examination of a 
number of alternative models of training outside teaching hospitals, including a mix of public 
and private accredited training facilities. 
Ancillary education:  Shortage of allergy/immunology specialists, regional inequality and 
privatisation of many hospital-based allergy services has a flow on effect in a lack of 
adequate exposure and training for other medical students (notably general practitioners) 
nurses, ancillary health care workers and the public.  Increased ancillary education in 
undersupplied areas is also considered a priority, since these staff assist clinicians in patient 
management, and are involved in community outreach schemes for patient and community 
education. 
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8. RECOMMENDATIONS FOR THE FUTURE 
In Australia there is a lack of public and professional appreciation of the impact of allergic 
and immune disorders on quality of life, and even less of the economic impact to society and 
individuals who suffer allergic disease.  Raising awareness of the economic and health 
impacts is an important factor in facilitating the early recognition and control of allergic 
disease. 
Development of a framework of best practice for management of allergic disease in Australia 
will be enhanced by: 
 timely access to specialist allergy/immunology services; 
 access to early and accurate diagnosis; 
 access to affordable and cost-effective therapy and novel therapies; 
 support for community and medical education outside the current paradigm; 
 support for local research to develop interventional strategies to reduce the burden of 
disease in the community; and 
 development of a model of allergy as a chronic disease. 
8.1 SPECIALIST ALLERGY/IMMUNOLOGY SERVICES 
There is significant regional variability in access to specialist allergy/immunology services 
within Australia, with some regions such as Tasmania and the Northern Territory having no 
access to specialist services.  Other States such as Queensland have no public hospital-
based services for dealing with the increasing number of children with allergic disorders.  
Anecdotal evidence suggests that in some cases minimum standards of care and service 
provision are not met.  It is possible that the shortage of mainstream services in Australia has 
also contributed to the proliferation of dubious allergy practice in the field of complementary 
and alternative medicine, where unproven techniques for diagnosis and treatment are used.  
The analysis in the previous chapter of this report suggests that there may be too few 
allergy/immunology specialists in Australia (and New Zealand) to meet the growing needs of 
the population, in terms of delivering direct care in dedicated allergy/immunology centres and 
in providing training for other specialists, general practitioners and practice nurses.  It should 
be possible for milder cases of allergy to be recognised and treated in primary medical care 
so that only the most severe or complex cases need referral to specialist services.   
Management by an allergy specialist is an effective model for patient care, as most patients 
with allergic disorders have multiple comorbidities, and organ based specialists are poorly 
equipped to manage disorders falling outside their particular specialty.  The community is 
likely to be best served by a combination of community and hospital-based specialist 
allergy/immunology services, and a well educated medical and paramedical community able 
to deal with more common and less serious issues.   
The overall supply of allergy/immunology specialists in Australia is inadequate and there are 
significant regional and rural difficulties in accessing specialist care.  Without prompt 
corrective action, the workforce may move towards a situation of worsening undersupply.  
The current projected levels of graduate output are unlikely to be sufficient to meet expected 
future requirements. 
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The shortage of services in Australia has been accompanied by a proliferation of dubious 
allergy practice in the field of complementary and alternative medicine, where unproven 
techniques for diagnosis and treatment are used.  These result in delayed and ineffective 
treatment, and at times inappropriate and occasionally harmful treatment.  This can place an 
additional burden on the conventional healthcare system, where patients need to be re-
educated and re-evaluated regarding the presence or absence of allergic disease, at times 
when none exists. 
Access to care is currently impeded by a number of factors including:  
 the rise in prevalence of allergic diseases saturating current service capacity; 
 regional inequalities in accessing specialist services in some States, Territories and 
rural areas; and 
 current and anticipated specialist workforce shortages. 
The provision of additional specialists is currently hampered by: 
 the relatively low number of trainees currently; 
 the lack of guaranteed training places in some institutions; and 
 health care system changes resulting in public hospitals becoming less willing to 
resource training positions or provide unfunded outpatient clinical services.  The 
privatisation (or closure) of many hospital-based allergy/immunology services has 
impacted not only the provision of some essential clinical services that cannot be 
provided in private practice, but clinicians report it also hampers the training of 
undergraduates, general practitioners, other specialities and nursing staff41. 
Changes in the epidemiology of allergic disease and allergy/immunology practice need to be 
recognised.  With increasing numbers of children being evaluated for food allergy comes the 
need to undertake deliberate food challenges to determine whether the child has grown out 
of a sensitivity, or in other cases, to prove or disprove clinical allergy in the patient with a 
positive allergy test.  Deliberate challenges with medication are also required under a 
number of other circumstances, including the evaluation of patients with possible drug 
sensitivity, and also in the management of patients with the aspirin triad, characterised by 
asthma, nasal polyps and aspirin allergy.  Such patients have frequent sinus infections, 
require repeat sinus surgery to remove nasal polyps and are high-level consumers of 
antibiotics.  If these patients are shown to be sensitive to aspirin, desensitisation procedures 
can improve quality of life, reduce the need for antibiotics, improve asthma control with less 
medication and reduce the need for further surgery.  
Rush desensitisation is a procedure most commonly used to treat patients with insect venom 
allergy.  Instead of weekly injections over many months (with the need for time off work, and 
multiple medical visits and waiting periods after an injection), the patient can reach 
maintenance within two half day sessions as an inpatient or hospital clinic.  While this 
procedure is resource intensive in terms of staff time and the need for inpatient facilities, it is 
likely to be cost effective long term as patients require less time off work, with fewer 
injections in the first few months of treatment, fewer outpatient visits to doctors (with the cost 
involved), and patients reach a protective dose quickly.  Further cost effectiveness analysis 
would be desirable to validate this in an Australian context.  Similar protocols may have a 
role to play in the future in the management of patients with allergic rhinitis and asthma, 
                                               
41
  R Mullins personal communication 15 October. 
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treated with aeroallergen extracts.  Since such procedures are of their nature potentially 
risky, they need to be undertaken within hospital-based institutions in most cases. 
Access to care would be enhanced by the following initiatives. 
 Guarantees of specific funding for current and additional specialist 
allergy/immunology training places:  It is important to note that one FTE specialist is 
required per training position for registrars, according to the criteria of the College of 
Physicians and pathologist criteria.  The ability to undertake training (whether it be for 
specialist registrar trainees, other specialties or general practitioners), is therefore 
entirely dependent on infrastructure which includes institutional-based allergy 
specialists. 
 Support for hospital-based allergy/immunology units to provide both inpatient 
and outpatient services: Funding of additional academic chairs in allergy/immunology 
is one option to consider, as such institutions attract those interested in clinical disease 
as well as research, and would be a focus for the introduction of novel treatments (such 
as immunotherapy for food allergy). 
 Specific funding for specialist outreach services for rural and remote areas.   
 Development of funding models (through Medicare Australia) for item numbers 
to support: 
 teleconferencing so that non-allergy specialists can access specialist advice, 
similar to current item numbers (353, 355, 356, 357 and 358) to support 
teleconsultation for psychiatric patients in remote areas; 
 telephone consultations between specialists and patients in remote areas where 
clinically appropriate; and 
 changing allergy practice that includes drug and food challenges within a hospital 
environment, and ‘rush immunotherapy’ procedures 
Ideally, training positions should be increased proportionately more in the comparatively less 
well endowed State of Queensland, as well as in South Australia and Victoria, to allow for 
outreach services or rotations through the Northern Territory and Tasmania respectively.  In 
the short term it is likely that expanded services in allergy/immunology in under serviced 
areas such as Tasmania, the Northern Territory and Queensland will require recruitment of 
specialists from other areas to establish units and train future specialists.  This may initially 
require outreach programs and specialist and trainee rotations to be negotiated across State 
borders.  Given recent changes in epidemiology, particular emphasis should be given to 
increasing the number of paediatric allergy/immunology trainees.  
8.2 ACCURATE AND EARLY DIAGNOSIS 
Access to accurate allergy and immunology testing is required to identify avoidable allergens, 
to identify targets for specific immunotherapy, and (at times) to exclude allergy as a potential 
contributor to symptoms.  Much of allergy assessment involves correcting misinformation.  
Access to accurate testing allows patients and their carers to undertake measures of proven 
effectiveness, and reduces the risk that the vacuum will be filled by unproven tests and 
procedures and ineffective treatments that are commonly promoted in the community. 
Accurate and early allergy diagnosis requires the registration of reagents for SPT, including 
the availability of positive control solutions such as histamine or codeine, some of which are 
currently not available or remain unregistered.   
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Methods of allergy testing are currently hampered by the financial bias towards measuring 
total IgE (a test of limited clinical usefulness) compared to measurement of allergen specific 
IgE.  Currently, Medicare rebates to pathology laboratories are structured so that 
measurements of more than four allergens during any single episode are not rebated to the 
requesting laboratory.  This encourages inappropriate test ordering by doctors to minimise 
the out of pocket cost to patients.  Unfortunately, this approach often provides confusing, 
irrelevant and sometimes misleading results.  It also impairs the care of patients who may 
have co-existent food and aeroallergen sensitivity. 
Patients with allergic disease often have more than one coexistent problem, and appropriate 
clinical care involves assessment of all conditions simultaneously.  A patient with allergic 
respiratory disease may have eczema, food allergy, or contact allergic dermatitis.  Contact 
allergic dermatitis is more common in patients with IgE mediated hypersensitivity, and may 
sometimes be confused by some general practitioners with angioedema/food allergy.  The 
current Medicare schedule does not provide for patient rebates for SPT for measurement of 
allergen specific IgE (relevant to immediate hypersensitivity to food, aeroallergens or sting or 
drug allergy), and patch testing (used to assessed contact allergic dermatitis) on the same 
occasion.  The current Medicare structure does not encourage the assessment of coexistent 
allergy related conditions, and has the potential to reduce efficiency by encouraging separate 
visits to assess and test for separate conditions.  This is of particular importance when 
assessing patients from remote areas, where access to specialist medical care is often more 
difficult.   
The specialty of allergy and clinical immunology deals with a relatively large number of rare 
and orphan diseases for which some genetic testing is available.  Because these conditions 
are rare, some tests are performed only occasionally, usually in the setting of 
hospital/university laboratories with specialised expertise.  Many of these low volume tests 
are labour intensive, cannot be automated, and economies from high volume turnover cannot 
be achieved.   
Access to accurate and clinically useful diagnostic tests would be enhanced by the following. 
 Access to diagnostic reagents for SPT and immunotherapy. This would require a 
collaborative approach between manufacturers, the Therapeutic Goods Administration 
and the ASCIA to identify key allergens to which access is required. 
 Revision of the Medicare schedule to: 
 facilitate measurement of a single allergen specific IgE to more than four 
allergens at a time (where clinically relevant relevance to the underlying clinical 
condition) would facilitate patient assessment; and  
 allow for simultaneous assessment of immediate (IgE-mediated) hypersensitivity 
and delayed hypersensitivity/contact allergic dermatitis; and 
 provide for ‘orphan tests’ for rare diseases and novel therapeutic agents. 
 Consider PBS subsidy for reagents such as penicillin minor determinants which 
are not affordable for some patients, in the context of diagnostic procedures such as 
intradermal testing for drug sensitivity.  
8.3 AFFORDABLE AND COST-EFFECTIVE MEDICAL THERAPY 
Allergic disease is not only common, but many patients have multiple coexistent disorders, 
each requiring specific interventions including prescribed or non-prescribed medication or 
treatments.  The genetic clustering of allergic disease often results in multiple individuals 
within the same family being similarly affected.  The costs of symptomatic treatments are 
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significant in patients who require them on a daily basis for substantial proportions of the 
year, and may be less cost effective long term than interventions such as immunotherapy, 
the only form of treatment shown to alter the natural history of disease.  The financial burden 
may also fall more heavily on those with lower incomes.  Further research is required in this 
area in relation to the equity impacts and incremental cost effectiveness of alternatives.  This 
would require a bottom-up cost analysis as previously described. 
The costs involved in care of allergic patients are not collected in official government 
statistics.  With the shift of some lower cost prescription medications to over the counter 
status, they are now outside of the PBS and Medicare safety nets.  Medications such as long 
term antihistamines or nasal steroids are thus available to Veterans Affairs patients, but not 
to other patients with identical conditions who have not served in the military.  Out of pocket 
costs have been shown to influence not only compliance but also the likelihood of 
complications of untreated disease - see Australian Centre for Asthma Monitoring (2007).   
Access to some therapeutic agents is hampered by the current registration process required 
for some biological agents (such as allergen specific immunotherapy) or the lack of Medicare 
funded subsidies for novel therapies for rare diseases.  To some extent this is because 
conventional measures of reliable evidence supporting treatments and diagnostic tests can 
only be obtained for common diseases.  The same level of evidence is more difficult to obtain 
for rare diseases unless the therapeutic effect is very substantial. 
Patient care would be enhanced if consideration were given to the following options, with 
safeguards to minimise the risk of abuse or cost blowouts. 
 Availability of higher potency nasal steroid sprays on authority prescription for people 
 with relapsing nasal polyps; and 
 with chronic allergic rhinitis requiring therapy for more than six months per year. 
 Availability of relatively nonsedating antihistamines on authority prescription for those 
requiring symptomatic treatment for chronic urticaria for more than three months. 
 Funding of anti-leukotriene therapy on authority prescription (initial three month 
approval) restricted to initial prescription by allergy/immunology specialists or 
respiratory physicians, in patients with the ‘aspirin triad’ in whom aspirin desensitisation 
is contraindicated or not tolerated. 
 Availability of specific allergen immunotherapy on authority prescription (initial six 
month approval), restricted to initial prescription by allergy/immunology specialists.  
This would require the development of costing models that recognise the difference 
between patient co-contributions for medication purchased on a monthly basis, from 
immunotherapy where allergen is manufactured for a specific patient and provided in 
treatment kits that are used for 6-12 months at a time.   
 The model used to fund allergen immunotherapy for honey-bee and wasp venom 
immunotherapy in patients with anaphylaxis (where the patient contribution is 
once for each 6-month supply) is an appropriate one to consider in this context. 
 Ability to add non-prescription items used for the treatment of allergic disorders to the 
Medicare safety net would make them more affordable. 
 Recognition of allergy as a chronic disease, with development of a model of care that 
incorporates recognition of costs of management, and proposes how the cost burden 
can be lessened for those on multiple medications, including those currently not on 
prescription.  
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 Support for trials of novel therapies (such as newer immunomodulatory agents and 
receptor antagonists) in patients with autoimmune and auto-inflammatory diseases 
where there is a rationale for therapy, and where alternative agents are poorly tolerated 
or toxic. 
 Development of mechanisms to extend the range of approved medications for novel 
indications, and then to make them more affordable for patients who require access. 
Medications with orphan indications, will find it difficult to obtain sufficient evidence of 
efficacy from large-scale placebo-controlled trials when the underlying condition itself is 
rare.  There are a number of examples of this including: 
 fluticasone for the treatment of eosinophilic oesophagitis which has been proven 
to be effective, but is currently only approved for the treatment of asthma; and  
 Mycophenolate has been approved for treatment of lupus nephritis, but not for 
the management of other related conditions.  
8.4 COMMUNITY AND MEDICAL EDUCATION OUTSIDE THE 
CURRENT PARADIGM 
Allergic disease is so common that even a substantial increase in the number of specialised 
allergy services in the community is unlikely to meet demand without increasing the skills 
base in primary care to deal with more straightforward cases.  The importance of quality 
evidence base training is paramount.  Poor training results in poorer quality care, undesirable 
outcomes, and increased uptake of unproven, ineffective and sometimes dangerous or 
expensive, alternative medical practices.  Unfortunately, there are a number of factors that 
have contributed to an erosion to the skills base in primary care and exacerbated the relative 
shortage of specialised services available compared to increasing demand, including: 
 the relative paucity of allergy-related content in current medical courses; 
 the absence of allergy services in some hospitals and the privatisation of others, 
resulting in fewer opportunities for undergraduate and postgraduate education; and 
 the current model of postgraduate medical education in general practice in Australia is 
built around the provision of sponsored meetings by pharmaceutical companies, 
resulting in a drug rather than disease-centred focus.  The educational opportunities 
available may be limited by some sponsors having less interest in funding activities for 
across-the-counter medication (most allergy medications) compared to those requiring 
a doctor’s prescription.  This model of postgraduate education is outmoded and does 
not serve the medical or wider community well. 
The care of patients with allergic disease would be enhanced by: 
 working with universities and medical schools to enhance immunology/allergy 
education, one of the most common disorders that doctors will encounter in general 
practice; and 
 increasing the diagnostic and management skills of general practitioners as well as 
related specialties (eg, paediatrics and respiratory physicians) to deal with relatively 
straightforward cases. 
These goals could be achieved (in part) by the following initiatives. 
 Undertake an audit of undergraduate medical curricula, audit the basic knowledge of 
trainees emerging from that curricula, identify deficits, and design educational content 
to rectify deficits. 
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 Reversing the trend in the last 15 years of privatisation of allergy /immunology clinics.  
Such clinics are the incubators of future trainees, and are the centres for 
undergraduate and postgraduate education in allergic disorders. 
 We need to reform the current model of postgraduate education, which is outdated and 
does not serve our patients or our community well.  This involves ensuring that a 
component of allergy/immunology is involved in the curricular of training of 
paediatricians, other related specialist, general practitioners and medical students.  
This may involve liaising with specialist advisory committees the Royal Australasian 
College of Physicians and other postgraduate bodies involved in training such as the 
Royal College of General Practitioners or Divisions of General Practice. 
 Funding specific educational initiatives, along the lines of the National Asthma 
Campaign, to enhance the skills needed to manage allergic disorders in general 
practice.  This may involve one or more of funding of educational seminars (perhaps 
through ASCIA or the Divisions of General Practice).  Such activities should 
concentrate on regional areas that are currently underserviced, including rural areas, 
where educational activities are more difficult to access.  Teleconferencing and video 
conferencing may form a useful method of service delivery.  
 The preparation and distribution of printed evidence-based educational materials, such 
as the ‘Is it Allergy?’ program initiated by the European Academy of Allergy Asthma 
and Immunology (with a similar program currently under development by ASCIA) is an 
important facet of education.  Materials on allergy prevention (already developed by 
ASCIA) require a more widespread distribution to baby health centres, obstetric 
services and maternity hospitals. 
 Upskilling of medical practitioners (GPs as well as selected specialties) can also be 
achieved by establishment of teaching clinics within public hospitals, as is currently 
being trialled at the Royal Children’s Hospital in Melbourne.  Teaching clinics require 
restructuring of currently operating service clinics for clinical service purposes rather 
than for teaching purposes.  Expansion of current clinics and restructuring to meet a 
service as well as teaching role would require a rollback of privatisation of public 
hospital clinics, and funding of new clinics where none exist. 
 Development of partnerships between specialty services and GPs, nursing, community 
health centres, other specialties, midwives and pharmacists to increase the general 
evidence-based knowledge of these health professionals, and counter widespread 
disinformation about allergic disorders in the community. 
8.5 LOCAL RESEARCH 
There is a need for locally based research on the epidemiology and identification of risk 
factors for development of allergic disease, to assist in the development of intervention 
studies that have proven successful in other disorders such as cardiovascular disease and 
Sudden Infant Death Syndrome.  
Public health care planning and workforce planning is also underpinned by an accurate 
estimate of the prevalence of some disorders in Australia, and changing prevalence, as 
noted most recently for food allergy in young children.  Furthermore, development of 
collaborative research programs within major hospital and university centres of excellence 
may facilitate the introduction of novel therapies (such as immunotherapy for food allergy) 
that may one day alter the natural history of disease and reduce burden of chronic disease.  
Support for uniquely Australian problems (such as Jack Jumper ant anaphylaxis research 
programs and studies of the aerobiology and clinical significance of potential native 
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Australian triggers of respiratory allergic disease) should be made a priority, as such 
problems will not be addressed by private funding or overseas interests. 
Special consideration might be given to commissioning the AIHW or a similar organisation to 
undertake a top-down study of the health system costs of allergic disease in Australia. 
8.6 DEVELOPMENT OF A MODEL OF ALLERGY AS A CHRONIC 
DISEASE 
Organ based specialties are poorly equipped and trained to handle disorders lying outside 
their particular specialty.  This can result in inappropriate review by multiple organ specific 
specialties, a practice that is time and cost-inefficient and may result in suboptimal care.  By 
contrast, management of allergic disorders by allergy specialists has been shown to be cost 
effective and reduce hospitalisation and cost of care in patients with asthma, chronic sinusitis 
and food allergy/anaphylaxis.  Education of patients to self-manage their condition has 
shown similar results. 
The cost effective management of patients with allergic disorders would be enhanced by: 
 Recognition of allergy as a chronic disease. This will facilitate development of a model 
of care that incorporates the management of coexistent disorders in the same 
individual in a cost-effective manner. 
 Development of models of care that incorporates service provision by specialists, GPs, 
pharmacists and other health professionals to provide care and evidence-based 
information in a timely manner.  This model will be underpinned by an educational 
model as outlined above. 
 An examination of how the cost burden can be lessened for those on multiple 
medications, including those currently not on prescription.  This may require a re-
examination of provisions of the current Medicare safety net and Pharmaceutical 
Benefit Scheme.  
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APPENDIX A – RESOURCES REQUIRED FOR ALLERGY 
SERVICES 
An overlap exists between clinical immunology and allergy, and other organ specialties.  
Most Australian and New Zealand Allergy and Clinical Immunology specialists have been 
trained in allergy and clinical immunology, and involved in the assessment and management 
of a variety of common disorders (eg. allergic respiratory disease, eczema, hives/urticaria, 
food, sting or drug allergy) as well as less common conditions (eg. vasculitis, immune 
deficiency, some autoimmune disorders).   
The role of hospital-based Allergy and Clinical Immunology services 
While many patients are managed in the community by general practitioners or 
allergy/immunology specialists in private practice, hospital based units are required not only 
to provide consultative services for hospital inpatients, but provide an essential infrastructure 
for services that cannot always be delivered in the community, including: 
 testing for some drug allergies; 
 drug or food challenges where reactions may be serious. The role of hospital-based 
tertiary referral units will be increasingly more important given the increasing number of 
children evaluated for possible food allergy; 
 provide “rush” desensitisation protocols to switch off serious allergic reactions to 
venomous insects (like bee or wasp) that either cannot be delivered in the community 
setting, are performed because routine immunotherapy is poorly tolerated, or for rural 
patients for logistic and safety reasons; 
 provision of ancillary services such as dietetic advice; 
 multi-disciplinary services and teams that may be required in some cases for example: 
 young children who may require the services of allergy specialists, paediatricians, 
dietitians and psychological services; 
 children and adults with primary immunodeficiency and multi-organ system 
disease; 
 the care of patients with rare diseases;  
 serve as a focus for research; and 
 are the locations where novel therapies (such as desensitisation to food) will first be 
trialled. 
Hospital-based services also play an important role in training of: 
 New specialists; 
 Medical students; 
 Hospital residents (some of whom will ultimately work in primary care/general practice);  
 Related speciality trainees (such as paediatricians, dermatologists, respiratory 
physicians, Ear Nose Throat surgeons) who may also assess patients with allergy-
related disorders; and 
 The general medical and paramedical community (eg. GP’s, nurses, dietitians) 
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Given the epidemiology, age distribution and nature of allergic disease in the community, 
provision for inpatient and outpatient facilities for the assessment and management of adults 
and children is required, as well as appropriately trained staff. 
Medical staff 
Most units will require the services of at least two specialists in Clinical immunology and 
Allergy. Since the natural history and prognosis of some allergies in children differs from that 
in adults (eg. food and insect venom allergy), expertise in paediatrics relevant to the 
problems under evaluation is essential. This may be provided by one or more of specialist 
paediatric Allergy and Clinical Immunology specialists, the input of paediatricians with an 
interest and expertise in Allergy and Clinical Immunology, or adult-trained Allergy and Clinical 
Immunology specialists with experience in assessing and managing children. Many patients 
present with complex and multisystem problems, and may need to be assessed and 
managed within the context of a multi-disciplinary team.   
Units will require at least one registrar (either vocationally training in the speciality or rotating 
from another service in internal medicine), and one resident medical officer for training and 
for supervision of inpatients (including food or drug challenges). 
Nursing staff 
The support of a specialist allergy clinic nurse is mandatory. Nurses have an important role 
in: 
 undertaking some allergy testing (skin prick testing, spirometry); 
 administering immunotherapy; 
 education of patients and the parents of young children in allergen avoidance, 
spirometry and inhaler technique and EpiPen training; 
 supervising of some challenge procedures; and 
 in community outreach programmes (eg. school anaphylaxis training programmes). 
Ancillary services 
Qualified adult and paediatric dietitians are required to give detailed advice to patients (and 
their care-givers) with food allergy, to assess the nutritional status of patients who have 
restricted their diets (either with medical advice or at their own instigation), to advise on how 
best to manage patients with multiple documented food allergy, and to advise patients with 
“food intolerance” how best to manage their diets to minimise symptoms without 
compromising nutrition. This is particularly important when managing young children, where 
restricted diets are more likely to impact on nutrition and growth. Physiotherapists have an 
important role to play in patients with immunodeficiency. As in any patients with chronic 
disease impacting on physical, psychological health and finances, access to social workers 
and psychology/psychiatric services is also important. 
Outpatient facilities 
Facilities should be available for: 
 skin allergy testing (skin prick and intradermal); 
 measurement of lung function (including supervising a patient’s inhaler technique);  
 fibreoptic rhinoscopy of the upper airways (desirable); 
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 patch testing for contact allergic dermatitis (or performed in association with 
dermatology services); 
 providing patient and parent education (including instructing on self administration of 
adrenaline);  
 administering allergen immunotherapy (desensitisation) with an appropriate 
observation area;  
 challenge facilities (eg. medication) for lower risk procedures; and 
 should have access to resuscitative facilities in case of adverse reaction to a challenge 
or an immunotherapy injection. Staff should be trained in resuscitative techniques. 
Inpatient facilities 
Inpatient facilities will be required for the investigation and management of patients with 
some disorders (eg. immune deficiency and systemic autoimmune disorders) and to provide 
challenge facilities in patients considered at higher risk of an adverse reaction. This may 
require facilities for day-stay and overnight stay for patients with suspected food allergy to 
prove or disprove sensitivity and allow liberalisation of diet if negative. These facilities cannot 
be easily provided in community-based allergy/immunology services. Facilities should be 
available for open as well as double blind, placebo controlled tests to identify or disprove 
food intolerance by giving suspected foods in disguised forms. For this purpose some 
pharmacies at specialist centres stock foodstuffs contained in special capsules, with placebo 
controls of similar appearance.  
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APPENDIX B – ALLERGY QUESTIONS IN THE NHS 
The next few questions are about other long term conditions, that is, conditions that have 
lasted, or are expected to last, for 6 months or more.  Apart from the conditions you have 
already told me about? 
(LTC_Q01) 
Do you have any of these conditions? 
(Prompt card 21) 
1 Yes 
5 No (go to LTC_Q05) 
(LTC_Q02) 
Which of these do you have? 
(Multiple response) 
10 Hayfever 
11 Sinusitis or sinus allergy 
12 Emphysema 
13 Anaemia 
14 Bronchitis 
15 Other allergy 
16 Epilepsy 
17 Fluid problems/fluid retention/oedema (Exclude those due to heart or circulatory problem) 
18 Hernias 
19 Kidney stones 
20 Migraine 
21 Psoriasis 
22 Stomach ulcer or other gastrointestinal ulcers 
23 Thyroid trouble/goitre 
24 Tuberculosis 
25 Back - slipped disc or other disc problems 
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26 Back pain or back problems (go to LTC_Q04) 
 
Population: All persons 
I would now like to ask you about asthma 
(ASTH_Q01) 
Have you ever been told by a doctor or nurse you have asthma? 
1 Yes 
5 No (go to next module) 
6 Don’t know (go to next module) 
(ASTH_Q02) 
Do you still get asthma? 
1 Yes 
5 No (go to next module) 
(ASTH_Q03) 
Do you have a written asthma action plan? 
1 Yes 
5 No (go to ASTH_Q08) 
6 Never heard of one (go to ASTH_Q08) 
7 Don’t know (go to ASTH_Q08) 
(ASTH_Q04) 
Did you get the asthma action plan from a doctor? 
1 Yes (go to ASTH_Q07) 
5 No 
(ASTH_Q05) 
(Did you get the asthma action plan from) a nurse? 
1 Yes (go to ASTH_Q07) 
5 No 
(ASTH_Q06) 
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(Did you get the asthma action plan from) a chemist? 
1 Yes 
5 No 
(ASTH_Q07) 
Is your action plan similar to this? 
(Prompt card 11) 
1 Yes 
5 No 
The next questions are about medication that you may have used or taken for your asthma in 
the last 2 weeks. Please do not include vitamin and mineral supplements, as well as any 
natural or herbal medicines, in your answer. 
(ASTH_Q08) 
Have you taken any medication for asthma in the last 2 weeks? 
1 Yes (go to ASTH_Q09) 
5 No (go to ASTH_Q10) 
6 Don’t know (go to ASTH_Q10) 
(ASTH_Q09) 
Sequence Guide: 
If NHS/NHSI go to ASTH_Q11 
If NATSIHS/IHS go to SG_ASTH_Q12 
(ASTH_Q10) 
Sequence Guide: 
If NHS/NHSI and ASTH_Q08=5 or 6 go to ASTH_Q18 
If NATSIHS/IHS go to next module 
(It might be easier to answer these questions if you have the medication in front of you) 
(ASTH_Q11) 
What are the names or brands of all the asthma medications you have used in the last 2 
weeks? 
Test entry : up to 3 names/brands 
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Mark 4 if more than 3 medications stated 
(ASTH_Q12) 
Sequence Guide: 
If NATSIHS/IHS/NHSI and ASTH_Q08=1 go to ASTH_Q13 
If NHS go to ASTH_Q14 
(ASTH_Q13) 
Was your asthma medication used for prevention, relief or both? 
1 Prevention 
2 Relief 
3 Both 
4 Neither 
5 Don’t know 
Sequence Guide: 
If NHSI go to ASTH_Q14 
If NATSIHS/IHS go to ASTH_Q18 
 (ASTH_Q14) 
How often did you use [name of medication] in the last 2 weeks? 
(Loop for each name/brand) 
1 Every day and/or night 
2 More than 3 days and/or nights a week 
3 1 to 3 days and/or nights a week 
4 Less than once a week 
5 Varies/as required 
(ASTH_Q17) 
During the last 2 weeks, have you used a nebuliser to administer any of these 
medications for your asthma? 
1 Yes 
5 No 
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6 Don’t know 
(ASTH_Q18) 
Sequence Guide: 
If NHS/NHSI go to ASTH_Q19 
if NATSIHS/IHS go to next module 
(ASTH_Q19) 
Have you taken any of these actions for your asthma in the last 2 weeks? 
(Prompt card 12) 
1 Yes 
5 No (go to next module) 
(ASTH_Q20) 
Which ones? 
10 Admitted to hospital as an inpatient (go to next module) 
11 Visited outpatient clinic (go to next module) 
12 Visited emergency/casualty (go to next module) 
13 Visited day clinic (go to next module) 
14 Consulted a doctor (General Practitoner or Specialist) 
15 Consulted other health professional (go to next module) 
16 Had days away from work/study (go to next module) 
17 Had other days of reduced activities (go to next module) 
18 Taken vitamin or mineral supplements (go to next module) 
19 Used natural/herbal medicines (go to next module) 
(ASTH_Q22) 
Did you consult a General Practitioner or a Specialist? 
1 General Practitioner 
2 Specialist 
End module 
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